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Osteogenesis Imperfecta (OI) is a clinically and genetically heterogeneous heritable 
bone dysplasia occurring in 1/15,000-20,000 births. OI is a collagen-related disorder, 
with the more prevalent dominant forms caused by defects in the genes encoding the α1 
and α2 chains of type I collagen (COL1A1 and COL1A2). Rare recessive forms of OI are 
caused by deficiency of proteins required for collagen post-translational modifications or 
folding. We identified deficiency of components of the ER-resident collagen prolyl 3-
hydroxylase (P3H) complex as a cause of recessive OI. The P3H complex, consisting of 
prolyl 3-hydroxylase 1 (P3H1), cartilage-associated protein (CRTAP) and cyclophilin 
B/peptidyl-prolyl isomerase B (CyPB/PPIB), modifies the α1(I) P986 and α2(I) P707 
residues of type I collagen. The most common P3H complex defects occur in LEPRE1, 
 
the gene encoding P3H1, and over one-third of these cases are due to a founder mutation 
we identified among individuals of West African and African American descent. Our 
screening of contemporary cohorts revealed that 0.4% of African Americans and nearly 
1.5% of West Africans are carriers for this mutation, predicting a West African frequency 
of recessive OI due to homozygosity for this mutation at 1/18,260 births, equal to de novo 
dominant OI. Furthermore, haplotype analysis of affected families was consistent with a 
single founder for this mutation, occurring 650-900 years ago (1100-1350 C.E.). Patients 
deficient in P3H1 and CRTAP have consistent bone phenotypes and collagen 
biochemistry. However, the rare cases of CyPB deficiency have variable findings distinct 
from P3H1/CRTAP. To clarify the OI mechanism of CyPB deficiency, we generated a 
Ppib knock-out mouse. In the absence of CyPB, only residual collagen prolyl 3-
hydroxylation is detectable in KO cells and tissues. The delay in collagen folding in KO 
cells is further increased upon cyclophilin inhibition, supporting CyPB’s role as an 
isomerase and the presence of redundancy for collagen ER PPIases. Site-specific 
alterations of collagen post-translational modification, particularly at residues involved in 
helical crosslinking, suggest that CyPB is critical to the function of collagen 
hydroxylases, especially LH1. Thus our studies indicate novel roles for CyPB, separate 
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Collagens are the most abundant proteins in vertebrates, accounting for 
approximately one-third of total protein mass in mammals. They not only provide 
extracellular scaffolds for organ development and tissue support, they also play crucial 
roles in regulating cell growth, differentiation and migration. The discovery of genes 
encoding collagens in invertebrates, such as sponges, Hydra and even hydrothermal vent 
worms, demonstrates the importance of these proteins in the animal kingdom. In humans 
the collagen family of proteins now comprises at least 28 proteins encoded by 46 genes. 
It is believed that this diverse array of collagens arose through a series of gene 
duplications and divergence, a process that played a key role in vertebrate evolution. 
The structural organization that defines collagenous protein is the combination of 
three left-handed alpha chains with the characteristic Gly-X-Y amino acid triplet repeat, 
where Gly is glycine and the X and Y residues are often proline and hydroxyproline. 
Upon synthesis in the ER, the polypeptide chains assemble into right-handed 
homotrimeric or heterotrimeric molecules depending on the collagen type. This helical 
domain of collagen functions to provide mechanical strength to tissues, while non-
collagenous domains assist in subunit assembly and stability, and possess biological 
signaling activities. The molecular diversity of the collagen family is enhanced by the 
existence of isoforms that use alternative alpha chains within a given collagen type, 
including alpha chains of differing collagen types, alternative promoters, variant splicing 




Based on structural and functional characteristics, three major classes of collagens 
have been proposed (Figure 1). Group 1 collagens, the fibril-forming collagens, each 
have an uninterrupted helical domain approximately 300nm in length. These collagens, 
including types I, II, III, V and XI, are secreted as procollagens, processed by specific 
Figure 1. The Collagen Family of Proteins. Collagens are classified into three groups according to 
structure, function and localization. The collagens include at least 28 proteins, encoded by 46 genes, 
which provide structural support for the extracellular matrix of tissues. Type I collagen, the most abundant 
protein in vertebrates, is a fibril-forming collagen. Adapted from Myllyharju and Kivirikko 9.  
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pericellular propeptidases and assemble into higher order structures, termed fibrils, in the 
extracellular matrix. Group 2 collagens (types IV and VII), commonly referred to as 
basement membrane collagens, contain interrupted extended triple helices greater than 
300nm in length. The short chain Group 3 collagens include those with uninterrupted 
helical regions (types VI, VIII and X), fibril-associated collagens with interrupted triple 
helices (FACIT collagens) such as types IX, XII and XIV, the transmembrane collagen 
types XIII and XVII, and collagens with multiple helices and interruptions 
(MULTIPLEXIN types XV and XVIII). Several additional proteins containing domains 
with collagenous triple helical conformations have been identified, including complement 
component C1q, adiponectin, ficolins, tumor necrosis factor and acetylcholinesterase. 
However, the absence of a structural role in extracellular matrix excludes their inclusion 
within the collagen family of proteins.  
 
Type I Collagen 
 
 Type I collagen, the most abundant protein in humans, is a heterotrimer consisting of 
two α1(I) and one α2(I) chains encoded by the COL1A1 and COL1A2 genes, 
respectively. COL1A1 is an 18kb gene localized to human chromosome 17q21.3-q22, 
while COL1A2 is a 38kb gene at chromosome 7q21.3-q22. The structures of both genes 
consist of 52 exons, 42 of which encode the major triple helical domain. The majority of 
the exons are 54bp, with the remaining exons being multiples of 54bp or combinations of 
54 and 45bp. Each exon begins with an intact glycine codon and encodes a specific 
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multiple of Gly-Xaa-Yaa triplets, reflecting the evolutionary origins of the separate 
collagen types by exon duplication 12.  
 
Type I collagen is mainly synthesized and secreted by fibroblasts and osteoblasts, 
cells whose primary function is de novo generation or replacement of the scaffolding of 
the extracellular matrix of skin, tendon and bone. The pro-alpha chains of type I collagen 
consist of 338 uninterrupted repeats of the Gly-Xaa-Yaa triplet comprising the helical 
region, flanked by globular domains at each terminus that are processed by pericellular 
propeptidases upon secretion from the cell (Figure 2). The amino and carboxyl 
propeptides of the pro-α1(I) chain consist of 139 and 246 residues, respectively, but are 
57 and 247 residues in length in the pro-α2(I) chain. At each end of the helix there are 
short stretches of 11-26 residues, referred to as telopeptides, which connect the helix with 
the globular domains and also contain the propeptidase cleavage sites. Within the helical 
Figure 2. Type I Procollagen Structure. The three pro-alpha chains consist of a central helical region 
with 338 repeats of the Gly-Xaa-Yaa triplet flanked by two globular propeptide domains. The amino and 
carboxyl globular domains are processed upon secretion by specific pericellular propeptidases. Figure 
adapted from Prockop et al 10. 
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region there is a requirement for glycine at every third position due to interior size 
constraints of the triple helix. Glycine is also involved in the major stabilizing force for 
the triple helix, which is provided by interchain hydrogen bonding between the NH-group 
in glycine of one alpha chain and the O=C group of the X position residue in a 
neighboring alpha chain. Further stabilization of the triple helical structure is provided by 
the X and Y-position residues, which are often proline and 4R-hydroxyproline. 
Additional stabilization of the collagen helix has been attributed to the interchain salt 
bridges that form between positively charged Y-position lysyl residues and negatively 
charged X-position glutamic/aspartic acid residues 13,14. The combination of hydrogen 
bonds, electrostatic interactions and hydrophobic forces create a rigid, yet flexible, rod-
like structure perfectly suited to provide support and organization to the extracellular 
matrix. 
 The organization of pro-α1(I) and pro-α2(I) peptide chains into the type I 
procollagen molecule begins with the coordinated expression of their mRNAs. Polysome-
associated COL1A1 and COL1A2 transcripts have been demonstrated to occur in a 2:1 
ratio in fibroblast and osteoblast extracts, and this ratio of transcripts reflects the total 
cellular pool of translatable transcripts 15. Translation products from polysome-bound 
transcripts are spatially organized on the cytoplasmic face of the ER membrane by an 
incompletely understood mechanism. Investigations of early stages of procollagen 
assembly identified nascent polysome-bound collagen chains that were able to assemble 
into pepsin-resistant molecules with a heterotrimeric structure. While folding of these 
partially translated alpha chains was probably induced by the isolation procedure, the 
existence of ribosome-associated alpha chains that could trimerize provided indirect 
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evidence that translation products translocate into the ER lumen in a coordinated manner 
16,17. Coordinated translation is directed by a conserved stem-loop structure adjacent to 
the translation initiation codon in the 5’UTR of α1(I) and α2(I) mRNAs 18. In murine 
fibroblasts lacking type I collagen due to the absence of endogenous Col1a1 transcripts, 
pepsin-resistant heterotrimeric collagen has been generated by expression of full-length 
α1(I) cDNA that includes the 5’ stem-loop. However, in cells expressing α1(I) cDNA 
with a conformation-defective mutant stem-loop or missing this noncoding structure, 
properly folded collagen molecules were not synthesized 19. These findings were 
extended to define the 5’ stem-loop as a binding motif. Incubation of cell extracts with 
RNA probes corresponding to the stem-loop sequence resulted in detection of an RNA-
protein complex by gel-shift assay. Subsequent analyses of cDNA library clonal lines 
with increased 5’ stem-loop binding led to the identification of La ribonucleoprotein 
domain family member 6 (LARP6) as the binding partner. RT-PCR amplification of 
α1(I) and α2(I), but not other transcripts, from immunoprecipitates of LARP6 from 
fibroblast extracts confirmed the in vivo binding of LARP6 to the stem-loop. Importantly, 
although mRNA levels remain unchanged, synthesis and secretion of type I collagen 
protein is decreased upon targeting of LARP6 transcripts by siRNA. Furthermore, the 
absence of LARP6 is accompanied by loss of collagen immunostaining at discrete foci 
within the ER. These data are consistent with a role for LARP6 in coordinated translation 
of collagen alpha chains 19. 
Upon completion of translation, one of the initial steps in collagen trimeric assembly 




folding of the trimeric molecule from the carboxyl to amino terminus (Figure 3). In 
addition to conferring solubility under physiological conditions and preventing 
aggregation, the globular propeptide domains on procollagen contain specific residues 
that are required for procollagen type-specific association. By exchanging regions of the 
C-propeptide of pro-α1(III) chains, which only form homotrimers, with regions of the 
pro-α2(I), which can only assemble as heterotrimers with pro-α1(I) chains, Bulleid and 
colleagues determined that procollagen chain association is driven by a 23-residue 
molecular recognition sequence residing within the C-propeptide 20. Although pro-α2(I) 
Figure 3. Procollagen Synthesis and Modification. The three pro-alpha chains assemble at the 
carboxyl propeptide alignment regions and are co- and post-translationally modified by lysyl 
hydroxylase, prolyl 3-hydroxylase and prolyl 4-hydroxylase. Some hydroxylysyl residues are 
subsequently glycosylated. The collagen helical region is no longer accessible to the modifying 
enzymes upon completion of folding. Figure from Prockop et al 10. 
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chains are normally degraded in the absence of pro-α1(I) chains, in these experiments 
pro-α2(I) chains containing fragments of the pro-α1(III) propeptide were able to form 
homotrimers.  
Another factor determining type-specific chain association resides in the highly 
conserved cysteine residues contained within the propeptide sequence of procollagen 
alpha chains. Fibrillar collagens that form homotrimers (pro-α1(I), pro-α1(II), pro-
α1(III), pro-α1(V)) contain 8 cysteines, while chains requiring heterotrimer assembly 
(pro-α2(I), pro-α2(V) and pro-α1(XI)) contain only 7 cysteines in their C-propeptides. In 
type I procollagen, the last four cysteine residues in each chain form intramolecular 
disulfide bonds important for folding into the comformation required for association, 
while the remaining residues participate in intermolecular crosslinks 21,22. It has been 
proposed that triple helix formation occurs before formation of interchain disulfides in 
the C-terminus of collagen molecules 20. However, this is unlikely since mutations of the 
cysteine residues and loss of disulfide bonds in the C-propeptide disrupt chain 
association, possibly by altering the folded conformation of the C-propeptide 23. In fact 
the importance of disulfide bonds to collagen assembly was first demonstrated by 
inhibition of procollagen folding in cells treated with a reducing agent 24. Formation of 
these disulfide bonds can proceed absent any enzyme catalysis. 
 
Post-translational Modifications of Collagen 
 
Biosynthesis of procollagen is a complex process that requires several co- and post-
translational modifications within the ER, including formation of inter- and intra-chain 
 
 10 
disulfide bonds, isomerization of peptidyl-prolyl bonds, hydroxylation of prolyl and lysyl 
residues, and glycosylation of hydroxylysine residues. The specific post-translational 
modifications occur before, and to a major extent enable, collagen helical folding. Once 
folding is complete the collagen alpha chains are inaccessible to the modifying enzymes 
which require a non-triple helical conformation 25. Given the number of post-translational 
modifications that are required, it is not surprising to find a diverse array of intracellular 
enzymes that interact with alpha chains during synthesis and maturation of the 
procollagen molecule. These crucial post-translational modifications are catalyzed by 
thioredoxins, 2-oxoglutarate dioxygenases, immunophilins and glycosyltransferases. 
  
Protein Disulfide Isomerase 
Disulfide bonds, predicted to occur in at least one-third of all secretory proteins, serve 
to aid in folding, stabilization and potentiation of assembly of multimeric peptides. The 
ER is an environment conducive to oxidation of proteins, thus a means to ensure that 
correct disulfide bonds are formed is essential for proper folding of cargo and ER quality 
control. This activity was first demonstrated for Protein Disulfide Isomerase (PDI), the 
founding member of the PDI family of thioredoxin proteins. In Homo sapiens, there are 
at least 21 members of the PDI family, although not all possess isomerase activity. PDI, 
encoded by the P4HB gene, is an ER-resident multifunctional enzyme that catalyzes the 
oxidation of thiol groups, as well as reduction and rearrangement of disulfide bonds in 
various cell surface and secreted proteins 26,27.  PDI is a 55 kDa protein with four 
thioredoxin domains (notated a-b-b’-a’). The internal “b” domains do not have redox 
cysteines, but contain hydrophobic motifs involved in substrate interactions. The two 
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external thioredoxin “a” domains of PDI contain the C-G-H-C active site residues that 
catalyze the formation, breakage and rearrangement of disulfide bonds 28,29. Oxidized 
PDI first interacts with the substrate via the hydrophobic motifs. Upon binding, PDI 
accepts an electron from the substrate nucleophilic cysteine, creating a mixed disulfide 
between the two proteins. A second electron transfer completes oxidation of the substrate, 
resulting in an enzyme that maintains reducing potential toward the substrate. 
Isomerization of aberrant disulfide bonds is achieved through repeated cycles of 
reduction and oxidation of the substrate disulfides 30. Release of the substrate allows PDI 
to be replenished to the oxidized state by a separate ER resident redox protein, Ero1. 
However, only PDI in the presence of glutathione has been demonstrated to accelerate 
formation of triple helices from reduced and denatured procollagen chains in vitro, 
connecting the ER redox system to collagen synthesis 31.   
Several “non-catalytic” interactions with other proteins raise the possibility that PDI 
is involved in ER retention and quality control. For instance, PDI forms covalent 
complexes with the C-propeptides of unassembled pro-α2(I) chains in the absence of pro-
α1(I) chains within the ER, but not with correctly assembled heterotrimers 32. This 
interaction has been shown to assist in preventing aggregation of unassembled pro-α 
chains that are retained in the ER 33. However, unassembled pro-α2(I) chains complexed 
with PDI lacking an ER retrieval signal can still be secreted 32. The KDEL-containing β 
subunit (PDI) of the prolyl 4-hydroxylase complex also serves to retain the α subunit 
(P4Hα) within the ER since it does not itself contain a COOH-terminal ER retrieval 
signal. Furthermore, α subunits form insoluble aggregates within microsomes in the 
 
 12 
absence of PDI in cell-free translation experiments, demonstrating the ability of PDI to 
act as a chaperone that inhibits aggregation of misfolded proteins 34. 
 
Prolyl 4-hydroxylase 
Proline represents 23% and 20% of the residues within the helical regions of the 
human α1(I) and α2(I) chains, respectively, while the Pro–4RHyp–Gly sequence occurs 
in approximately 10% of collagen amino acid triplets 35. The presence of 4R-
hydroxyproline (4Hyp), which occurs exclusively in the Y-position of X-Y-Gly collagen 
triplets, endows collagen with its stability at physiological temperatures. This function of 
Hyp is easily demonstrated by the increased melting temperature of fully hydroxylated 
type I collagen (Tm = 39°C) compared to the unhydroxylated form (Tm = 24°C) 36. Short 
synthetic peptides containing variable (X-Y-Gly)n triplets have been used extensively to 
investigate stabilization of the triple helix by 4-hydroxyproline. These studies led some 
investigators to hypothesize that hydrogen bonding between water molecules and the 
hydroxyl group of Hyp provides the major stabilizing force to the collagen helix 37,38. 
Others have proposed that hydroxylation at the 4-position introduces an electronegative 
element that induces a C’-exo pucker to the pyrrolidine ring, which favors the trans 
conformation of the peptidyl-prolyl bond 39-41. This mechanism for stabilization of the 
helical conformation is supported by experiments in which the hydroxyl group was 
replaced with an electronegative, non-hydrogen bonding flourine at the 4-position to 
create (Pro-R-Flp-Gly)10 peptides, resulting in a higher thermal stability than any known 
collagenous decapeptide 42. Hence, hydroxylation of prolyl residues favors the trans 
conformation of the peptidyl-prolyl bond that is required for helical folding 43.  
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The co- and post-translational hydroxylation of proline residues in X-Pro-Gly 
sequences of collagens is catalyzed in the ER by prolyl 4-hydroxylase (P4H) 44,45. The 
enzyme consists of two distinct α and β polypeptides, the β subunits being identical to 
the multifunctional enzyme protein disulfide isomerase (PDI/(P4Hβ) and the 59-kDa α 
subunits (P4Hα) being a unique gene product 46,47. Three isoforms of the P4Hα subunit, 
α(I), α(II), and α(III), have been identified in mice and humans. In most tissues, 
particularly in skeletal muscle, liver, heart, lung and skin, α(I) is the most highly 
expressed subunit 48-50. The α(II) subunit is the main form in chondrocytes and 
endothelial cells. Both α(I) and α(II) forms are highly expressed in fibroblasts and 
osteoblasts 51. Although the α(III) mRNA is expressed at very low levels in many fetal 
and adult tissues, the highest levels of transcripts have been identified in placenta, liver 
and skin. Co-expression studies in insect cells have demonstrated that the isoforms 
associate in an α2β2 tetramer with PDI, but do not form mixed complexes 49. Considering 
that sequence analysis has revealed higher identity between the α(I) and α(II) isoforms 
(65%) than with the α(III) subunit (35-37%), this arrangement potentially allows for 
substrate-specific interactions with P4H variants 48. Furthermore, 20% residual P4H 
activity towards an unhydroxylated type I procollagen substrate was observed in cell 
lysates from fibroblasts lacking P4Hα1 subunits. Although the P4Hα(I) null mouse is 
embryonic lethal, the phenotype is attributed to disruption of type IV collagen-containing 
basement membranes rather than defects in type I collagen thermal stability or fibril 
structure. Lehmann et al demonstrated that, in type I collagen synthesized by 13 normal 
control fibroblast cell lines, 46-49% of prolyl residues were hydroxylated, correlating 
with the fraction of prolyl residues that occur in the Y-position 52. However, analyses of 
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identical type I collagen peptide fragments derived from bone, skin and tendon has 
revealed that the extent of prolyl hydroxylation can vary between tissues and at different 
ages 53,54. These data suggest tissue-specific and substrate-specific interactions between 
collagen types and P4H isoenzymes 55. 
The catalytic activity of P4H was first demonstrated in microsomal fractions 56, and 
the enzyme was subsequently purified from chick embryos 57,58. Biochemical and 
sequence analyses have shown that P4H is a member of the 2-oxoglutarate dioxygenase 
family of enzymes that also includes the prolyl 3-hydroxylases and the lysyl 
hydroxylases. Accordingly, most of the conserved amino acid residues occur in the C-
terminal region of the alpha subunits, which contain the catalytic active site including two 
histidine residues and an aspartate residue 50. The active site is believed to consist of 
portions of the α and β subunits, since antibodies to the β subunit inhibit the hydroxylase 
activity of the tetramer, although it is unknown if these findings reflect antibody 
interference with subunit assembly 59. However, it should be noted that alpha subunits 
from simpler life forms such as green algae are expressed and function as monomers 60. 
Interestingly, the substrate-binding domain of prolyl 4-hydroxylase alpha subunits has 
been demonstrated to be distinct from the catalytic domain. Sequencing of trypsin-
protected fragments of poly-proline peptides bound to tetrameric P4H in vitro identified 
an approximately 100-residue region separate from the C-terminal catalytic site 
responsible for interaction between alpha subunits and proline-containing substrate 61.  
As with lysyl hydroxylase and prolyl 3-hydroxylase, activity of P4H requires a 
nonhelical substrate, Fe++, 2-oxoglutarate, O2 and ascorbate 25,44. During this reaction the 
2-oxoglutarate is decarboxylated, with one oxygen atom incorporated into the succinate 
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product and the other oxygen into the hydroxyl group of proline 62. The role of ascorbate 
in this reaction is not entirely clear, since the enzyme can complete several catalytic 
cycles without it 63. However, impaired 4-hydroxylation of collagen proline residues and 
the resulting extracellular matrix deficiency in scurvy is well characterized 64. The 
minimum substrate requirement for hydroxylation is a single X-Pro-Gly tripeptide, and 
free proline is not hydroxylated by P4H 65. While proline is the preferred residue in the 
X-position, hydroxylation can also occur with other residues, such as alanine, at this 
position 66. In (Pro-Pro-Gly)5 synthetic peptides, the proline residues in the Y-position of 
the third and fourth triplets are preferentially hydroxylated 67.  
 
Lysyl hydroxylases 
The lysyl hydroxylases (LH), members of the 2-oxoglutarate dioxygenase protein 
family, catalyze the formation of 5-hydroxylysine residues in collagens and other proteins 
with collagenous sequences by the addition of a hydroxyl group to lysine residues in X-
Lys-Gly, X-Lys-Ala or X-Lys-Ser triplets 68. Hydroxylysine residues serve as substrates 
for attachment of carbohydrate groups to pro-alpha chains and for the formation of 
intermolecular crosslinks in higher order structures of collagen. The human lysyl 
hydroxylase family consists of LH1-3, encoded by PLOD1 (procollagen-lysine 2-
oxoglutarate 5-dioxygenase 1), PLOD2 and PLOD3, respectively. These hydroxylases 
have approximately 60% amino acid identity, due to their formation by gene duplication 
and intron lengthening during evolution 69. The highest degree of homology occurs 
within the carboxyl-terminal region that contains the LH active site, structurally similar 
to the active site domain found in prolyl hydroxylases, which are also classified as 2-
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oxoglutarate dioxygenases. Despite lacking a C-terminal KDEL ER-retrieval tetrapeptide, 
the three LH isoenzymes are luminally-oriented membrane-associated enzymes 70. 
Although the three lysyl hydroxylases have similar substrate specificity for short 
synthetic peptides in vitro 71, recent discoveries have provided new insights into the 
unique functions of the individual isoenzymes in vivo.  
In a pair of articles representing the first biochemical characterization of an inborn 
error of human collagen metabolism, Krane and colleagues demonstrated deficiency of 
procollagen lysine hydroxylation in a subset of patients with Ehlers-Danlos syndrome 
(EDS), a group of connective tissue disorders that share the common features of joint 
laxity, scoliosis and skin hyperextensibility. Amino acid analysis of dermal collagen from 
two sisters revealed a decrease in hydroxylysine content to 5% of normal, with variable 
reductions in bone, but normal levels of hydroxyproline and other amino acids 72. These 
studies demonstrated that crude cell lysates from cultured patient fibroblasts showed an 
85-90% reduction in enzymatic hydroxylation of fibroblast-derived unmodified 
procollagens. The absence of collagen lysyl hydroxylation in two affected siblings within 
a clinically normal extended pedigree fit a recessive inheritance pattern, suggestive of a 
specific enzymatic deficiency 73. It would be twenty years before cloning of the full-
length PLOD1 cDNA led to the identification of homozygous nonsense mutations in a 
cohort of EDS type VIA patients, whose dermal tissue exhibited severely reduced lysyl 
hydroxylase activity 74.  
While subsequent studies of patients with LH1 deficiency have confirmed 
insufficiency of helical hydroxylysine on analysis of hydrolyzed dermis or reduced 
enzymatic activity in cultured skin fibroblasts, amino acid quantitation of EDS VIA 
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patient collagens has also shown normal levels of hydroxylated lysine residues within the 
telopeptides 75,76. Royce et al demonstrated that highly purified LH1 from chick 
fibroblasts was able to hydroxylate lysyl residues of CNBr-derived peptides of 
unmodified procollagen corresponding to the helical region, but was unable to 
hydroxylate lysyl residues within peptides corresponding to the non-helical regions of 
collagen 77. Conversely, biochemical analysis of bone-derived collagen from Bruck 
Syndrome 2 patients revealed underhydroxylation of telopeptide lysyl residues, but 
normal hydroxylation of helical residues 78. These findings provided strong 
circumstantial evidence for the existence of a unique lysyl hydroxylase specific for the 
collagen telopeptides. Indeed, Valtavaara et al reported the isolation and characterization 
of cDNA clones encoding a novel isoform of lysyl hydroxylase, which they called lysyl 
hydroxylase-2 (PLOD2) 79. In contrast to the other isoenzymes, LH2 contains an extra 
exon, designated 13A, which results in 2 forms of mRNA referred to as LH2a (short 
form) and LH2b (long form), respectively 80. Several lines of evidence have confirmed 
LH2 as the specific collagen telopeptidyl lysyl hydroxylase. First, the level of expression 
of Plod2 increases drastically during the mineralization phase of differentiation in BMSC 
cultures, the timing of which corresponds to increased telopeptide-derived crosslink 
formation 81. Second, overexpression of LH2b, but not LH2a, LH1 or LH3, increases 
collagen telopeptide lysyl hydroxylation and crosslink formation in MC3T3 cells in 
culture 82. Third, homozygosity mapping in two pedigrees with multiple siblings affected 
by Bruck Syndrome localized a candidate gene defect to chromosome 3q23-q24. 




The third human lysyl hydroxylase, LH3, is evolutionarily the oldest of the LH 
isoforms 69. Similar to its single ortholog in C. elegans, human LH3 is a multifunctional 
enzyme with lysyl hydroxylase (LH), galactosyltransferase (GT) and glucosyltransferase 
(GGT) activities (see Glycosyltransferases, below). Investigations of LH3 activity using 
truncated or mutagenized recombinant enzyme against collagen substrates in vitro have 
established that GT and GGT activity is attributed to the N-terminal portion of LH3 83,84. 
Inactivation of LH3 lysyl hydroxylase activity in a knock-in mouse reduces 
hydroxylation of types IV and V collagens, but not types I, II and III collagens, and 
causes structural changes in tissues, particularly in basement membranes 85. Since types 
IV and V collagens are more extensively hydroxylated than collagens I, II and III, the 
decreased helical lysine hydroxylase activity indicates a lack of compensation by LH1 
and LH2 in vivo. Still, the moderate phenotype of this mouse model, compared to the 
embryonic lethality of the LH3 knockout, suggests that the most significant role for this 
enzyme does not reside in its LH activity 86. 
Several features of collagen lysine post-translational modification remain to be 
clarified. Although it has been demonstrated that LH1 activity is specifically directed to 
collagen helical lysine residues, overexpression of rat Plod1 cDNA in CHO cells has 
been shown to increase telopeptide pyridinium crosslink production, which is known to 
require Plod2 activity 87. As mentioned above, most of the collagen biochemical data on 
EDS VI has been limited to patient dermal samples and demonstrate almost complete loss 
of lysyl hydroxylation. However, in the few cases of LH1 deficiency in which other 
tissues have been analyzed, lysyl hydroxylation of collagen from cartilage and bone was 
only reduced 10-50% versus normal control collagen 72. It has also been noted that 
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cultured skin fibroblasts with severely reduced lysyl hydroxylase activity (12-16% of 
control values) synthesize hydroxylysine-deficient collagen (8-9% of control values), 
while direct quantitation of dermal samples from the same patient demonstrate only 
moderate reductions in hydroxylysyl residues (60-80% of control values) 88. Furthermore, 
quantitation of collagen hydroxylation in several tissues isolated from Plod1-/- mice have 
revealed marked variation in the magnitude of hydroxylysine deficiency. Supporting the 
ability of the two remaining isoenzymes to modify helical lysine residues, investigators 
found a 70-80% decrease in Hyl content in collagen isolated from skin, cornea and tail 
tendon, although lung, femur and aorta-derived collagens were underhydroxylated by 
only 15-35% compared to wild-type murine collagens 89. These findings are not entirely 
surprising since each LH isoform can be found at variable levels in collagen-expressing 
tissues, with unique patterns of expression arising at later stages of development 90. For 
instance, northern analyses show that at early embryonic stages of development (E7-15) 
murine Plod1 is expressed at levels higher than Plod2 and Plod3. However, transcripts 
for Plod 3 increase dramatically at E15 almost to the levels seen for Plod1. Yamauchi 
and colleagues have observed dramatic increases in expression of Plod1, Plod2 and 
Plod3 in differentiating murine BMSC cultures, including at the proliferative 
preosteoblastic phase (Plod1), matrix producing osteoblast transition (Plod3), and in 
matrix mineralizing osteocytes (Plod2) 81. Finally, there is no current explanation for 
expression of two separate forms of LH2; the long form (LH2b) is believed to 
hydroxylate telopeptides, but no function has been proposed for the short form (LH2a). 
These studies suggest that plasticity in substrate-specific modifications of collagens by 
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LH isoforms is a complex process involving developmental-, tissue- and cell -specific 
regulation. 
 
FK506 Binding Protein 65 KDa  
Three classes of peptidyl-prolyl isomerases (PPIases) are encoded in the human 
genome and include the cyclophilins (CyPs), the FK506-binding proteins (FKBPs) and 
the parvulins. PPIases are responsible for the catalysis of cis-trans isomerization of 
peptidyl-prolyl bonds, important for folding of proteins rich in proline. Cyclophilins and 
FKBPs, considered “immunophilins”, are so named based on their inhibition by the 
immunosuppressive drugs cyclosporine A and FK506, respectively. Immunophilins have 
been found in every cellular compartment and tissue as membrane-bound, soluble or 
secreted proteins 91. They have been implicated in various cellular functions such as the 
regulation of heat shock response, steroid receptor and ion channel activity, cell-cell and 
cell-matrix interactions, transcription and translation 92. More importantly for proteins 
within the secretory pathway in humans, at least two cyclophilins and six FKBPs have 
been identified as ER resident proline isomerases 93. The search for specific ligands to 
these isomerases as a means to understand their physiological functions has provided 
insights into the roles of cyclophilin B and FKBP65 in collagen biosynthesis.  
Fkbp10, which encodes FKBP65, was first cloned and sequenced from a cDNA 
library during a search for differentially expressed genes in murine fibroblasts 
undergoing neoplastic progression 94. Sequence analysis predicted the presence of four 
PPIase domains, two calcium-binding EF hand motifs and a C-terminal ER retrieval 
tetrapeptide. Subsequent studies of recombinant FKBP65 verified that the putative 
 
 21 
isomerase was able to accelerate the isomerization of the peptidyl-prolyl bond within a 
succinyl-Ala-Ala-Pro-Phe-nitroanilide substrate in vitro with a catalytic efficiency similar 
to other FKBP family members. This activity was inhibited by FK506 and rapamycin 95. 
The first evidence for an in vivo role of FKBP65 came from a series of investigations 
designed to identify specific chaperones for tropoelastin in chondrocytes 96. 
Coimmunoprecipitation of FKBP65 with tropoelastin from cell lysates provided the first 
identification of a proline-rich ligand for an FKBP within the secretory pathway. The 
investigators speculated that FKBP65 facilitated folding and trafficking of tropoelastin 
through post-ER compartments, and might facilitate crosslinking of elastin into the 
extracellular matrix. 
Since approximately one-sixth of the primary sequence of collagen alpha chains 
consists of proline residues, peptidyl-prolyl isomerization has long been considered the 
rate-limiting step in collagen folding, as only trans peptide bonds can be incorporated 
into the collagen triple helix 97. The possibility that FKBP65 is involved in this process 
was investigated by Bachinger and colleagues. They isolated FKBP65, along with several 
other collagen-interacting proteins, as eluates of chick embryo extracts applied to a 
gelatin-Sepharose column 98. Analysis of purified FKBP65 activity in vitro revealed that, 
in contrast to other FKBPs, its highest activity was towards leucine- and alanine-
containing peptides that more closely resemble collagen telopeptide compared to helical 
sequences. In contrast to the other FKBPs, the isomerase activity of FKBP65 toward a 
succinyl-Ala-Ala-Pro-Phe-nitroanilide substrate is inhibited 25% in vitro, but only 
marginally against procollagen in vivo, in the presence of either FK506 or CsA 98,99. 
Another feature of FKBP65 that distinguishes it from other FKBP family members is that 
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it is retrotranslocated from the ER and degraded by the proteosome under conditions of 
ER stress, arguing against a specific role as a folding chaperone 100. In addition, the rate 
of refolding of denatured collagen in vitro was only minimally increased in the presence 
of purified FKBP65 99. These studies prompted investigators to consider other roles for 
FKBP65 in collagen biosynthesis. A putative chaperone function for FKBP65 is 
suggested by its ability to inhibit thermal aggregation of citrate synthase and rhodanese in 
a concentration-dependent manner. This activity is not affected by the presence of FK506 
or CsA. Perhaps the most significant information generated on FKBP65 from the in vitro 
characterization studies was the observation that it interacted with fully folded collagen 
and inhibited fibril formation 101.  
A fuller picture of FKBP65 function in vivo has now emerged with the identification 
and biochemical characterization of patients with bone dysplasia caused by recessive 
mutations in the gene encoding FKBP65. In the absence of FKBP65, in vivo folding is 
normal as suggested by normal electrophoretic migration on SDS-PAGE and amino acid 
analysis of type I collagen synthesized by patient fibroblasts 102. Normal folding was 
demonstrated in a direct intracellular folding assay showing identical rates of collagen 
folding in patient and normal control fibroblasts 103. Significantly, Barnes et al recently 
reported an almost complete loss of collagen telopeptide lysyl hydroxylation in patients 
lacking FKBP65 protein, resulting in a 90% decrease in type I collagen crosslinked into 
extracellular matrix in deposition assays in culture 103. These biochemical findings have 
also been identified in patients with Bruck syndrome, caused by PLOD2 deficiency. 
Furthermore, clinical observations of patients with FKBP10 mutations suggest that the 
phenotypic spectrum of mutations in FKBP10 overlaps with Bruck syndrome. It remains 
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to be determined if FKBP65 interacts directly with PLOD2 to affect its activity. 
Alternatively, given Bachinger’s findings that FKBP65 directly interacts with type I 
collagen and inhibits fibril formation in vitro 101, it is possible that isomerization of the 
telopeptide substrate by FKBP65 is required for PLOD2 activity 103. However, this is less 
likely since there are no prolyl residues adjacent to PLOD2-modified lysines in the 
telopeptide primary sequence. 
 
Prolyl 3-Hydroxylation Complex         
Trygvasson and colleagues first demonstrated that 3-hydroxyproline and 4-
hydroxyproline were synthesized by unique enzymes using crude rat kidney extracts 104. 
Renal cortex was used because it is rich in type IV collagen, which contains up to fifteen 
3-hydroxyproline residues per alpha chain, in contrast to type I collagen which contains 
only two 3-hydroxyprolines per trimer. Unhydroxylated type IV procollagen incubated 
with kidney extracts in the presence of antiserum to prolyl 4-hydroxylase demonstrated 
both decreased P4H and P3H activity. In the absence of P4H antibody, purified prolyl 4-
hydroxylase was unable to catalyze the 3-hydroxylation of prolines on the unmodified 
collagen substrate. A partially purified protein fraction with prolyl 3-hydroxylase activity 
was subsequently isolated from chick embryo extracts and was found to have a molecular 
weight of 160kDa by gel filtration 105. Since the Gly-Pro-4Hyp sequence is found at 
numerous triplets and 3Hyp is only found in Gly-3Hyp-4Hyp triplets in collagen, the data 
suggested that the substrate sequence for 3-hydroxylation is Gly-Pro-4Hyp.  
The mechanism of collagen prolyl 3-hydroxylation has, until recently, been poorly 




of a single X-position residue (3Hyp-4RHyp-Gly) in each of the α1(I) chains at Pro986. 
By comparison, 3-hydroxylation of several X-position proline residues occurs in types IV 
and V collagens. Bachinger first isolated the enzyme catalyzing the 3-hydroxyl 
modification of type I collagen from chick rER extracts and demonstrated that it was part 
of a complex consisting of prolyl 3-hydroxylase 1 (P3H1), cartilage-associated protein 
(CRTAP) and peptidyl-prolyl isomerase B/cyclophilin B (PPIB/CyPB) (Figure 4) 106. 
Further evidence in support of a complex containing P3H1, CRTAP and cyclophilin B 
was provided with cosedimentation of these three proteins from affinity column-purified 
chick rER extracts in a 1:1:1 ratio on a sucrose gradient 107. Confirmation of the 
components and function of the prolyl 3-hydroxylase complex was provided by Morello 
and colleagues, who demonstrated that deficiency of a single component abrogated 
complex activity 107. Since P3H1 is able to independently 3-hydroxylate collagen 
Figure 4. The Collagen Prolyl 3-Hydroxylation Complex. Prolyl 4-hydroxylase (P4H) modifies 
approximately 90 proline residues in the Y-positions of the Gly-Xaa-Yaa triplets in each alpha chain 
of type I collagen. Prolyl 3-hydroxylation, a minor post-translational modification, occurs at the X-
position residues α1(I) Pro986 and to a lesser extent at α2(I) Pro707 in type I collagen. Prolyl 3-
hydroxylation also occurs at α1(II) Pro986 in type II collagen, and at several residues in type V 
collagen. This modification is performed by the ER-resident collagen prolyl 3-hydroxylation 
complex, consisting of P3H1, CRTAP and CyPB. Figure from Marini et al 2.   
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substrate in vitro 106, it is now believed that, in vivo, P3H1 serves as the enzymatic 
component while CRTAP functions as a “helper” protein for the complex. 
Cyclophilin B, also known as peptidyl-prolyl cis-trans isomerase B (CyPB/PPIB), is 
thought to be the major, and possibly unique, peptidyl-prolyl cis-trans isomerase 
involved in collagen folding. Inhibition of CyPB by cyclosporine A (CsA) treatment 
slowed the rate of collagen folding, resulting in overmodification of lysyl and prolyl 
residues as determined by delayed electrophoretic migration of collagen alpha chains on 
SDS Urea-PAGE 108. It should be noted, however, that CsA is a notably non-specific 
inhibitor and molecules other than CyPB would have been inhibited. As discussed in 
detail below, the characterization of the Crtap and P3h1 knock-out mouse models, and 
null mutations of the CRTAP, LEPRE1 (P3H1) and PPIB genes in patients with recessive 
osteogenesis imperfecta have demonstrated the importance of the proteins in this 
complex for normal collagen formation and bone development.  
Despite the identification 50 years ago of 3-hydroxyproline residues as a minor 
component of fibrillar collagens, very little interest was shown in the possible function(s) 
of this modification until the recent discoveries that deficiency of components of the 
modifying complex caused severe bone disease (see below, “Recessive OI”). Type I 
collagen synthesized in culture by cells lacking components of the complex is 
overmodified by lysyl hydroxylase, a hallmark feature of delayed folding of the collagen 
helix 109,110. Furthermore, the P3H complex has been shown to accelerate the rate of 
folding of denatured rhodanese and type III collagen, neither of which contains any 3-
hydroxyproline residues, due to its PPIase activity towards these substrates 111. Since 
cyclophilin B PPIase activity is negligible in the absence of P3H1 and CRTAP, and the 
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PPIase activity of the complex is inhibited by cyclosporine A in vitro, the P3H complex 
has also been characterized as an isomerase. The complex is believed to function as a 
collagen chaperone, since in vitro it is able to inhibit thermal aggregation of citrate 
synthase and fibril formation of type I collagen 111, suggesting an additional role in 
preventing premature aggregation of procollagen within the secretory pathway. Absence 
of P3H1 or CRTAP greatly reduces the extent to which CyPB can bind denatured 
collagen in vitro, indicating that CyPB-collagen binding depends upon the other 
components of the complex. These data suggest that an additional role of the complex is 
to shuttle cyclophilin B to its collagen substrate 112. Given the distinct intracellular 
activities attributed to the P3H complex, Bachinger has described it as a post-translational 
modification complex, isomerase and molecular chaperone 111. 
Eyre and colleagues have focused on the potential extracellular role of the 3Hyp 
modification. They have noted differences in 3Hyp site occupancy of fibrillar collagens 
from mammals and lower vertebrates as evidence of a functional role for the modification 
other than as a coincidental mark of intracellular complex chaperone activity 113. 
Specifically, the 234-residue interval of 3Hyp sites in type I/V and II/XI heterotypic 
fibrils is closely aligned to the approximately 237-residue D-periodic spacing of collagen 
fibrils. In addition, human type III collagen lacks the α1(I) 3Hyp986 residue and in vitro 
can only form microfibrils, while in vivo it is found as a minor component of type I/V 
heterotypic fibrils. These findings suggest a putative extracellular role of 3Hyp residues 
in fibrillar assembly through the formation of hydrogen bonds between adjacent collagen 
triple helices 113. This hypothesis is supported by the crystal structure of a synthetic 
peptide containing 3Hyp, showing that the hydroxyl group in the Xaa position of the 
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Xaa-Yaa-Gly collagen triplet points away from the helical axis 114. In addition, the often-
charged residue Xaa position of the collagen helix is the most solvent accessible, 
potentially allowing for its involvement in a variety of protein-protein interactions. 
Furthermore, in studies testing self-association of collagen peptides, absence of the 
hydroxyl group at the α1(I) P986 residue abrogated self-binding 115. It is interesting that 
the α1(I) P986 residue overlaps a major ligand binding region (MLBR3) in type I 
collagen, and substitutions in this region of the α1(I) collagen chain in humans result in 
lethal bone disease 116. However, in vivo confirmation of the extracellular role of the 




Following hydroxylation of helical residues by LH1 (PLOD1), some hydroxylysine 
(Hyl) residues are further modified by the addition of carbohydrates, forming the 
disaccharide Glc(α1-2)Gal(β1-O)Hyl. Glycosylation of collagen was first described by 
Grassman and Schleich over 70 years ago 117. However, it was not until the late 60’s that 
the nature of collagen glycosylation was characterized as either a galactosyl or 
glucosylgalactosyl group attached via O-glycosidic linkage to hydroxylysine residues 118. 
The extent and heterogeneity of hydroxylysine glycosylation in collagens varies to a large 
degree between collagen types and species. Furthermore, the ratio of monosaccharides 
and disaccharides in a given collagen type varies with age, as well as within and between 
tissues 119. The factors that determine the differences in collagen glycosylation is an area 
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of active investigation, and cannot be solely explained by the levels of expression of the 
genes that encode the modifying enzymes. 
As with other modifying enzymes that interact with the collagen helical region, the 
glycosyltransferases require an unfolded molecule since the triple helix conformation 
inhibits the addition of carbohydrate subunits. Two of these enzymes, which are 
themselves glycoproteins, have only recently been identified as ER-resident 
galactosylhydroxylysyl transferases, GLT25D1 and GLT25D2 120,121. Both enzymes, 
which transfer the sugar unit of UDP-galactose to hydroxylysine residues, are unable to 
glycosylate free hydroxylysine and require a collagen alpha chain peptide fragment 
length of at least 500-600Da as a substrate 122,123. The second glycosylation reaction that 
occurs during collagen synthesis and folding is the attachment of UDP-glucose to 
galactosylhydroxylysyl residues. The multifunctional Lysyl Hydroxylase 3 
(LH3/PLOD3) enzyme is believed to be the galactosyl glucosyltransferase that performs 
this modification in vivo. Although lysyl hydroxylase 3 (LH3) is a multifunctional 
enzyme possessing lysyl hydroxylase (LH), hydroxylysyl galactosyltransferase (GT) and 
galactosylhydroxylysyl glucosyltransferase (GGT) activities in vitro, knock-down of 
Plod3 expression in MC3T3 cells has demonstrated decreased glucosylation of type I 
collagen, accompanied by increased galactosylhydroxylysine with normal hydroxylysine 
levels 124. Further support for LH3 possessing GGT activity in vivo comes from studies 
specifically suppressing this activity in human skin fibroblasts using a polyclonal 
antibody directed toward the amino terminal GGT domain 83. Knocking out the Plod3 
(LH3) gene also proved that functional redundancy for LH and GT activity exists in vivo, 
and that it is the loss of GGT activity due to the absence of LH3 that results in a 
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connective tissue phenotype in mice 85,125. Recently, Salo and colleagues have identified a 
connective tissue disorder in a single proband caused by compound heterozygosity for 
mutations in the PLOD3 gene 126. Findings included absence of glucosyl-galactosyl-
pyridinium crosslinks in urinary collagen degradation products, as well as decreased 
GGT activity of proband serum and lymphoblast extracts against a collagen substrate in 
vitro. However, the authors also determined that all three enzymatic activities (i.e., LH, 
GT, GGT) of recombinant proteins generated from each mutant allele were decreased 
compared to normal recombinant LH3 126.  
The biological significance of collagen glycosylation remains unclear, although 
several functions have been proposed. Amino acid analysis of hydrothermal vent worm 
cuticle collagen suggests that despite its low proline content, a high content (>18%) of 
threonine residues glycosylated with di- and tri-saccharides of galactose impart a high 
thermal stability (37°C), compared to the 28-36°C melting temperature of human type I 
collagen from various tissues 127,128. Of note, as the extent of glycosylation within a 
specific collagen type increases, so does the temperature at which the protein denatures. 
This suggests a role for glycosylation in stabilizing the triple helix by restricting the 
conformational space of the alpha chains and “locking” them into the folded state. 
Another possibility is that the saccharides prevent access of water to the peptide 
backbone, thereby creating a hydrophobic effect preventing unfolding of collagen 129. It 
has also been suggested that additional roles of glycosylation of collagen include 
increased resistance to enzymatic degradation, mediation of interactions with endocytic 
receptors involved in matrix remodeling, regulation of binding interactions with 
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noncollagenous extracellular matrix proteins, promotion of angiogenesis, regulation of 
collagen fibril growth and tissue mineralization (see below). 
 
Heat Shock Protein 47 KDa  
Serine proteinase inhibitor clade H (SERPINH1) is an ER resident collagen-specific 
binding protein. It is commonly referred to as Heat Shock Protein 47 kDa (HSP47) due to 
its initial characterization as a heat-shock response protein, rather than as a component of 
the intracellular ER stress response 130. Expression of Hsp47 occurs in all cells that 
produce collagens at levels that correspond to the amount of collagens being synthesized. 
Loss of HSP47 expression in mice is incompatible with survival of developing embryos 
due to defective maturation of several collagen types 131. The mechanism by which 
HSP47 facilitates normal collagen synthesis, secretion and processing has been a 
controversial topic since its initial characterization in chick embryos, as colligin in mice, 
and as gp46 in rats 132. 
In contrast to the manner in which other chaperones interact with collagen in the ER, 
HSP47 preferentially binds fully folded triple helical collagen molecules. Using collagen 
model peptides, Koide and coworkers demonstrated that, in vitro, the motif recognized by 
Hsp47 is X-(Pro/Thr)-Gly-X-Arg-Gly, but only within the context of a folded collagen 
helical structure 133-136. Recently Widmer et al have presented the crystal structure of 
HSP47 complexed with a homotrimeric collagen synthetic peptide, characterized as two 
molecules attached on opposite sides of the collagen helix in a clamp-like fashion 137. As 
there exist 27 and 32 putative binding motifs within the helical regions of the α1(I) and 
α2(I) chains, respectively 134, it is possible that as many as 25-30 evenly spaced HSP47 
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binding sites exist on the surface of normally folded type I collagen molecule. Binding to 
collagen occurs in a pH-dependent manner; Hsp47 transiently interacts with folded 
monomers at neutral pH, which is found in the ER, and dissociates at a pH below 6.3 as 
is found in the Golgi. In cellulo, Hsp47 remains bound to collagen when ER to Golgi 
trafficking is inhibited with Brefeldin A treatment. However, in cells treated with 
monensin to inhibit vesicular transport from the trans-Golgi no association of Hsp47 and 
collagen was detected. These findings demonstrate binding of Hsp47 to collagen in the 
ER, but dissociation from collagen molecules in the ERGIC and/or cis-Golgi 
compartment 138. Upon dissociation from collagen, HSP47 recycles back to the ER via 
KDEL receptors 139. 
Procollagen is thermally unstable and denatures at physiologic conditions in the 
absence of HSP47 140, and loss of functional HSP47 results in collagen that is susceptible 
to proteolytic cleavage 131,141. Thus it would appear that HSP47 is essential for 
stabilization of the folded collagen helical conformation. In cells lacking expression of 
Hsp47, Type I collagen shows normal helical modification and slower secretion kinetics, 
resulting in a dilated ER due to accumulation of collagen. Other cellular findings in the 
Hsp47 knockout mouse include defective N-propeptide processing of secreted 
procollagens 142. The requirement of both a conserved recognition sequence and proper 
substrate conformation for N-propeptidase cleavage suggests that, in the absence of 
HSP47, collagen helical folding cannot be stabilized. These findings are in addition to 
observations that Hsp47 inhibits fibril formation in vitro 143. Since collagen is thought to 
be transported as (aggregate structures) through the Golgi stack by a process of cisternal 
maturation 144, a role for Hsp47 in preventing intracellular collagen aggregation seems 
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plausible. Therefore, the cumulative data supports a function for Hsp47 in assisting 
collagen molecules by inhibition of helical denaturation and preventing premature 
aggregation during transport through the secretory pathway. 
 
Collagen Trafficking, Secretion and Processing 
 
ER Cargo Selection and Vesicular Export 
Once post-translational modification and folding is complete, the procollagen 
molecules must be transported through the secretory pathway for deposition into the 
pericellular space. In the conventional secretory pathway model, proteins destined for 
secretion are sorted at ER exit sites (ERES) and loaded into COPII-coated vesicles for 
transport to the Golgi 145. In general, the process of ER-derived vesicle formation begins 
with insertion of Sec12(GEF)-activated Sar1-GTP into the outer leaflet of the ER 
membrane, recruiting dimerized Sec23/Sec24, which has GAP activity. Binding and 
concentration of cargo is thought to be mediated by Sec24. This complex forms the first 
layer of coat proteins on the membrane, referred to as the prebudding complex. 
Recruitment of Sec13/Sec31 dimers follows, with Sec31 interacting directly with Sec23, 
completing assembly of typical COPII-coated vesicles that are 60-90nm in diameter. 
Fibrillar procollagens, however, are greater than 300nm in length, suggesting that 
transport proceeds by a COPII-independent mechanism, or alternatively, that COPII 
carrier size can be specifically regulated under special circumstances to accommodate 
larger cargo. This debate has led to the recent identification of novel roles of previously 
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known proteins involved in trafficking, as well as identification of collagen-specific 
cargo adaptors that enable formation of “megacarriers” (Figure 5) 146.   
 
The first clues to how collagens are packaged and transported evolved from 
experiments that took advantage of the fact that ER export of collagens is inhibited under 
scorbutic conditions 147. In the absence of ascorbic acid, a cofactor for prolyl 
hydroxylases, collagen is underhydroxylated and retained in the ER. Upon addition of 
ascorbic acid, collagen is transcriptionally and translationally upregulated, while folding 
and secretion efficiency is increased. This “pulse” technique has allowed several 
investigators to follow collagen molecules through the secretory pathway. Using TEM 
analysis, Pacifici and Iozzo were the first to observe remodeling of the RER upon 
upregulation of collagen synthesis 148. These investigators noted morphologic changes in 
the size and shape of specific regions of RER; rather than uniform, oval-shaped cisternae, 
Figure 5. Procollagen Trafficking. Procollagen molecules concentrate at ER exit sites in preparation 
for transport to the Golgi complex. The formation of COPII-coated “megacarriers” is mediated by the 
interaction of collagen-specific cargo receptors (TANGO-like proteins), COPII component Sec23, 
SEDL and Sar1. Transport vesicle growth is regulated by an incompletely understood mechanism 
involving ubiquitylation of SEC13/31 by the CUL3/KLHL12 complex. HSP47 and CyPB accompany 




some portions of the organelle developed into large, saccular structures containing 
concentrated collagen. Interestingly, using immunofluorescence microscopy Miranov et 
al noted that concentration of procollagens occurs in regions of the ER that are distinct 
from the sites where vesicular stomatitis virus glycoprotein (VSVG) concentrates 149. 
Since VSVG binds directly to the COPII subunit Sec23/24 150, the authors hypothesized 
the existence of a collagen-specific cargo receptor for recruitment to the ERES.  
Recent work in Drosophila has uncovered novel components of the cellular secretory 
pathway invloved in collagen trafficking 151. In this study, investigators utilized a 
genome-wide library of 22,000 dsRNAs to screen for genes required for protein secretion 
in cells stably-transfected with expression constructs encoding horseradish peroxidase 
(HRP) driven by an inducible promoter. Knock-down of expression of genes required for 
secretion was performed by screening for decreased peroxidase activity by 
chemiluminescence. Genes with roles known to indirectly affect secretion were then 
filtered out, including those involved in apoptosis, mitosis, transcription, translation, and 
metabolism. Intracellular localization studies by immunofluorescence validated at least 
10 genes whose knockdown resulted in Golgi disruption. In humans, these proteins 
correspond to TANGO1 (Transport ANd Golgi Organization) and cTAGE1-8 (cutaneous 
T-cell lymphoma-associated antigen).  
TANGO1 (MIA3), a 1907-residue protein, colocalizes to ER structures containing 
Sec16L, a component of endoplasmic reticulum exit sites (ERES) in mammalian cells 152. 
It has an N-terminal lumenal portion that potentially interacts with collagen through a Src 
homology 3 (SH3) domain that recognizes proline-rich sequences, followed by a 
transmembrane domain, and a cytoplasmic coiled-coil and C-terminal proline-rich 
 
 35 
domain (PRD) 153. The PRD of TANGO1 was demonstrated to directly interact with 
COPII components Sec23/24 but not Sec31 by yeast 2-hybrid, providing further evidence 
of its ERES localization. However, the connection to collagen was made by identification 
of type VII collagen as a binding partner by mass spectrometric analysis of TANGO1 
immunoprecipitates from HeLa extracts. Furthermore, given the ERES localization and 
the observation that knockdown of TANGO1 expression by siRNA in human fibroblasts 
and keratinocytes led to a specific reduction in type VII collagen secretion, it was 
concluded that TANGO1 was a type VII collagen-specific cargo receptor 152. Although a 
direct in vivo interaction between the SH3 domain of TANGO1 and collagens other than 
type VII has not been reported, Mia3/Tango1-null mice are perinatal lethal due to global 
defects in collagen secretion 154. Increased intracellular accumulation in culture and 
reduction of extracellular matrix deposition in tissues of several collagen types was 
observed, including interstitial fibrillar collagens (I, II, III) in murine fibroblasts, and 
basement membrane collagens (IV) in endothelial cells.  
Follow-up analyses of TANGO-like proteins have revealed additional insights into 
collagen export from the ER 155. Costaining with Sec31A, but not with ERGIC53 or the 
COPI component β-COP, determined that cTAGE5 also localized to ERES. Although 
cTAGE5 is structurally similar to TANGO1, it lacks an SH3 collagen binding domain. 
Immunoprecipitation of either cTAGE5 or TANGO1 pulls down the other protein, 
suggesting the two form a complex at the ERES; binding in vitro occurs 
stoichiometrically in a 1:1 ratio. This interaction occurs between the corresponding 
coiled-coil motifs in each protein, but does not involve the PRD domain of TANGO1, 
since constructs lacking this domain are still able to from a complex. Yeast two hybrid 
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assays have shown that, similar to TANGO1, the PRD domain of cTAGE5 directly 
interacts with Sec23/24. Furthermore, knockdown of cTAGE5 expression results in 
decreased secretion and increased intracellular accumulation of collagens. As neither 
TANGO1 nor cTAGE5 have been observed at locations other than ERES, a model has 
been proposed suggesting that the primary role of these components is to block 
recruitment of Sec13/31 long enough to allow continued growth of collagen-containing 
COPII carriers 156. One can also hypothesize that further specificity of large cargo is 
obtained by TANGO1 interactions with different cTAGE partners, however no evidence 
for this yet exists.  
Another protein that has recently been shown to interact with TANGO1 is Sedlin 
(TRAPPC2), encoded by SEDL 146. Mutations in SEDL result in Spondyloepiphyseal 
dysplasia tarda (SEDT), which phenotypically overlaps the osteochondrodysplasias 
caused by structural defects in type II collagen, encoded by COL2A1 157-159. The 
pathophysiology of both disorders has been linked to defects in secretion of components 
of the extracellular matrix 160. In chondrocytes, SEDL knockdown blocks ER export of 
type II collagen, but not VSVG. Selective ER retention of type I collagen by SEDL RNAi 
is also achieved in fibroblasts, while export of noncollagenous proteins such as CD8α, 
albumin and α1-antitrypsin remains unaffected. Co-immunoprecipitation confirmed a 
direct interaction between TANGO1 and Sedlin in these cells, explaining the selective 
effect on collagen secretion. Overexpression of TANGO1 increases Sedlin recruitment to 
the ERES and increased collagen export from the ER. Conversely, TANGO1 depletion 
decreases recruitment of Sedlin to the ERES. These findings prompted investigators to 
further characterize the role of Sedlin in collagen export from the ER 146. Western 
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analysis demonstrated increased levels of Sar1-GTP in Sedlin-depleted cells, findings 
that were duplicated in cells depleted of the TRAPP-I complex component Bet3 161. 
Given these findings and since immunofluorescence detects overlapping signals for 
SEDL and Bet3 at ERES, investigators have hypothesized that, as a TRAPP-I 
component, Sedlin directly regulates activity of Sar1. This hypothesis is plausible given 
that in vitro Sedlin is the only TRAPP-I subunit that binds to Sar1, and Sedlin 
immunoprecipitates from cell lysates with Sec23 only in the presence of Sar1. In 
addition, fibroblasts from patients with SEDT reveal budding collagen-containing 
vesicles at the ERES that are reduced in size, suggesting TANGO1 and TRAPP-I 
coordinate growth of collagen megacarriers at ERES by regulation of Sar1 activity. 
Further investigation should aim to characterize the nature of the interaction between 
TANGO1 and the SEDL-Sec23-Sar1 complex. 
While investigating the role of ubiquitylation enzymes in stem cell division, Jin and 
colleagues observed that knockdown of the ubiquitin ligase CUL3 caused mouse ES cells 
to become compacted and nonproliferative. This phenotype was reversed by growth on 
exogenously derived extracellular matrix 162. Absence of cell surface integrins was noted. 
The preliminary findings suggesting a role for ubiquitylation in integrin-mediated cell-
matrix interactions, since in the absence of surrounding extracellular matrix, cells 
endocytose plasma membrane-bound integrin receptors 163. Mass spectrometry of affinity 
purified proteins capable of binding CUL3 revealed KLHL12 as the partner of CUL3 in 
ubiquitin ligase. Additional affinity purification procedures to isolate substrates of  
CUL3-KLHL12  identified the COPII components SEC13/31 as binding partners. 
Immunoprecipitation further refined this interaction as occurring between KLHL12 and 
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SEC31. These surprising observations correlated with studies colocalizing SEC13/31 and 
KLHL12 at ERES, as well as COPII coats of forming large vesicles. More importantly, 
transfection of cells with mutant forms of KLHL12 resulted in loss of monoubiquitylation 
of SEC31, and absence of collagen-containing large vesicle formation at ERES. Loss of 
ubiquitylation of COPII components results in accumulation of type IV collagen, with no 
effects on secretion of other cargoes such as fibronectin or EGF receptor. How 
ubiquitylation of SEC31 regulates vesicle size is unknown. Since ubiquitylation is known 
to target substrates to the proteasome, one possible explanation is that degradation of 
outer components of the COPII coat allows for continued growth of vesicles. 
Alternatively, modification of SEC31 may recruit an unidentified effector that delays 
COPII budding or promotes polymerization of vesicle coats 162.   
 
Post-ER Trafficking of Procollagens 
Little is known about intra-Golgi transport of procollagens. Based on serial sectioning 
and immunolabeling of procollagens released from scorbutic block, Miranov et al have 
described flattened and elongated tubular saccules, large enough to contain 300nm long 
procollagen trimers, protruding from the ER 149. Upon separation from the ER, these 
procollagen-labeled structures were found to consist of multiple saccules that were 
partially stacked and devoid of ribosomes. These investigators proposed that multiple 
procollagen-containing saccular structures from the ER fuse to form new cis-Golgi 
cisternae. By following a synchronized wave of procollagen with antibodies recognizing 
helical collagen, Bonfanti et al have observed procollagen trafficking from the ER 
through the Golgi apparatus. In this study collagens were released from the ER of 
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scorbutic fibroblasts in a synchronized wave of migration into and through the Golgi and 
followed by immunoelectron microscopy. As expected, COP-I and clathrin coated buds 
and vesicles were observed in the vicinity of Golgi cisternae. However, no collagen-
labeled vesicles were observed to separate from the Golgi stack during maturation of 
collagen-containing cisternae 144. Thus the small amount of evidence so far obtained on 
trafficking of collagen through the Golgi apparatus is consistent with a model for 
cisternal maturation, in which cargo progresses in an anterograde direction without 
exiting the cisternae in which it is contained. 
In both corneal epithileal cells and tendon fibroblasts, packaged collagen molecules 
have been observed to be transported to the cell surface and released into the pericellular 
space via “collagen condensation vacuoles” 164. These collagen-filled vesicles were also 
found to be fused with the cell membrane and open to the cell exterior with portions of 
their contents protruding into the extracellular space. The vesicular membranes contained 
on their cytoplasmic surface an unknown coat material, similar to that described on 
coated vesicles by Roth and Porter, and later described as clathrin 165,166. There is some 
evidence to suggest that the late secretory pathway is involved in the initial organization 
of collagen fibrils 167. Using a combination of three-dimensional electron microscopy 
(serial section reconstruction) and biochemical approaches, Kadler’s group has shown 
that during embryonic development processing can occur within Golgi to PM carriers 
(GPCs) co-transporting procollagens with propeptidases. Furthermore, these GPCs were 
found to extend to the plasma membrane, where they protruded from the cell surface. 
These plasma membrane extensions, termed “fibripositors”, were observed to deposit 
pre-assembled collagen fibrils in alignment with the existing matrix 168. However, these 
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findings have only been observed in murine embryonic tendon fibroblasts and likely 
represent a developmental and tissue-specific response to the requirement for maximal 
matrix deposition in the growing organism. It was not noted whether clathrin associated 
with the cytoplasmic surface of fibropositor membranes. At later stages of development 
procollagen is secreted into the pericellular environment and processed for lateral 
accretion into growing fibrils. 
 
Procollagen Processing 
Upon secretion into the extracellular matrix, the N- and C-terminal globular domains 
of procollagen are cleaved by specific propeptidases. Since procollagen molecules are 
secreted as highly concentrated bundles into the pericellular space, the propeptides 
provide solubility to the molecule while ensuring steric constraints that prevent premature 
fibril formation. In fact, persistence of type I collagen N- and C-propeptides in tissues 
results in disorganized collagen fibrils with abnormally decreased diameters 169,170. 
However, immunoelectron microscopy studies have provided evidence that suggests a 
normal role for the presence of propeptides of types III and V collagens on heterotypic 
fibril surfaces in maintaining fibril diameters 171,172.   
The first evidence for the existence of processed fragments of type I procollagen 
came from observations that fragile skin in cattle with dermatosparaxis was caused by a 
defect in the cleavage of N-terminal portions of type I procollagen 173. Since cell extracts 
from unaffected cattle were able to remove the retained N-terminal portions of 
procollagen from the affected cattle, this defect was attributed to absence of a specific N-
propeptidase. Since this initial study, it has been found that three procollagen N-
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proteinases from the ADAMTS (a disintegrin and metalloproteinase with 
thrombospondin motifs) family of metalloproteinases are involved in specific cleavage of 
type I procollagen 174. The prevalent type I procollagen N-propeptidase, also known as 
ADAMTS-2, cleaves the Pro-Glu and Ala-Glu bonds in pro-α1(I) and pro-α2(I) N-
telopeptide regions, respectively 175. Procollagen N-propeptidase requires a substrate with 
a correctly folded hairpin conformation, as demonstrated by the loss of cleavage of 
procollagens that are either heat-denatured or misfolded due to structural defects 176,177. 
Misfolding of the cleavage site occurs due to splicing defects leading to absence of the 
cleavage site or substitutions in the first 90 residues of the helical region of type I 
collagen. In these cases missense and splicing mutations in α1(I) or α2(I) result in 
retention of N-propeptides and subsequent incorporation of pN-collagen into fibrils, 
leading to thinner diameter fibrils and causing Ehlers-Danlos types VIIA or VIIB, 
respectively, or Osteogenesis imperfecta/Ehlers-Danlos (OI/ED) phenotype 177,178. 
Although ADAMTS-3 and -14 can also process the amino propeptide of type I 
procollagen, their expression is insufficient to compensate for the absence of ADAMTS-2 
in cases of type VIIC Ehlers-Danlos syndrome, in which transverse images of patient 
dermal fibrils take on the appearance of “heiroglyphs” 169,179,180.  
The procollagen C-propeptidase was termed BMP1 (bone morphogenetic protein 1) 
because it was initially copurified from extracts of demineralized bone with other 
proteins that could induce ectopic bone formation when implanted into soft tissues of 
rodents 181. In addition to BMP1, procollagen C-proteinase activity is attributed to the 
alternatively spliced BMP1 mammalian tolloid protein (mTld) and two related homologs 
known as mammalian tolloid-like 1 and 2 (mTll1 and mTll2) 182-185. The activity of these 
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enzymes has been shown to be increased up to ten-fold by the procollagen C-proteinase 
enhancer (PCOLCE1 and 2) proteins, which bind to and induce conformational changes 
in the procollagen substrate 186-188. There is no dependence on substrate conformation for 
BMP1/type I procollagen C-propeptidase, which processes the C-propeptide by cleavage 
at the Ala-Asp bond in the C-telopeptides of the pro-α1(I) and pro-α2(I) chains 186,189. 
However, mutations that alter the peptide sequence of the substrate cleavage site in either 
of the alpha chains result in retention of C-propeptides. In kinetic experiments using 
purified C-propeptidase against type I procollagen substrate in vitro, Njieh et al 
demonstrated that propeptide cleavage occurs sequentially, with both α1(I) propeptides 
being processed before the α2(I) propeptide 190. Sequential cleavage is supported by in 
vivo data showing that patient fibroblasts with mutations of the α1(I) cleavage site 
produce very little mature collagen. However, patient fibroblasts with α2(I) cleavage site 
mutations produce collagen with mature α1(I) chains, but not mature α2(I) chains 191. In 
these patients, incorporation of pC-collagen into extracellular matrix causes smaller 
diameter fibrils with irregular cross-sections, leading to an osteogenesis imperfecta 
phenotype with unusually high bone mass 191. A similar phenotype, characterized by high 
bone density with recurrent fractures, was found in a consanguineous pedigree with a 
recessive missense mutation in BMP1 192. Defective C-propeptide processing in dermal 
tissue of Bmp1-knockout mice results in collagen fibrils that are thinner and have a 
“barbed wire” appearance, presumably due to extrusion of retained C-propeptides from 
the fibril surfaces 193. It is hypothesized that incorporation of partially processed 
procollagens with retained C-propeptides affects the normal mineralization process by 
increasing intrafibrillar spacing or acting as nucleators of mineralization 191. These 
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studies also demonstrate that, despite the expression of three unique genes encoding four 
tolloids, there is an absence of redundancy in the C-propeptidase activity of these 
enzymes. 
Beyond the well-described roles of propeptides in chain association, molecular 
solubility and prevention of premature fibrillogenesis, there is some experimental 
evidence of non-triple helical fragments of procollagen in regulating collagen expression 
by an inhibitory feedback mechanism. Weistner et al first described an inhibitory effect 
of type I and III procollagen N-propeptides on translation of type I procollagen mRNA in 
a cell-free system 194. Bornstein’s lab demonstrated that transfection of cDNA expressing 
type I procollagen N-propeptide reduces intracellular and secreted levels of type I 
procollagen, but not fibronectin, thrombospondin or SPARC in fibroblast cultures 195. 
Cell fractionation studies have also shown that decreased expression of collagen 
transcripts coincides with the appearance of radiolabeled C-propeptides in the nucleus of 
fibroblasts in culture 196. These findings are supported by the identification of propeptides 
bound to the plasma membranes of fibroblasts and endothelial cells, with subsequent 
internalization by receptor-mediated endocytosis 197,198. Furthermore, a mechanism for 
this process has been proposed following the identification of type I procollagen 
propeptide-integrin interactions in binding assays, in addition to the use of antibodies to 
α1β1 and α2β1 integrin subunits in blocking fibroblast attachment to C-propeptide-
coated surfaces in culture 199,200. However, it is not yet clear how internalized propeptides 








Collagen molecules that are secreted into the pericellular space self-assemble into 
higher order structures known as fibrils, which provide mechanical support, confer 
resistance to compressive forces within tissues, and mediate cell attachment to 
extracellular matrix. In bone, skin and tendon, collagen fibrils are comprised of a 
combination of unique collagen types, including type I, III, V and XI collagens, and are 
therefore considered heteropolymers 171,201. As viewed by electron microscopy, 
heterotypic type I collagen-containing fibrils appear cylindrical with a cross-striated 
periodic banding pattern (Figure 6). This appearance is a consequence of lateral assembly 
of collagen molecules (monomers) with a longitudinal displacement of approximately  
 
Figure 6. Collagen Fibril Structure. Upon secretion into the extracellular matrix, mature 
collagen molecules self-assemble into a quarter-stagger array. Visualization by electron 
microscopy reveals the cross-striated staining pattern of fibrils, referred to as the collagen D-




234 amino acids, commonly referred to as the “quarter-staggered array”202. For every five 
laterally aligned collagen molecules, this displacement creates alternating segments 
where all five monomers overlap and gap regions where only four molecules overlap. 
These repeating gap and overlap regions are approximately 67nm apart and comprise the 
collagen D-period. Although fibril formation is a self-assembly process driven by 
electrostatic and hydrophobic forces 203, regulation of longitudinal and lateral growth are 
separately achieved by several factors, resulting in a diverse array of fibrils that vary 
within and between tissues with respect to diameter, length and spatial organization.  
 
Fibril Nucleation 
Since the 1950s, investigators have sought to reproduce the process of collagen fibril 
formation in vitro to elucidate the mechanism of fibrillogenesis. Early in vitro 
experiments relied on the light scattering properties of soluble collagen monomers versus 
those of insoluble, aggregated collagens in solution 204,205. For instance, Gross and 
colleagues first observed that the opacity of a collagen solution increased with heating 
but decreased with subsequent cooling in a time-dependent manner 206. Increased opacity 
correlated with aggregated collagen that formed striated fibrillar structures similar to 
those observed in collagen-rich tissues by microscopy. These findings were quickly 
followed by those of Bensusan and Hoyt, who noticed that while the rate of opacity (i.e., 
fibril formation) could be influenced by collagen concentration, ionic strength and pH of 
the solution, there was always a preceding lag period for the reaction 204. The “lag phase” 
was believed to entail a nucleation event whose precise nature was unknown due to 
limitations of the turbidity method 207. However, the presence of a lag phase and the 
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requirement of a critical concentration for in vitro fibril formation suggested the existence 
of a template “microfibril” 208. Shortening of the lag phase and increasing the rate of fibril 
growth could be achieved in successive rounds of fibril formation and dissolution, 
presumably due to the presence of trace amounts of covalently bonded microfibrils. 
Indeed, these unbanded template microfibrils with diameters less than 15nm were 
isolated from lag phase reactions and identified by electron microscopy 209,210. Thus the 
nucleation event in fibrillogenesis was not driven by the formation of covalent bonds, but 
instead involved lateral alignment of monomers guided by electrostatic, hydrophobic 
forces and hydrogen bonding 211. It is during the ensuing exponential growth, termed the 
propagation phase, that fibrils with characteristic D-periods are formed 212.  
 
Regulation of Fibril Architecture 
Comper and Veis first noted an effect of the presence of specific residues within 
collagen monomers on fibril formation 213. Pepsin-resistant collagen helices, which are 
shorter than naturally processed collagens due to proteolysis of the entire telopeptide 
sequence, have a longer lag phase and higher critical concentration required for 
nucleation of fibril growth. Using synthetic peptides with sequences corresponding to the 
telopeptide regions, Prockop and Fertala were able to completely inhibit self-assembly of 
collagen I into fibrils in vitro, as detected by dark field light microscopy and PAGE 
analysis 214. Furthermore, far western analysis demonstrated that peptides with the α2(I) 
C-telopeptide sequence were found to bind directly to collagen I monomers in the region 
corresponding to residues 781-794. These findings were later confirmed by in vitro 
fibrillogenesis studies using collagens synthesized by fibroblasts from a patient whose 
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mutation resulted in deletion of these same residues. Fibrils formed from type I collagen 
lacking residues 766-801 of the α1(I) chain were longer than fibrils comprised of only 
normal control type I collagen 215. It was first noted by Kadler and colleagues that fibrils 
formed in vitro contained three distinct domains with two major sites for collagen 
binding: blunted ends that lacked growth, a central shaft with slow lateral growth, and a 
rapidly-growing tapered end 216. These data support a model for collagen fibril growth as 
a two-step process that determines the rates of lateral and longitudinal accretion of 
collagen monomers 217. In this model, disruption of either parameter affects the other; 
hence, delayed lateral accretion due to structural defects in collagen monomers results in 
increased length of fibrils 215. There is additional evidence for a role of lateral interactions 
between collagen monomers in determining fibril diameters. Type I collagen, which 
forms 50-100nm diameter fibrils, has a slower rate of fibril growth than types II and III 
collagens, which form 10-30nm diameter fibrils both in vitro and in vivo 218. These 
differences in fibril size are likely mediated by unique lateral interactions between 
heterotrimeric type I collagen monomers compared to homotrimer types II and III 
collagens.  
Other proteins, including small leucine-rich proteoglycans (SLRPs) and minor 
collagens are known to regulate formation of type I collagen heterotypic fibrils. For 
instance knockout of the Col5a1 gene in a lethal murine model of Ehlers-Danlos 
Syndrome results in absence of type I collagen-containing fibrils in the embryonic 
mesenchyme despite normal secretion of type I collagen, hinting to a possible role in 
fibril nucleation in vivo 219. Haploinsufficiency of either Col5a1 or Col11a1 results in 
type I collagen-containing fibrils with abnormally large diameters and disorganized 
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surfaces, supporting a role in the regulation of lateral growth of fibrils 220. The collagen-
binding proteoglycans decorin and biglycan interfere with type I collagen incorporation 
into fibrils, resulting in reduction of fibril diameters in vitro 221. These findings have been 
confirmed in vivo, in that mice lacking decorin or biglycan expression have larger 
diameter, disorganized type I collagen-containing fibrils in tendon, skin and bone 222. 
Space-filling representations of several proteoglycans model horseshoe-shaped SLRPs 
binding collagen molecules via their concave surface, thereby blocking lateral association 
of additional collagen molecules 223. Conversely, lumican- and fibromodulin-deficient 
mice exhibit fibrils with smaller diameters 222. Furthermore, a study of in vitro 
reconstitution of fibrils using differentially glycosylated collagens extracted from various 
tissues suggested that increased extent of modification results in longer lag phase, slower 
growth rates and thinner diameters of fibrils, possibly due to lateral steric hindrance or 
interference of hydrophobic or electrostatic interactions 224. These data demonstrate that 
fibril formation is regulated by specific interactions of type I collagen monomers with 
each other, as well as with other components of the extracellular matrix. 
 
Crosslinking 
The formation of covalent intermolecular crosslinks between collagen monomers is 
the final step of collagen biosynthesis. Crosslink formation not only stabilizes collagen 
fibrils but also provides tensile strength to the extracellular matrix (Figure 7). This 
reaction is now known to be catalyzed by the extracellular metalloenzyme lysyl oxidase 
(LOX), a monoamine oxidase that converts the side-chain amine group of specific lysine 
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and hydroxylysine residues to aldehydes 225. LOX is unable to oxidize free lysyl residues 
or lysyl residues within unhydroxylated collagens, which cannot form fibrils. Instead,  
 
 
Figure 7. Lysyl Oxidase-Mediated Collagen Crosslinking. Oxidative deamination of lysyl 
residues by lysyl oxidase is followed by a condensation reaction between specific telopeptidyl 
and helical lysyl residues. The structure of crosslinks is tissue-specific and is also determined 
by hydroxylation status of the lysyl residues. In bone, some divalent crosslinks (HLNL and 
DHLNL) can mature to trivalent crosslinks (LP and HP). Figure from Eyre and Weis 11. 
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oxidation of these residues occurs on collagen monomers at the surface of forming fibrils, 
or those contained within loosely packed aggregates, but not on mature native fibrils 
isolated from tissues 226. The aldehyde groups within the resulting allysine and 
hydroxyallysine residues then condense with corresponding aldehydes on adjacent 
collagen monomers 227-230. The majority of intermolecular covalent bonds have been 
demonstrated by mass spectrometry of CNBr and tryptic peptides to occur between lysyl 
(or hydroxylysyl) residues located at distinct positions in the telopeptide and helical 
regions of mature type I collagen: α1(I)Ntelo9LYS/HYL x α1(I)930HYL, 
α1(I)Ctelo16LYS/HYL x α1(I)/α2(I)87HYL and α2(I)Ntelo5 LYS/HYL x α2(I)933HYL. These 
intermediate divalent aldol condensation products form dehydrolysinonorleucine (Δ-
LNL), dehydrohydroxylysinonorleucine (Δ-HLNL) and dehydrodihydroxy-
lysinonorleucine (Δ-DHLNL) reducible crosslinks that contain Schiff base double bonds. 
Further maturation of crosslinks is not enzyme-catalyzed, but is instead spontaneous and 
reflects the local environment surrounding the crosslink site. In general, mature crosslink 
formation follows two pathways, depending on the tissue and types of complementary 
lysyl residues involved 231. In skin, crosslink formation predominantly involves allysine, 
nonglycosylated hydroxylysine and/or histidine residues. Along with LNL, HLNL and 
DHLNL, dermal tissue contains an additional reducible crosslink, tetravalent 
histidinohydroxy-merodesmosine (HHMD), as well as a nonreducible trivalent 
histidinohydroxylysinonorleucine (HHL), which forms at α1(I)Ctelo16LYS/HYL x 
α1(I)87HYL x α2(I)92HIS 232. The hydroxyallysine route for crosslink formation is found 
preferentially in load-bearing tissues such as bone, tendon (type I collagen), and cartilage 
(type II collagen). For the hydroxyallysine route, the formation of one trivalent 
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nonreducible 3-hydroxypyridinium (lysyl or hydroxylysyl pyrodinolines) crosslink from 
two pre-existing reducible divalent crosslinks occurs in most tissues except skin. The 
absence of this type of mature crosslink in dermal tissue may be due to its susceptibility 
to UV-induced bond alterations 233. The majority of hydroxypyridinium crosslinks occur 
at α1(I)Ctelo16LYS/HYL x α1(I)Ctelo16LYS/HYL x α1(I)/α2(I)87HYL, and less frequently at 





The collagen crosslinked into the extracellular matrix of bone tissue functions as a 
scaffold for the development of a multifunctional mineralized tissue. Together, the 
protein and mineral phases of bone tissue interact to form a composite material with 
mechanical, physical and biological properties that exceed its constituent components. In 
addition to giving structural support for the body and protection to organs, the bones of 
the skeleton also permit movement by acting as levers for muscles, maintain mineral 
homeostasis, serve as reservoirs for growth factors and cytokines, and provide an 
environment for hematopoiesis in marrow spaces. Furthermore, these functions are 
dependent on the material properties and strength of the tissue, determined by its 
architectural organization, mineral extent and structure, organic content and the rate of 





The Process of Bone Formation 
The bones of the skeletal system are formed through two distinct mechanisms, both of 
which involve initial condensation of mesenchymal osteochondral progenitor cells. The 
first type of bone formation process, intramembraneous ossification, occurs in the flat 
bones of the craniofacial skeleton and ribs. This process involves direct differentiation of 
mesenchyme-derived precursor cells into osteoblasts. In contrast, formation of the long 
bones, including humeri, tibiae and femurs, proceeds by a two-step process known as 
endochondral bone formation, where development of a cartilagenous anlage by 
chondrocytes precedes the development of ossified tissue (Figure 8). 
During embryonic development mesenchymal precursors aggregate at sites of future 
long bone development. These bipotential osteochondral progenitors differentiate into 
chondrocytes, which organize into columnar layers and secrete components of the 
cartilage extracellular matrix, including type II collagen and aggrecan. By the time 
formation of a cartilage “model” is complete, chondrocytes with unique proliferative 
capacity become organized along the longitudinal axis into distinct zones within the 
matrix. At the center, less proliferative cells become hypertrophic, express type X 
collagen and mineralize the surrounding cartilaginous matrix. Formation of this central 
ossified region, termed the primary center of ossification, is followed by vascular 
invasion of the mineralized matrix, allowing for the introduction of osteoclastic and 
osteoblastic progenitor cells. Osteoclasts secrete proteases that degrade the type II 
collagen-containing cartilaginous matrix, while osteoblast precursors differentiate and 
replace the degraded cartilage with a type I collagen-rich matrix. The primary center of 
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ossification then expands towards the ends of the cartilage model as cartilage is replaced 
by bone matrix. 
 
Figure 8. Endochondral Bone Formation and Mineralization. A, Endochondral bone 
formation begins with development of a cartilage model, followed by vascularization of the 
tissue and replacement with a mineralized matrix by osteoblasts. B and C, primary mineral 
deposition occurs on the surface and between collagen fibrils. D, cortical bone of the diaphysis. 
E, trabecular bone is located in the metaphyseal region of long bones. Bone formation diagram 
adapted from Gilbert 3. Mineral images adapted from Weismann et al, Beniash et al 4,5. Micro-




In long bones, secondary centers of ossification form at each end of the cartilage 
model so that a cartilaginous growth plate remains between the primary and secondary 
centers of ossification. Within the growth plate, chondrocytes are organized into zones 
that reflect their states of differentiation. Proliferative chondrocytes are found within the 
cartilage matrix farthest from the primary center of ossification. Closer to the 
mineralizing front, chondrocytes with high secretory activity are found in multicellular 
clusters. Adjacent to the primary center of ossification, hypertrophic chondrocytes are 
arranged into columns. These cells model and mineralize their surrounding matrix prior 
to cell death. Therefore, bone elongation occurs as a result of growth plate migration 
away from the primary center of ossification, accompanied by replacement of 
mineralized cartilage for bone.  
Bone formation without prior resorption on periosteal surfaces increases the size and 
modifies the shape of bone according to a genetic blueprint and in response to the 
prevailing mechanical loads applied 236. This process of initial bone formation and 
shaping, or modeling, occurs mainly during the growth phase of the skeleton but also 
during fracture healing. Altering the shape of a skeletal segment also requires resorption 
of some surfaces without replacement of the tissue, which is also considered modeling. 
The replacement of the cartilage anlage by mineralized tissue and development of a 
marrow cavity during early endochondral bone formation is a primary example of the 
process of bone modeling. Modeling is most active during embryonic development and 




Types of Bone 
The bone collar that forms between the growth plates eventually becomes a hollow, 
marrow-filled shaft termed the diaphysis. This tissue is composed primarily of compact, 
nonporous cortical bone. The outer periosteal surface of the diaphysis is an area of active 
bone deposition. The inner endosteal surface faces the marrow cavity, where bone 
resorption exceeds formation. Thus, the diaphysis and marrow cavity tend to expand with 
increasing age. Below the growth plates, bone is composed of a network of mineralized 
matrix with a sponge-like appearance, termed trabecular bone, that comprises the 
metaphysis. The secondary ossification center at each end of long bones, enclosed within 
the epiphysis, is also composed of trabeculae. Both trabecular and cortical bone are 
composed of osteons, which consist of concentric layers of mineralized tissue. These 
concentric layers, termed lamellae, acquire their extraordinary strength as a result of the 
alternating orientations of collagen fibrils within the rings. In cortical bone each osteon 
surrounds a Haversian canal, which contains the bone’s nerve tissue and blood vessels. 
 
Bone Mineralization 
The organic phase of bone is composed mostly of collagen fibrils, which function as a 
scaffold upon which calcification occurs. In addition to collagen, unmineralized matrix 
contains non-collagenous proteins believed to regulate mineralization, including 
proteoglycans, glycoproteins, and γ-carboxyglutamic acid-containing molecules, and 
phosphoproteins 4. The most important of these mineral-regulating proteins are the 
SIBLINGs (Small Integrin-Binding LIgand, N-linked Glycoproteins), which include 
osteopontin (OPN), bone sialoprotein (BSP), dentin matrix protein 1 (DMP1), dentin 
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sialophosphoprotein (DSPP), and matrix extracellular phosphoglycoprotein (MEPE) 238. 
Some of these proteins have been studied for their role in promoting or inhibiting 
mineralization in vivo and in vitro. DMP1, BSP and DSPP appear to promote 
mineralization, since they are highly acidic proteins capable of binding Ca++, while OPN 
has been reported to inhibit mineralization 239-242. The NCPs, collagen scaffold, and 
mineral components are deposited within the extracellular matrix by osteoblasts, 
demonstrating the central role that these cells have in bone modeling. 
The inorganic phase of bone tissue consists of hydroxyapatite, which forms a 
hexagonal crystal lattice made of calcium, phosphate, and hydroxide (Ca5(PO4)3(OH)). 
However, approximately 4-7% of bone mineral is apatite in which a phosphate group or a 
hydroxyl ion is substituted by carbonate 243. The mechanism for mineral nucleation and 
growth remains a controversial topic. An early hypothesis proposed direct nucleation of 
crystals by precipitation of apatite upon the surface of matrix components, which include 
NCPs as well as collagen. More recently, evidence has emerged for matrix mineralization 
as a cell-mediated process of vesicular delivery of mineral components. Specifically, 
vesicles have been observed by microscopy to bud off from the plasma membrane of 
hypertrophic chondrocytes and mineralizing osteoblasts, and associate with sites 
corresponding to initial mineral formation prior to matrix mineralization 244,245. Originally 
discovered by TEM analysis of growth plate cartilage and bone, these “matrix vesicles” 
have been described as 20-200nm spherical bodies bounded by a lipid bilayer, and often 
found associated with small crystals of apatite mineral 246-248. 
Proteomic and mass spectrometry analysis of components isolated from cartilage and 
osteoblast cultures has demonstrated that matrix vesicles are enriched in tissue non-
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specific alkaline phosphatase (TNAP), nucleotide pyrophosphatase phosphodiesterase 
(NPP1/PC-1), PHOSPHO1, annexins (ANX), integrins and phosphatidylserine (PS) 249. 
Identification of these components suggests a mechanism for mineralization. For 
instance, annexins are Ca++ and phospholipid binding proteins which form calcium 
channels through membranes 250. NPP1 suppresses mineralization by increasing the 
extracellular concentration of the calcification inhibitor, pyrophosphate (PPi), whereas 
TNAP promotes mineralization by hydrolyzing PPi and increasing the concentration of 
the mineralization promoter, inorganic phosphate (Pi) 251. Wu and coworkers have 
provided evidence for matrix vesicles binding to native, but not denatured Type I 
collagen via interaction with integrins and other proteins 252. Furthermore, Golub et al 
have described the appearance of hydroxyapatite crystals precipitating inside vesicles 251. 
Thus, it seems likely that mineralization proceeds by initial formation of apatite within 
vesicles and integrin-mediated binding of matrix vesicles to fibrils, followed by a mineral 
growth phase on the fibril (Figure 8).  
Bone matrix is not uniformly mineralized. Primary mineralization begins, on average, 
5-10 days after deposition of the organic matrix, and proceeds until approximately 50-
60% of the mineralizing region is filled 253,254. In early bone, mineralized tissue has a 
composition of approximately 25% organic, 50% inorganic, and 25% water. Following 
primary mineralization, the rate of mineralization slows down and a secondary phase 
begins. Propagation of the mineral from the surface to the interior of the fibril continues 
through the gap spaces, which accounts for the differences in the ratios of organic, 
inorganic and water components of bone tissue during development. At later stages of 
development, mature bone tissue has a composition of approximately 30% organic 
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material, 60% inorganic material, 7% water and less than 3% lipids 255. As bone tissue 
matures, mineral replaces water in the longitudinal gap spaces separating collagen 
monomers and between fibrils, a process that can take years to complete 254. 
 
The Cellular Components of Bone 
The cell type responsible for bone formation is the osteoblast (Figure 9). Although the 
events that regulate the development of osteoblasts from their precursor cells in vivo 
remain to be fully characterized, studies have demonstrated that these cells are derived 
from bone marrow mesenchymal stem cells (MSCs) that differentiate in response to local 
and systemic factors, including various cytokines, growth factors and hormones. In  
 
Figure 9. The Cellular Components of Bone. Old bone is removed (resorbed) by osteoclasts, 
which are myeloid cells that develop from the hematopoietic lineage. New bone is generated 
from osteoblasts that develop from mesenchymal progenitors in the bone marrow. Once they are 
completely encased within the mineralized extracellular matrix osteoblasts terminally 
differentiate to osteocytes. Bone health is regulated by a balance between osteoclasts and 
osteoblasts, which are able to influence each other’s activities through cell-cell interactions. 
Osteocytes function to monitor the status of the surrounding tissue. Figure from Nicholls et al 1. 
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addition to members of the TGFβ and WNT superfamilies, several interleukins and non-
collagenous proteins (NCPs) of the extracellular matrix affect osteoblast activity. Vitamin 
D3, parathyroid hormone (PTH), estrogen and leptin are among the systemic factors that 
influence recruitment and maturation of bone forming cells 256. However, MSCs in 
culture require only serum, ascorbate, the glucocorticoid dexamethasone, and β-
glycerophosphate to differentiate into committed osteoblasts 257. The initial signaling 
events associated with osteoblast differentiation occurs via Indian hedgehog (Ihh), which 
is required for endochondral bone formation 258. IHH induces expression of the 
transcription factor RUNX2 (Cbfa1), the master regulator in osteoblast differentiation. 
RUNX2 regulates the expression of osteoblastic markers such as type I collagen 
(Col1a1), bone sialoprotein (Ibsp), osteocalcin (Bglap2), and osteopontin (Spp1), all key 
components of mineralizing bone matrix. It is maximally expressed in osteochondral 
progenitors, as well as in early stages of osteoblastic differentiation. Runx2 KO mice 
display absence of intramembranous and endochondral ossification 259,260. An additional 
target gene of RUNX2 is Osterix (Sp7), which is essential for commitment of 
preosteoblastic cells to differentiate into mature matrix-producing osteoblasts 261.  
Osteocytes comprise over 90% of the cell population in adult bone. Formation of 
these cells was historically thought to be a passive process of osteoblasts becoming 
encased in osteoid that mineralizes, followed by terminal differentiation into osteocytes 
(Figure 9). However, osteocytogenesis involves changes in morphology and function that 
differ from matrix-depositing osteoblasts. As the osteoblast transitions to an osteocyte, 
the expression of genes required for matrix deposition shifts to those required for 
mineralization and tissue maintenance, including upregulation of osteocalcin (BGLAP2), 
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phosphate-regulating gene with homologies to endopeptidases on the X chromosome 
(PHEX), matrix extracellular phosphoglycoprotein (MEPE), dentin matrix protein 1 
(DMP-1), fibroblast growth factor 23, (FGF-23) and sclerostin (SOST) 262. These proteins 
are directly involved in the regulation of bone mineralization, since inactivating 
mutations in the genes that encode them result in a number of metabolic bone disorders. 
For example, autosomal recessive hypophosphatemic rickets in patients is due to 
mutations in DMP1 263. Phex mutations result in osteomalacia and rickets, owing to 
elevated levels of FGF-23 in osteocytes 264. Since both Dmp1 and Phex downregulate 
FGF-23 expression, mutations in these genes cause downstream defects in the role of 
FGF23 in maintaining normal phosphate levels, which in turn maintains normal bone 
mineral content. This occurs because, in the absence of either Dmp1 or Phex, FGF-23 is 
elevated in osteocytes and in the circulation, leading to phosphate excretion by the 
kidney, thereby reducing circulating phosphate, which is in turn responsible for 
osteomalacia and rickets 265. 
The primary morphological feature of the osteocyte is the formation of multiple 
branched filipodial processes, similar to dendrites, that extend towards the mineralizing 
front and vascular spaces in bone. This is an invasive process requiring cleavage of 
collagen and other matrix molecules by MT1-MMP, a membrane-anchored proteinase, 
the absence of which results in reduced dendritic processes 266. This unique 
morphological feature may be controlled by E11/gp38, also known as podoplanin, which 
is a specific marker of osteocytes 267. One of the proposed roles of these dendritic 
processes is to allow these cells to sense and communicate responses involved in mineral 
homeostasis and bone repair. This is made possible by virtue of a network of 
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interconnecting canaliculi within bone tissue in which osteocytic processes make 
intercellular connections through gap junctions consisting of connexins. Very little is 
known about the bone fluid that flows through the osteocyte canalicular system, except 
that a molecular weight/mass cutoff of 70 kDa, the size of bovine serum albumin (BSA), 
exists 268. However, this size cut-off would not exclude small signaling molecules.  
Mature osteoclasts are multinucleated cells of hematopoietic origin, derived from 
bone marrow mononuclear precursors of the monocyte-macrophage lineage 269, whose 
primary role in bone is to resorb existing bone tissue (Figure 9). Osteoclastogenesis is a 
multistage process that includes commitment, differentiation, multinucleation, and 
activation of osteoclast precursors. Analagous to the role of Runx2 in osteoblast 
maturation, the transcription factor PU.1 is responsible for commitment of precursor to 
the osteoclastogenic phenotype. PU.1-null mice are unable to form osteoclasts and 
macrophages, but are still able to form monocytes 270. Expression of the c-FMS gene, the 
receptor for M-CSF (macrophage colony stimulating factor), is dependent on both PU.1 
and MITF transcription factors. However, M-CSF can upregulate expression of its own 
receptor by stimulating PU.1 expression 271. Activation of c-FMS by M-CSF has been 
shown to be necessary for the proliferation and survival of osteoclast progenitor cells, and 
loss of function mutation in the Mcsf gene (op/op mice) results in an osteopetrotic 
phenotype due to the lack of osteoclasts 272. 
Differentiation and multinucleation of osteoclasts occurs upon interaction of RANK+ 
mononuclear precursors and a cell expressing RANKL. Osteoblastic cells in the bone 
marrow express two cytokines required for osteoclast precursor (OCP) differentiation 
into mature osteoclasts: macrophage-colony stimulating factor (M-CSF) and receptor 
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activator of NF-κB ligand (RANKL). M-CSF binds to its receptor, c-fms, on OCPs and 
activates signaling through MAPK and ERKs during the early phase of OCP 
differentiation 273. RANKL binds to its receptor, RANK, on the surface of OCPs, 
activating signaling through NF-κB, c-Fos, phospholipase Cγ (PLCγ) and nuclear factor 
of activated T cells c1 (NFATc1) to induce differentiation of OCPs into osteoclasts 274. T 
and B lymphocytes also express RANKL and promote osteoclast formation in pathologic 
states such as rheumatoid arthritis 275,276. Osteoclast formation and activity is also 
balanced by a number of cytokines, most notably by osteoprotegerin (OPG), which binds 
to RANKL as a decoy receptor and prevents its interaction with RANK 277. Thus the 
RANK/RANKL/OPG axis is considered a major determinant of bone resorption and bone 
mass.  
Activation of immature multinucleated osteoclasts to the mature bone-resorbing 
multinucleated osteoclast begins with the generation of a ruffled membrane in contact 
with the bone surface via αvβ3 integrin. Simultaneously, an intracellular actin ring forms 
the sealing zone, which isolates the resorptive microenvironment between the ruffled 
membrane and bone from the surrounding extracellular space. Osteoclasts resorb bone by 
secreting H+ via Atp6v0d2 and Cl− through the osteoclast chloride channel, ClC-7, in 
addition to proteases, such as cathepsin K and matrix metalloproteinases (MMPs), into 
the extracellular compartment beneath the ruffled part of their basal cell membrane to 
dissolve the mineral and matrix components of bone simultaneously 278. In addition to 
their role in bone resorption, osteoclasts also regulate differentiation of osteoblast 
precursors through RANK-RANKL interaction, participate in immune responses, and 
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secrete cytokines that can affect their own functions and those of other cells in 
inflammatory and neoplastic conditions affecting bone 279. 
 
Cellular Crosstalk 
Wnts are a family of 19 secreted glycoproteins involved in multiple signaling 
cascades essential for embryonic development and tissue regeneration. Binding of Wnts 
to Frizzled (Fzd) and its co-receptor LRP5/6 recruits Dishevelled (Dsh) to stabilize 
intracellular β-catenin, a signaling protein which enters the nucleus and complexes with 
T-cell factor/lymphoid enhancer factor (TCF/LEF) as a transcription factor 280. Several in 
vivo studies have demonstrated a role for Wnt signaling in the regulation of osteoblast 
survival and differentiation. For example, activating mutations in LRP5 in humans result 
in a high bone mass phenotype with decreased bone marrow fat content 281,282. 
Conversely, LRP5 inactivating mutations are the genetic cause of osteoporosis 
pseudoglioma (OPPG) syndrome, which is a recessive disorder characterized by low 
bone mass and increased marrow fat 283. Lrp6 KO mice are not viable and show defective 
limb development, while haploinsufficiency reduces total and trabecular bone mineral 
density 284,285. Conditional knockout of β-catenin in skeletal mesenchymal cells promotes 
chondrogenesis but inhibits osteoblasts differentiation 286. Knockdown in osteoblasts has 
also shown a role for β-catenin in postnatal bone remodeling in mice, since its absence 
leads to osteopenia and increased osteoclast recruitment 287. In addition, overexpression 
of Frzb (frizzled-related protein), a Wnt antagonist, blocks ectopic bone formation by 
human periosteal cells in mice 288. These studies have demonstrated that Wnts directly 
promote bone formation by activating target genes required for osteoblastic 
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differentiation, including Osterix, Runx2 and alkaline phosphatase (Alp), while 
simultaneously suppressing transcription of adipogenic transcription factor peroxisome 
proliferator-activated receptor-γ (PPAR-γ) 289,290.    
Another antagonist of Wnt which has received recent attention as a potential target 
for anabolic treatment of bone disease is Sclerostin (Scl), encoded by SOST. The role of 
Sclerostin in bone development first came to attention when the progressive skeletal 
overgrowth disorders, sclerosteosis and van Buchem disease, were found to be caused by 
inactivating mutations in the SOST gene 291,292. Loss of sclerostin activity in human 
patients is associated with high bone mass, abnormally increased osteoblast activity and 
elevated bone formation markers 293. These findings have been recapitulated in Sost KO 
mice, which have elevated bone density and bone mechanical strength 294. 
Overexpression of Sost in transgenic mice induces osteopenia by blocking the association 
of coreceptors Lrp5/6 with Fzd, which inhibits differentiation and stimulates apoptosis of 
osteoblasts 295,296. Thus by secreting sclerostin into the canilicular network of bone, 
osteocytes are able to regulate bone mass by inhibition of Wnt signaling 297. 
The transforming growth factor-beta (TGFβ) superfamily is a large family of growth 
factors that includes TGFβs, Nodal, activins, and bone morphogenetic proteins (BMPs). 
TGFβ is assembled as a biologically inactive propeptide homodimer, termed the small 
latent complex (SLC). The SLC is secreted into the extracellular matrix as a noncovalent 
complex with latent TGFβ binding proteins (LTBPs), which together are referred to as 
the large latent complex (LLC) 298.  Since LTBPs bind to fibrillins, which are major 
structural components of connective tissue microfibrils and elastic fibers, TGFβ can be 
retained in its latent form until it is released by osteoclast-mediated bone turnover. 
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Hence, many of the manifestations of Marfan Syndrome (OMIM #154700) in patients 
with mutations of fibrillin-1 (FBN1) reflect excessive TGFβ signaling, including aortic 
aneurysm and lung pathology 299. 
TGFβ transmits signals across the plasma membrane through formation of 
heteromeric complexes of type I and II serine/threonine kinase receptors (TGFβRs). The 
type I receptor is phosphorylated following activation of the type II receptor and initiates 
intracellular signaling through phosphorylation of Smad2 and -3 300. Activated Smads 
form a complex with co-Smad and Smad4 and translocate into the nucleus to direct 
transcriptional response involved in osteoprogenitor commitment, proliferation and 
differentiation 301. TGFβ1 has been shown to activate β-catenin signaling and modulate 
osteoblastogenesis in hMSCs 302. TGFβ1-deficient mice display reduced bone growth and 
mineralization 303. In humans, heterozygous missense mutations of TGFβ1 have been 
associated with Camurati-Engelmann disease (OMIM #131300), a rare autosomal 
dominant bone dysplasia with cortical thickening of the diaphyses of the long bones 304. 
TGFβ2 and TGFβ3 double knockout mice are embryonic lethal and lack the distal 
portions of the ribs 305. Since Tgfbr2 directly phosphorylates the PTH type I receptor 
(PTH1R) cytoplasmic domain, mice with Tgfbr2 deleted in osteoblasts have increased 
bone mass due to constitutive activation of PTH1R 306,307. PTH couples the processes of 
bone resorption and formation by enforcing simultaneous internalization of Tgfbr2 and 
PTH1R 307.  
The bone morphogenetic proteins (BMPs) were first identified as constituents of 
demineralized bone extracts capable of inducing endochondral bone formation 308. BMPs 
were subsequently purified from bovine bone and identified as members of the TGF-β 
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superfamily 309. Similar to the TGFβRs, there are two receptors subtypes, BMPR-I and 
BMPR-II, that dimerize upon ligand binding and transduce their signal through activated 
Smads 1, 5 and 8. BMP-activated Smads interact with Runx2 to induce osteoblast-
specific gene expression and differentiation 310. In human and rat marrow stromal cells, 
BMP2, 4, 5, 6, and 7 all have strong osteogenic capacity 311,312. Addition of BMP2 to 
these cells substantially increases ALP and BGLAP2 (osteocalcin) expression, while 
short-term exposure irreversibly induces bone formation 313,314.  
Since loss of either BMP2 or BMP4 results in embryonic lethality with severe 
impairment of osteogenesis, most studies utilizing mouse models for BMPs have relied 
upon conditional KO alleles to delineate their function in skeletal morphogenesis. Mice 
lacking BMP2 in long bones develop spontaneous fractures that fail to resolve 315. 
Combined loss of Smads 1, 5 and 8 results in severe chondrodysplasia 316, while deletion 
of either Smad1 or -4 in osteoblasts leads to lower bone mineral density, decreased bone 
volume, decreased bone formation rate, and reduced numbers of osteoblasts 317,318. 
However, not all BMP activity induces bone formation. BMP-3 limits skeletal progenitor 
cell differentiation to mature osteoblasts, Trabecular bone volume of BMP-3-deficient 
mice is two-fold greater than that of wild-type mice 319. Mice with conditional deletion of 
BMPR-IA in collagen-expressing tissues have increased bone volume and mass, with 
shortened limbs and growth deficiency, due to decreased osteoclastogenesis through the 
RANKL-OPG pathway, as well as inhibition of Wnt signaling through increased 
expression of sclerostin 320-323.  
It should be noted that signaling between bone cells is multidirectional and regulates 
both osteoblast and osteoclast recruitment and differentiation. For example, conditioned 
 
 67 
medium from osteocyte-like cells is known to support osteoblast differentiation, as well 
as mesenchymal stem cell differentiation, supporting the theory that osteocytes 
orchestrate bone remodeling through increased secretion of growth factor M-CSF 324,325. 
More importantly, immunohistochemical staining for RANKL enhances the visibility of 
dendritic processes of osteocytes, showing RANKL expression on these processes and 
suggesting that osteocytes support osteoclast formation. It has also been reported that 
apoptotic osteocytes are capable of inducing bone remodeling through an unidentified, 
RANKL-independent mechanism, by recruiting and evoking a phagocytic response from 
osteoclasts 326.   
Cellular crosstalk between osteoblast and osteoclast lineage cells, as described above, 
is the key mechanism by which bone tissue is replaced in the adult skeleton. This process 
of tissue turnover, or remodeling, is the only normal physiologic process for altering the 
organic and inorganic components of bone after puberty. The process of remodeling does 
not change the size or shape of a bone, but is instead a process of maintaining the health 
of the existing tissue. Resorption of existing tissue occurs at focally discreet points on 
endocortical and trabecular surfaces, followed by replacement with collagenous osteoid. 
During remodeling, osteoclasts and osteoblasts colocalize at the bone surface in bone-
remodeling compartments (BRC), which are separated from the surrounding environment 
by a monolayer of flat cells that show osteoblast-like cell markers 327. These bone-lining 
cells deposit a thin layer of collagen matrix, generating an enclosed “canopy” that 
surrounds the site of active bone remodeling 328. Canopy cells have also been reported to 
degrade matrix left over by osteoclasts by secreting high levels of MMP-13 at locations 
adjacent to the osteoclast-bone interface 329. Although little is known about canopy/bone-
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lining cells, it has been proposed that these cells represent early OB lineage cells that 
later differentiate into bone-forming osteoblasts 330. BRC canopies are physically 
associated with capillaries, which allows for recruitment of both osteoclast and osteoblast 
progenitors from the bone marrow, and pre-osteoclasts associate with canopy-capillary 
connection points 330.   
 
Assessment of Bone Formation and Quality  
Bone strength, as defined by resistance to fracture under normal loading conditions, is 
determined by material and structural properties 235. The cortical femoral diaphysis is 
structurally similar to a tube, and its geometric properties can be calculated from 
measurements of cortical dimensions to provide estimates of bone strength. The predicted 
strength, or moment of inertia (MOI), reflects both the amount and distribution of tissue 
in cortical bone and correlates well with breaking strength. Independent of size and 
shape, the material properties of bone encompass the properties of the constitutive 
components of bone, including the organic and inorganic phases of the mineralized tissue 
331. In healthy bone tissue, the mineral density distribution (BMDD), as determined by 
quantitative backscattered electron imaging (qBEI), should reflect a heterogenous 
density. Heterogeneity of mineral density encompasses newer, less mineralized tissue, 
and older, more mineralized tissue. A higher rate of turnover, as is seen in osteoporosis 
and other bone pathologies, is indicated by an increased fraction of tissue with mineral 
density that is lower than in healthy bone since there is less time for secondary 
mineralization to occur 332. In contrast, a decreased rate of bone turnover will result in a 
shift to greater mineral density. Although it is counterintuitive to consider mineral density 
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higher than normal as detrimental to bone strength, mineral increases the stiffness of 
bone. This property of mineral causes bone to become more brittle, requiring less energy 
to fracture 333. Thus, hypermineralized bone may be just as susceptible to fracture as 
undermineralized bone.  
Bone strength, however, is not only determined by the amount of mineral, but also by 
the number, size and orientation of bone mineral crystals. Crystallinity, as measured by 
Fourier-Transform Infrared Imaging (FT-IR) Spectroscopy, is a parameter that expresses 
crystal size and perfection 334. Homogeneity of crystal, with a preponderance of either 
small or large crystals, is associated with increased bone brittleness as is seen in 
osteoporosis 335. An additional component contributing to bone material properties is the 
organic (collagen) phase. Increased collagen content relative to mineral indirectly 
decreases the stiffness of bone by lowering the BMDD. Furthermore, collagen crosslinks 
provide tensile strength to bone tissue by increasing its flexibility, allowing it to absorb 
energy on impact. Both mineral and collagen content of bone tissue can be assessed by 
Raman spectroscopy, since differences in mineral or organic matrix composition affect 
the Raman spectrum. Alterations of vibrational frequencies of amide groups of collagen, 
and phosphate and carbonate groups of bone mineral can be used to determine 
differences in mineral-to-matrix ratios, as well as crystallinity 336.    
The structural properties of bone are described by the microarchitecture and geometry 
of the bone tissue 235, which can be assessed by magnetic resonance imaging (MRI) and 
computed tomography (CT) 337. For cortical bone, diameter and thickness (CtTh) have a 
dramatic impact on mechanical integrity 338. Long bones are geometrically similar to 
tubes, making the periosteal radius, cortical cross-sectional area (CsAr) and length factors 
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that contribute to bone strength, in addition to material properties. In fact, increased bone 
strength is associated with increases in cortical diameter and thickness, while individuals 
with thinner cortices are at an elevated risk for fractures 339. Also, increases in tissue 
porosity can be caused by an imbalance of bone formation and resorption during 
remodeling as the individual ages, contributing to decreased bone strength. In trabecular 
bone, the microarchitecture of the trabecular network has a substantial affect on bone 
strength. Trabecular bone volume (TrBV), which is a reflection of trabecular number 
(TbN) and thickness (TbTh), determines strength in a non-linear manner 340. Also, the 
orientation of trabeculae relative to loading, as well as their connectivity, can determine 
the extent to which strain is resisted 341. Bone with widely separated, thick trabeculae 
having few connections is less resistant to compressive forces than bone with numerous, 
highly connected trabeculae because increased connectivity reduces the area that is 
unsupported 342. Still another parameter for bone strength is anisotropy, which is the trait 
of an object that possesses different values for a given parameter, such as strength, when 
measured in different directions. In trabecular bone, an anisotropic structure is one that 
would demonstrate different strength or mechanical integrity attributes dependent on the 
direction of loading. Accordingly, femoral trabecular tissue is better constructed to 
withstand applied vertical loads compared to horizontal stresses.  Anisotropy of 
trabecular bone is not only affected by trabecular thickness, orientation, and connectivity, 
but also by material properties 343. 
The contributions of the structural and material properties of bone can be determined 
by examination of its mechanical properties. Like other objects in nature, the application 
of force to a segment of bone will result in the generation of an internal resistance known 
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as stress. Stress, expressed as force/area, is equal in magnitude but opposite in direction 
to the applied force. Three types of stress exist: tension (stretching), compression and 
shear (parallel, but opposite forces produced by torsion). However, most forces applied to 
bone are a combination of these three types of stress. For example, bending of a long 
bone produces tensile forces on the convex side and compression on the concave side. 
The deformation of the bone, or strain, is the difference in the length of the long bone 
due to the stress. By knowing the size of the specimen, the force applied, and the extent 
of the deformation produced by that force, the mechanical properties of a bone sample 
can be deduced by analysis of the stress versus strain comparison 7. By convention, the 
loading condition (stress) is plotted on the y-axis and strain on the x-axis (Figure 10). 
The resulting curve plots the load-versus-deformation relationship. Two regions of the 
curve are used to define the material properties of the sample being analyzed. The linear  
 
Figure 10. Stress-Strain Curve for Cortical Bone. The relationship between load applied 
(stress) and resulting deformation that occurs (strain) for a given bone sample can be plotted as 
a stress-strain curve of bone loaded in bending. The slope of the curve within the elastic region 
is the elastic modulus and is a measure of the sample stiffness. The area under the curve 
indicates the amount of energy required for failure of the sample, and is independent of the 
size and shape of the bone (i.e., material properties). The yield point represents the amount of 
load required to permanently damage the bone. The post-yield strain is inversely proportional 




portion of the stress-strain curve, the elastic region, represents the amount of force that 
can be applied without inflicting permanent damage on the sample. In the linear region, 
the slope of the stress-strain curve represents the elastic modulus, which is a measure of 
the stiffness or rigidity of the sample. The maximum stress that can be applied without 
permanent deformation of the sample is the elastic limit; the point on the curve 
corresponding to this limit is the yield point. Further loading beyond this point will cause 
permanent deformation of the material, represented on the curve as the plastic region, 
and continues to the point at which the sample being analyzed reaches the breaking point 
(i.e., point of failure). The strength of a bone specimen is determined by calculating the 
maximum stress applied at the point of failure, and is referred to as the ultimate strength 
of the sample. When the various stresses that are applied to bone exceed the ultimate 
strength of the tissue, a fracture will occur.  
What information about bone material properties can be obtained by observation of 
its mechanical properties? Under certain pathological conditions, bone fails before 
undergoing permanent deformation; this lack of plasticity is characteristic of brittle 
material. In contrast, a flexible material will demonstrate a decreased slope within its 
elastic region, which will be shifted since the material can endure greater strain before 
reaching its yield point. However, more specific characteristics of bone material 
properties can be ascertained. Biomechanical testing of demineralized bone has 
demonstrated that the mineral component contributes the major portion of the tensile 
strength, while the slope of the plastic region is a function of the collagen component 344. 
Furthermore, the contribution of the mineral component to bone strength is a function of 
 
 73 
the crystallinity of the mineral 345. In general, elasticity (stiffness) is related to the mineral 
phase and plasticity (ductility, toughness) to the organic matrix 344,346. 
Another tool that is useful for investigating bone pathology is histomorphometry. 
Bone histomorphometry is a quantitative histological examination of an undecalcified 
bone biopsy to obtain quantitative information on bone remodeling and structure 347. 
Labeling agents taken before the procedure deposit at sites of bone formation allowing a 
dynamic analysis. Labeling fluorochromes, such as tetracyclines, are incorporated into 
the bone at sites of new bone formation, binding irreversibly to hydroxyapatite at the 
mineralization front. In animal models, bone formation is often measured by dual-calcein 
and xylenol-orange labeling. Administration of these fluorochromes, with a drug-free 
interval of 10 to 14 days between the two courses, results in the formation of dual-labeled 
sites where bone formation was ongoing during the entire labeling sequence. Bone 
histomorphometric parameters are assessed in two dimensions by means of histology, 
where the structural and remodeling parameters are measured on sections. The static 
parameters that can be obtained with this technique provide information about osteoid 
volume (OV/BV), given as the percent of a specified volume of bone tissue that consists 
of unmineralized bone (osteoid). More importantly, dual-labeled histomorphometry can 
yield informative dynamic bone remodeling parameters related to bone formation rate. 
Mineralizing surface (MS/BS, %) is a measure of the proportion of bone surface upon 
which new mineralized bone was deposited during the period of labeling. Mineral 
apposition rate (MAR), a measurement of the linear rate of new bone deposition, is the 
mean distance between the double labels, divided by the time interval between their 
application. Bone formation rate (BFR/BS), the amount of new bone formed in unit time 
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per unit of bone surface, is calculated by multiplying the mineralizing surface by the 
mineral apposition rate. In addition, the mineralization lag time (Mlt/day) represents the 
average time interval between osteoid formation and its subsequent mineralization, which 
is calculated by dividing the osteoid width by the apposition rate. Thus, dynamic 
histomorphometric parameters can provide insight into defects of osteoblast function and 




Osteogenesis imperfecta (OI), also known as Brittle Bone Disease, is a heritable 
disorder of connective tissue with an estimated incidence of approximately 1 in 15,000-
20,000 births 348-351. The most common clinical features of OI include bone fragility and 
deformity, and growth deficiency (Figure 11). Additional variable symptoms associated 
with OI include blue sclerae, hearing loss, dentinogenesis imperfecta and pulmonary 
deficiency 352. The original Sillence Classification, which preceded the identification of 
the molecular causes of OI, is used to describe the range of phenotypic severity in this 
disorder and is based on radiological and clinical criteria 348. Type I, the mildest form of 
OI, results from quantitative defects of type I collagen synthesis which causes an 
osteoporotic phenotype due to matrix insufficiency 353. More severe bone disease, 
including perinatal lethal type II, progressive deforming type III and moderate type IV 
OI, results from defects in type I collagen primary structure. An updated form of the 
original classification has been proposed to attribute the Sillence types only to cases with 
 
 75 
collagen quantitative and structural defects, with additional OI types assigned to recently 
discovered novel gene defects 354.  
 
Dominant Osteogenesis Imperfecta 
OI is primarily caused by dominant mutations in the two genes encoding the type I 
collagen α1(I) and α2(I) chains, COL1A1 and COL1A2, respectively. More than 1500 
independent OI-causing mutations have now been identified in these genes 116. A 
majority of these mutations (80%) are de novo single nucleotide changes that result in 
 
primary structural defects of type I collagen alpha chains, leading to glycine substitutions 
within the Gly-Xaa-Yaa amino acid triplet. The second most common mutations occur at 
splice sites, which lead to exon skipping or intronic retention 116. Nearly one-third of 
glycine substitutions in the α1(I) chain, but only one-fifth of substitutions in the α2(I) 
Figure 11. Clinical Features of Classical Osteogenesis Imperfecta. The hallmark clinical 
symptoms of osteogenesis imperfecta (OI) include growth deficiency, fractures from minimal 
trauma and blue sclerae. X-rays of OI probands reveal bowing and fractures of long bones, 
compression of vertebrae, and a bell-shaped rib cage. Severity of symptoms, including frequency 
of fractures, can vary and is described by the original Sillence Classification system. Figures 
courtesy of Joan C. Marini, MD, PhD.  
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chain, result in a lethal phenotype. Additionally, substitutions for glycine by residues 
with charged or branched nonpolar side chains are associated with the most severe 
clinical phenotypes. Lethality also correlates with position of the substitution on the alpha 
chain; those that occur within major ligand-binding regions (MLBR2 and MLBR3) of the 
collagen helix on the α1(I) chain and within α2(I) proteoglycan binding sites along the 
fibril are exclusively lethal 116. 
The mechanism by which collagen structural mutations cause disease is incompletely 
characterized. Collagen trimer formation begins with the association of pro-alpha chains 
through an alignment region in the carboxyl globular domains, followed by folding which 
proceeds toward the amino terminus in a zipper-like fashion. Since only glycine residues 
can fit into the sterically restricted inner aspect of the collagen helix, substitutions by 
amino acid residues with larger or charged side chains interfere with the folding process. 
The delay in helix folding caused by the glycine substitution in a collagen alpha chain 
exposes the portion of the chains amino-terminal to the substitution to the modifying 
enzymes in the endoplasmic reticulum for a longer period of time 355,356. Hence, defects 
in the primary structure of an alpha chain result in overmodification of all chains in the 
trimer. Detection of collagen overmodification, as observed by delayed electrophoretic 
migration of alpha chains on polyacrylamide gel electrophoresis, is the basis for the 
biochemical diagnostic test for classical osteogenesis imperfecta (Figure 12). A gradient 
in overmodification can be demonstrated by PAGE analysis of CNBr cleavage products 
of collagens harboring structural defects occurring along the alpha chain; substitutions 
located at the carboxyl terminus result in a greater extent of overmodification than those 




defects are believed to disrupt noncovalent inter- and intrachain bonds, leading to local 
unwinding of the triple helix. At the tissue level, abnormal collagen that is secreted into 
the extracellular matrix may disrupt cell-matrix and cell-cell interactions, collagen-
noncollagenous protein interactions, fibril formation, or mineralization of bone in a 
dominant-negative manner 354. However, the tissue-level pathologies in OI are ultimately 
due to defects in the structure of the collagen molecule itself. 
 
Mouse Models of Dominant Osteogenesis Imperfecta 
Although collagen is also the most abundant structural protein of the extracellular 
matrix of skin and tendon, the primary structural defects of type I collagen result in a 
clinical phenotype defined primarily as a bone disorder. The invasive nature of bone 
tissue procurement and scarcity of pediatric normal control and OI bone tissue has 
Figure 12. Standard Biochemical Determination of Type I Collagen Overmodification. 
Pepsin digestion of radiolabeled procollagen removes the propeptides from the molecule. The 
resulting collagen molecules are electrophoresed on SDS-Urea polyacrylamide gels and 
visualized by autoradiography. Structural defects in the collagen molecule delay folding of the 
helix and expose the alpha chains to the post-translational modification enzymes for a longer 
period of time. Due to the carboxyl to amino direction of folding, a gradient of 
overmodification can be detected and correlates with the position of the structural defect on the 
alpha chain. Figure adapted from Marini et al 2. 
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limited the majority of the investigations on human samples to skin and fibroblasts. The 
generation of mouse models of OI has made it possible to investigate the relevant tissues 
and cells involved in OI pathology. Mouse models of dominant OI that express mutant 
collagen transgenes have been generated but their usefulness is limited since they reflect 
a mosaic condition, consistent with a less severe phenotype than in fully-expressing 
heterozygous OI patients 358-360.  
Three murine models of OI are currently in common use, including two mice with 
classical OI knock-in substitutions and a third mouse model that synthesizes type I 
collagen lacking an α2(I) chain. The Brtl mouse, which was the first knock-in murine OI 
model developed , is heterozygous for a missense mutation in Col1a1 that results in an 
α1(I) G349C substitution 361. This mouse reproduces the molecular and phenotypic 
features of the child with moderate type IV OI on whose mutation it was modeled 361. 
Heterozygous Brtl mice demonstrate a 30% perinatal lethality rate. Although surviving 
Brtl mice have normal life expectancy, they exhibit undermineralization of calvaria, long 
bones and vertebral bodies, flared rib cages with multiple beads of callus, and 
dentinogenesis imperfecta. Growth deficiency in the Brtl mouse is evident, as 
heterozygous mice weigh 30% (5-7g) less than their wild-type littermates. The Brtl 
mouse has been more thoroughly investigated than the α2(I) G610C mouse, also referred 
to as the OOA mouse since it models a COL1A2 founder mutation in an Old Order Amish 
population in the Ohio River Valley 362. The phenotypically less severe α2(I) G610C 
mouse has mild to moderate OI (types I/IV), as is seen in the OOA population 362. 
Offspring are produced with normal Mendelian distribution, suggesting absence of 
perinatal lethality with normal life expectancy. The main features of this mouse model of 
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mild to moderate dominant OI include osteoporotic long bones and moderate growth 
deficiency; mice with the α2(I) G610C weigh approximately 10% less than wild-type 
littermates through their lifespan. The third mouse model with a collagen defect, the 
oim/oim mouse, is the most studied mouse model of OI. However, it should be noted that 
the specific mutation in this mouse strain is atypical of OI because it causes the 
occurrence of α1(I)3, which is not a normal component of bone or skin tissue. Oim 
harbors a naturally occurring single nucleotide deletion in the portion of Col1a2 that 
encodes the interchain alignment region of the C-propeptide, so that α2(I) chains cannot 
be incorporated into normal heterotrimers, resulting in synthesis and matrix deposition of 
exclusively α1(I) homotrimers in homozygous mice 363. A similar mutation has been 
described in only one human case, who harbored a 4-bp deletion in COL1A2, causing 
severe progressive deforming OI and leading to death from pulmonary complications in 
the 3rd decade 364. Interestingly, most of the small number of reported human cases 
lacking α2(I) chain synthesis have mutations at the N-terminus of the alpha chain, 
resulting in Ehlers-Danlos syndrome rather than OI 365,366, so homotrimer itself is not 
responsible for OI. Production of α1(I) homotrimers causes a severe phenotype in the 
mouse, including limb deformities, osteopenia, growth deficiency, skeletal fractures and 
progressive kyphoscoliosis. These features are consistent with the severe progressive 
deforming OI in the human patient, making oim the most severe mouse model of OI 
caused by collagen structural defects. Specifically, oim weighs 30% (7-15g) less than 
wild-type littermates throughout its lifespan and, unlike Brtl and OOA mice, suffers from 
spontaneous fractures of long bones and ribs.  
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Common bone features caused by collagen structural defects are revealed by µCT 
scans of trabecular and cortical bone. Brtl has proven to be especially useful for 
investigating the contributions of the organic and inorganic phases to bone strength 367. 
Brtl mice have significantly lower aBMD than their wild-type counterparts. Micro-CT 
analysis of 2-month Brtl bone has revealed femoral cross-sectional area (CSA) and 
cortical thickness (CtTh) that are decreased by 28% and 32%, respectively. Based on 
geometric parameters alone, the predicted bone strength of Brtl femurs is less than wild-
type femurs, with MOI that is decreased by one-half. Trabecular bone parameters also 
reflect the decreased bone mass in Brtl; BV/TV is decreased by one-third, due to 
decreased trabecular number (TbN). By 14 weeks of age, however, Brtl demonstrates 
slight improvements in bone structural parameters. CtTh and CSA are decreased 10% and 
14%, respectively, with MOI predicting a 10% decrease in bone strength compared to 
wild-type mice. Trabecular parameters at 14 weeks show BV/TV reduced by one-third 
and TbN decreased by 25%. In the α2(I) G610C defect mouse, micro-CT analysis of 2 
month femurs demonstrate a modest 10% reduction in cross sectional area with normal 
CtTh. Trabecular BV/TV and TbN are decreased by half compared to wild-type 
littermates. In the oim/oim mouse, whole bone structural properties reflect decreased 
bone matrix deposition with severe reductions in bone mass, femoral length, and femoral 
cortical thickness (CtTh) and cross-sectional area (CSA) throughout life 368-370. At 14 
weeks of age oim/oim mice, the severest of the three models, show 20% and 26% 
reductions in CtTh and CSA, respectively, versus wild-type mice 369. Trabecular bone 
parameters are also reduced; BV/TV is decreased 25% and TbN is slightly reduced by 
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6% compared to wild-type. These geometric parameters predict that oim/oim bone 
strength (MOI) is decreased by half. 
On mechanical testing, murine OI bone with collagen defects has reduced stiffness, 
breaking strength and post-yield displacement. Brtl bone on mechanical testing showed 
significantly lower stiffness (↓25%), yield (↓30%), ultimate load (↓33%) and post-yield 
displacement (↓50%). At 14 weeks Brtl bone has improved mechanics, with stiffness, 
yield load and ultimate load reduced 20%, 15% and 23%, respectively. Mechanical 
testing of α2(I) G610C femurs shows about the same extent of reduced bone strength as 
Brtl. While the mineral content of bone contributes substantially to its stiffness, collagen 
tends to dominate the properties of the post-yield region of the stress-strain curve. It 
would appear from the post-yield displacement that once the bone starts to break, the 
presence of the mutated collagen offers less resistance to complete failure in G610C OI 
mice, suggesting that the abnormal collagen in the bone is organized in a structurally 
abnormal manner due to the mutation and/or there is a general reduction in the amount of 
collagen per unit volume of bone. In oim/oim, mechanical testing has demonstrated a 
weaker bone than Brtl or OOA. Oim/oim femurs withstand significantly less load to 
failure (~50%) compared to wild-type bone; stiffness and ultimate load are comparably 
decreased. In addition, Oim/oim bone has significantly less post-yield deformation than 
wild-type bone 368,369,371. Interestingly, these reduced material properties do not exist on 
analysis of demineralized samples; the ultimate strains of wild-type bone matrix and 
oim/oim bone matrix are essentially equivalent 372. 
Bone mineralization is altered in all three OI murine models, all of which model the 
paradoxical hypermineralization of OI bone. The Brtl mouse demonstrates post-pubertal 
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adaptations in geometric parameters and material properties of Brtl femurs. From 2 to 3.5 
months of age the aBMD of Brtl femurs increased at a rate greater than wild-type, 
although aBMD remains decreased relative to wild-type mice at 1, 2 and 6 months of age. 
However, increased vBMD at these ages relative to wild-type mice, with a more dense 
and homogenous mineral content of cortical and trabecular tissue, illustrates the 
hypermineralization of bone that is found in patients with OI 367,373,374. Raman spectral 
analysis of Brtl bone also suggests a change in mineral:matrix ratios in Brtl; at 2 months 
of age the mineral:matrix ratio is greater than wild-type, but at 6 months of age the 
mineral:matrix ratio is significantly lower than wild-type 367. An additional difference 
between 2- and 6-month bone that was revealed by Raman analysis was that the mineral 
component of Brtl bone has a greater carbonate-to-phosphate ratio than wild-type. It is 
possible that this represents an alteration in non-collagenous components of the 
extracellular matrix that influence mineralization. The OOA mouse has not been studied 
in the same detail as Brtl. It does share the reduced femoral aBMD measured by DXA 
analysis, and the increased mineral:collagen ratio measured by Raman, and also found in 
Brtl. Altered mineralization of oim/oim bone has also been reported. Femoral tissue from 
these mice has a mineral phase with abnormal chemical composition, a two-fold higher 
mineral:matrix ratio, lower mineral carbonate content and less crystalline structure 375,376. 
In both cortical and trabecular bone qBEI analysis shows that bone tissue has a greater 
material density (increased Ca++ peak), while the heterogeneity of mineral content is 
decreased in cortical bone, but increased in trabeculae 369. However, the 
hypermineralization of oim/oim bone does not result in increased material strength. Thus, 
while the brittleness of oim/oim bone is largely related to disorganization of the mineral 
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phase, the abnormal collagen scaffold serves as a template for abnormal mineral 
deposition. Hypermineralization of bone tissue in the mouse models of OI is consistent 
with higher mean mineralization density in OI patient bone samples measured by qBEI. 
Histomorphometric analysis offers insight into cellular function in the Brtl and oim 
mouse models of OI. Brtl osteoblast surface/bone surface (ObS/BS), mineral apposition 
rate (MAR) and bone formation rate (BFR) are equivalent to wild-type at 2 months, 
suggesting quantitatively normal osteoblast matrix production at this age. However, Brtl 
mice demonstrate a postpubertal decline in MAR and BFR that reflects reduced matrix 
production by osteoblasts 377. The concurrent disproportionate increase in osteoclast 
number and activity in postpubertal Brtl bone by a RANKL-independent mechanism 
suggests a secondary effect of the matrix on these cells 377. These observations offer a 
possible explanation of how post-pubertal adaptions of Brtl bone occur, in which bone 
stiffness and strength attain wild-type values through stronger bone material properties, 
despite having reduced geometry 367. Importantly, the concurrence of improved bone 
parameters and development of cellular uncoupling in postpubertal bone of Brtl mice 
offers insight into patients with dominant osteogenesis imperfecta, in which fracture 
frequency is noted to decrease after puberty 378. Histomorphometric studies of oim/oim 
bone conclude that the fraction of mineralizing surface per bone surface (MS/BS) is 
significantly increased, while mineral apposition rate (MAR) and bone formation rate 
(BFR) are significantly decreased 379. Concurrent with decreased osteoblast functioning, 
bone remodeling in oim/oim mice is increased, as determined by greater levels of bone 
degradation products in urine 380. While the specific mechanism underlying dysregulated 
bone remodeling is unknown, increased osteoclast precursors with greater resorptive 
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activity in oim/oim have been observed 381, and may be due to a higher Rankl/Opg ratio 
and higher expression of TNFα in immature osteoblasts 382. 
Although the cellular and tissue data from mouse models increase our understanding 
of OI pathophysiology, they are limited by an imperfect correlation with findings in 
patients with OI. For example, the mechanism of bone dysplasia in mice with collagen 
structural defects is not the same in each model and also differs from OI patients. Neither 
Brtl nor oim has femoral histomorphometry that is identical to that reported from two 
groups of children with types III and IV OI, who have high bone turnover with coupled 
osteoblasts and osteoclasts 383,384.  The murine models do mirror the changes evident in 
bone structural parameters reported in two studies analyzing iliac crest bone biopsies 
bone from OI pediatric populations 383,384. Patients with collagen structural defects (types 
III and IV OI) in both studies demonstrated decreased structural parameters, including 
reduced CtWi, BV/TV, TbN and TbTh. Indicators of bone formation and turnover, such 
as decreased MAR and increased OcS/BS are found in both humans and mouse models of 
OI. In contrast to the mouse models, children with OI have increased ObS and BFR/BS, 
demonstrating the high turnover state of OI bone 383,384. However, the oim mouse has a 
higher rate of bone turnover than is seen in OI children, with relatively greater elevation 
of ObS, OcS, and BFR 380, compared with normal controls. OI children also have 
decreased MAR 383, in contrast to oim osteoblasts which maintain an MAR comparable to 
WT mice 380. In Brtl mice, there is an uncoupling of cellular responses; OcS is elevated, 
although ObS remains normal, and both bone formation rate and MAR are decreased. In 




Collagen-Related Osteogenesis Imperfecta 
In addition to the well-described collagen mutations, a new paradigm for 
osteogenesis imperfecta as a collagen-related bone disease has emerged with the 
discovery of novel gene defects. Among OI patients whose collagen modification was 
found to be normal, whole exome sequencing has identified mutations in SERPINF1 and 
IFITM5. In 2000, a subset of OI patients exhibiting a dominant mode of inheritance in the 
absence of COL1A1 and COL1A2 mutations were classified as having type V OI 385. 
These patients exhibited a distinct triad of distinguishing features, including calcification 
of the forearm interosseous membrane, a radiodense metaphyseal band at the growth 
plates of long bones and a tendency towards formation of hyperplastic callus at sites of 
bone trauma 385,386. Histological examination of type V OI bone described an irregular 
“meshlike” pattern of lamellar bone under polarized light in these patients. In 2012, two 
groups identified an identical heterozygous mutation in the 5’ untranslated region of 
IFITM5 (interferon-induced transmembrane protein 5), encoding the 15kDa osteoblast 
cell surface-localized bone-restricted ifitm-like protein (Bril) 387,388. The IFITM5 c.-
14C>T mutation, which introduces a novel upstream translation initiation codon, has 
since been found in all patients presenting with type V OI.  
SERPINF1 encodes pigment epithelium-derived factor (PEDF), a 50-kDa secreted 
glycoprotein that binds type I collagen and functions as an inhibitor of angiogenesis 389. 
Patients with deficiency of PEDF have a recessively inherited severe skeletal phenotype 
due to a mineralization defect, referred to as type VI OI 390. Alteration of the orientation 
of bone lamellae in type VI OI is described as a “fish-scale” pattern on polarized light 
microscopy 391.  
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The majority of the recent novel gene defects identified in collagen-related OI are 
recessively inherited and involve proteins responsible for post-translational modification 
or processing of type I collagen. For example, defects in the specific pericellular C-
propeptidase for type I collagen (bone morphogenetic protein 1, BMP1) have been 
associated with a high bone-mass form of OI 192. Interestingly, a similar phenotype is 
found in OI patients with dominant mutations in the C-propeptidase cleavage site of type 
I procollagen 191. Also, a mutation in SERPINH1, which encodes a collagen-specific 
folding chaperone (HSP47), has been characterized in a single case of severe recessive OI 
due to homozygosity for a missense mutation (p.Leu78Pro) 141. A missense mutation of 
SERPINH1 results in a similar severe phenotype in dachshunds 392. Homozygosity for a 
null SerpinH1 allele in mice results in a lethal phenotype 131. Deficiency of HSP47 causes 
delayed cellular secretion of collagen, which shows increased susceptibility to proteases 
in vitro, supporting a role for this protein in intracellular stabilization of the collagen 
helix. Mutations in FKBP10, which encodes the collagen chaperone and peptidyl-prolyl 
cis-trans isomerase FKBP65, result in a range of phenotypes that includes OI, OI with 
contractures (Bruck syndrome type 1), and a contracture syndrome with osteopenia 
(Kuskokwim disease) 102,393,394. Defects in FKBP65 result in deficiency of collagen 
telopeptidyl hydroxylation, a modification known to be catalyzed by lysyl hydroxylase 2 
(LH2; PLOD2). The overlapping phenotypes of Bruck syndrome type 2, caused by LH2 
deficiency, with FKBP65 deficiency suggests that interaction of these proteins is required 
for LH2 activity, or alternatively, that FKBP65 isomerase activity is required for the 




Collagen 3-Hydroxylation Defects: Recessive OI 
Recessive forms of OI were first postulated in the original Sillence classification. 
Although additional gene defects have since been identified, it was the discovery that 
deficiency of proteins involved in collagen prolyl 3-hydroxylation underlie the majority 
of recessive cases that generated the new paradigm for OI. This expanded view of OI as a 
collagen-related bone dysplasia was the result of the convergence of four independent 
lines of investigation incorporating bone histomorphometry, collagen biochemical 
analyses, genetic mouse models and clinical molecular genetics approaches to unsolved 
cases of severe to lethal bone disease. The importance of the collagen 3-hydroxylation 
complex to collagen assembly has been made clear by the characterization of a Crtap 
knock-out mouse, and null mutations of the genes encoding P3H1, CRTAP and CyPB in 
patients with severe or lethal bone dysplasia. 
Morello and colleagues demonstrated that CRTAP was important for development 
by characterizing its expression in several chick, murine and human tissues 395-397. Crtap 
was first identified in a subtracted cDNA library during screening for uniquely expressed 
genes in hypertrophic chick chondrocytes in culture 395. Northern analysis of mRNA from 
various embryonic chick tissues detected Crtap transcripts in tissues including skin, heart 
and lungs. Using an antibody raised against a short peptide sequence from the chick 
protein, Crtap expression was detected in tibial and femoral epiphyses, articular cartilage 
and lower hypertrophic cartilage. In human tissues, expression of CRTAP was identified 
in heart, lung, small intestine and skeletal tissue 397. A more direct role for Crtap in 
skeletal development was suggested by subsequent localization of transcripts to several 
murine tissues by in situ hybridization using the full-length cDNA as a probe. Murine 
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tissues containing high levels of Crtap transcripts corresponded to tissues also containing 
types I and II fibrillar collagens, such as the growth plate, bone collar and calcified 
cartilage of the chondro-osseous junction 107. This distribution of CRTAP was confirmed 
by immunohistochemical analysis using an antibody directed against CRTAP-specific 
peptides. Although light staining for CRTAP protein was identified in the cartilage 
matrix by immunohistochemistry, the majority of CRTAP was intracellular. Accordingly, 
co-transfection of murine chondrocytes with myc-tagged full-length Crtap cDNA and 
ER-targeted GFP showed colocalization of CRTAP with the endoplasmic reticulum. 
More specifically pertaining to bone, RT-PCR analysis confirmed expression of Crtap in 
both osteoblasts and osteoclasts 107.  
Prolyl 3-hydroxylase 1 (P3H1) is a multifunctional protein that has now been 
independently identified three times. It was first isolated from a rat yolk sac tumor cell 
line as a novel matrix chondroitin sulfate proteoglycan 398. A 100kDa protein was 
purified from a high-density proteoglycan fraction of conditioned media and used for 
generation of a polyclonal antibody. This antibody was subsequently used for 
immunoscreening of a rat cDNA library. The authors isolated a single clone, found to 
contain a fragment coding for the COOH terminal region of a novel cDNA. The sequence 
was used to isolate a full-length transcript by a cDNA capture assay, producing a 3.1 kb 
transcript predicted to encode a 728 amino acid leucine-proline enriched proteoglycan. 
The COOH terminal fragment was translated for production of a peptide to generate a 
polyclonal antibody for immunodetection. Termed Leprecan, the proteoglycan was 
detected in the ER and Golgi of CHO cells transfected with the full-length cDNA. 
Furthermore, despite containing a carboxyl terminus KDEL endoplasmic reticulum 
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retrieval signal, Leprecan was shown to be secreted by rat L2 cells and localized to 
basement membrane of several rat tissues by immunostaining. Using the polyclonal 
antibody recognizing the C-terminus to Leprecan, strong staining was seen in basement 
membranes of the vasculature and smooth muscle of several organs, including 
glomerulus, mesangial matrix and tubules of kidney, liver, and skeletal muscle, as well as 
the pericellular matrix surrounding chondrocytes in cartilage. 
The human homolog of Leprecan, Gros1, was isolated as a potential growth 
suppressor located at chromosome 1p31 399. In this study two alternatively spliced 
transcripts encoding 41- and 84-kDa proteins denoted as Gros1-S and Gros1-L, 
respectively, were identified. The first 360 residues of the 736 amino acid, 84 kDa 
isoform are identical to the predicted translated sequence of the Gros1-S variant.  Gros1-
S, however, utilizes a cryptic exon (exon 5b) in intron 5 while also retaining the entire 
intron 7 sequence, leading to a premature stop codon and, presumably, the generation of a 
truncated 363 amino acid peptide. This smaller variant would lack the carboxyl leucine 
repeat and P4H domain. Semiquantitative PCR analysis has demonstrated that Gros1-L is 
the dominantly expressed form in adult human tissues, such as heart, placenta, lung and 
kidney 400. In human fetal tissues Gros1-S predominates in brain and thymus, while both 
forms of the transcript are seen in equimolar ratios in liver, skeletal muscle, spleen and 
pancreas. It is important to note, however, that expression of the Gros1S variant has not 
been confirmed at the protein level. 
The isolation of the protein responsible for collagen 3-hydroxylation was 
accomplished when Bachinger and colleagues purified P3H1 106. By gelatin affinity 
chromatography, several proteins from rER extracts of chick embryos, including P3H1, 
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were shown to interact with denatured collagen alpha chains. A low pH elution fraction 
of the partially purified rER extract was then used to generate a monoclonal antibody to 
P3H1. Subsequent coelution of P3H1, CRTAP and CyPB from a P3H1 affinity column 
suggested the presence of a collagen-interacting complex in the ER. Immunostaining 
localized P3H1 to tissues expressing fibrillar collagens, such as dermis, cartilage and 
tendon. Additional staining was observed in kidney calyx, interlobular septum of the liver 
and smooth muscle layer of the aorta. In contrast to the staining pattern for Leprecan in 
rat tissues 398, no staining for P3H1 was seen in kidney cortex, liver parenchyma and 
skeletal muscle. These differences in immunostaining may be due to the use of different 
species (rat versus chicken) at different developmental stages (postnatal versus 
embryonic). More importantly, the antibody used to stain rat tissues recognizes the 
carboxyl half of the protein, which has a high degree of homology to the carboxyl halves 
of the P3H2 and P3H3 isoforms 2. The localization issue has been addressed by 
Myllaharju and coworkers, who have investigated the substrate specificity of the P3H2 
isoform and found that it preferentially 3-hydroxylated synthetic peptides corresponding 
to sequences found in type IV collagen compared to a peptide containing the type I 
collagen 3-hydroxylation site 400. Since basement membranes are rich in type IV 
collagen, it is possible that P3H1 is the primary isoform expressed in tissues rich in type I 
collagen while P3H2 functions in basement membranes. Support for this is seen in the 
pattern of immunostaining with polyclonal antibodies generated from synthetic peptides 
corresponding to regions of nonidentity in the murine P3H1 and P3H2 sequences. It was 
shown that P3H2 was strongly expressed in mouse tissues where basement membranes, 
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and therefore type IV collagen, are found, while staining for P3H1 was weak in these 
tissues 400. 
The third member of the 3-hydroxylation complex is peptidyl-prolyl isomerase B 
(PPIB), which does not have any structural similarities to CRTAP or the prolyl 3-
hydroxylases (P3H1-3). Peptidyl-prolyl cis-trans isomerase B (PPIB), also known as 
Cyclophilin B, is an immunophilin, a family of proteins with PPIase activity. 
Immunophilins are responsible for the catalysis of cis-trans isomerization of peptidyl-
prolyl bonds and are divided into three groups: cyclophilins, which are inhibited by 
cyclosporine A (CsA), FK506-binding proteins, and the parvulins. PPIB is known to play 
a central role in the in vivo folding of procollagens in the endoplasmic reticulum. 
Procollagen alpha chain association occurs at the carboxyl-terminal propeptides, which 
are the last portions of the polypeptide to be translated. Although the collagen triple helix 
can only accommodate peptide bonds that are in the trans conformation, there is 
sufficient time for the formation of an equilibrium state of unfolded alpha chains in which 
as much as 12% of X-Pro bonds in type I procollagen are in the cis conformation, as 
determined by nuclear magnetic resonance 401. Hence, it is the function of peptidyl-prolyl 
cis-trans isomerase to catalyze the efficient folding of procollagen alpha chains into the 
triple helical structure. PPIase activity is especially important for type I collagen folding, 
since nearly one-sixth of its primary sequence consists of proline residues. 
Evidence in support of the role of PPIB in collagen folding has been presented by 
Bachinger and colleagues, who used partially purified enzyme to study the in vitro rate of 
folding of type III procollagen 402. In this study the authors observed the formation of 
collagen helices in the presence and absence of PPIB, monitored by optical rotary 
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dispersion, as well as formation of protease-resistant collagen helices determined by 
PAGE analysis. It was concluded that PPIB increased the rate of folding 3-fold, and that 
cis-trans isomerization of the X-Pro bonds in collagen alpha chains is the rate-limiting 
step of helical folding 403. Complementary findings by Steinmann and colleagues 
supported an in vivo role of PPIB 108 in collagen folding. Treatment of fibroblasts with 
cyclosporine A (CsA) induced overmodification of type I collagen along the full length 
of the alpha chains. Since CsA binds to and inhibits the isomerase activity of PPIB by an 
incompletely characterized mechanism 404, it is believed that loss of cis-trans prolyl 
isomerization and subsequent delayed folding results in collagen overmodification. This 
was supported by amino acid analysis, which demonstrated an increase in the proportion 
of hydroxylysine residues from 21% of lysyl residues in normal control collagen to 28% 
of lysyl residues in treated cells. Furthermore, electrophoretic mobility of collagens 
synthesized during inhibition of modification by α,α’-dipyridyl in the presence of CsA 
was indistinguishable from collagens synthesized in the presence of α,α’-dipyridyl alone, 
showing that the delayed electrophoretic mobility of collagens synthesized in the 
presence of CsA was due to overmodification. These data demonstrate that direct 
inhibition of PPIB results in collagen overmodification and imply that helix folding is 
delayed. However, it has yet to be determined whether treatment with CsA disrupts the 
functioning of PPIB as a component of the 3-hydroxylation complex, or if CsA blocks 
PPIB from becoming a component of the complex. It should also be noted that CsA is a 
nonspecific inhibitor, and that its effect on collagen folding may not be due solely to 
inhibition of PPIB/CyB. Furthermore, defects in CRTAP or P3H1 have not yet been 
linked to defective isomerization of proline residues in collagen. 
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Cartilage-Associated Protein (CRTAP) Deficiency 
Identification of the first human cases of CRTAP deficiency paralleled 
characterization of the Crtap knockout mouse 109. To elucidate the in vivo function of 
CRTAP, a knock-out mouse was generated by replacing the first two exons of the Crtap 
gene with a neo cassette 107. This mouse model of Crtap deficiency had recessively 
inherited impaired bone development characterized as an osteochondrodysplasia, which 
included growth deficiency, osteopenia, shortening of the femurs (rhizomelia) and 
progressive kyphosis. Consistent with localization of Crtap to the growth plate, the 
proliferating chondrocytes of the Crtap-/- mouse were disorganized. Absence of CRTAP 
resulted in loss of 3-hydroxylation of the P986 residue in α1(I) chains of skin and bone, 
as well as α1(II) collagen chains of cartilage, demonstrating CRTAP’s in vivo role as a 
crucial component of the collagen 3-hydroxylation complex 107,405. The electrophoretic 
migration of collagen synthesized by Crtap-/- calvarial osteoblasts was examined; 
collagen bands were broad, consistent with post-translational overmodification. In 
addition, collagen fibrils in the extracellular matrix of skin and bone were reported to 
have increased diameters 107.  
Loss or decrease of type I collagen prolyl 3-hydroxylation in Crtap-/- mice has 
revealed multiple abnormalities of connective tissue, especially abnormal structural and 
material properties of bone 107,405. At the tissue level, absence of Crtap results in deficient 
production of osteoid and excess mineral in bone tissue. In 12-week trabecular bone 
BV/TV, TbTh and TbN are decreased 62%, 37% and 50%, respectively, while TbSp is 
twice that of wild-type mouse trabecular bone. The reduced structural parameters 
correlate with static and dynamic histomorphometric analysis, which demonstrates 
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reduced bone formation parameters in Crtap-/- mice 107. Both ObS/BS and MS/BS are 
normal, indicating normal osteoblast numbers. However, the mineral apposition rate 
(MAR) and bone formation rate (BFR/BS) are decreased 37% and 50%, respectively. 
Also, indices of matrix deposition in vivo, such as osteoid thickness (OTh), osteoid 
surface/bone surface (OS/BS), osteoid volume/bone volume (OV/BV) and mineralization 
lag time (Mlt) were significantly decreased 107. Hence, the osteoblasts in Crtap-/- bone 
tissue are producing matrix at a slower rate, but the matrix is mineralizing faster than in 
wild-type bone. These findings are supported by the BMDD in femurs from Crtap 
deficient mice, which reveals increased mineral content compared to wild-type mice 406. 
As expected, the heterogeneity of mineral (CaWidth) and the fraction of low mineralized 
bone matrix (CaLow) were highest in metaphyseal bone and lowest in the cortical 
midshaft, since metaphyseal bone is metabolically more active than cortical bone. 
However, in both cortical and trabecular bone the average (CaMean) and most frequently 
measured (CaPeak) calcium concentrations are increased in Crtap-/- as compared to wild-
type bone, indicating either a decrease of bone turnover or an alteration in mineralization 
kinetics. However, since surface-based parameters of bone remodeling (i.e., osteoclast 
numbers and activity) are normal in the Crtap-/- mice, the increase in mean and peak 
calcium concentrations is consistent with an increased rate of mineralization 107. This is 
presumably due to either a loss of the 3-hydroxylation modification or an altered 
collagen:noncollagenous protein ratio in bone tissue. Thus the bone phenotype of the 
Crtap knockout mouse generated interest among researchers investigating potential 
candidate genes for recessive OI. 
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With the development of diagnostic methods to completely sequence the type I 
collagen genes from patients with osteogenesis imperfecta, it became clear that 10-15% 
of these patients did not have collagen mutations. A subset of these patients were also 
shown to synthesize overmodified collagens despite the lack of a defect in collagen 
primary structure, suggesting that overmodification was caused by a defect in a protein(s) 
that interact(s) with collagen in the endoplasmic reticulum 2. In addition to the recessive 
osteochondrodysplasia of the Crtap-/- mouse and the association of P3H1 and CRTAP 
with denatured collagen, the mapping of type VIII OI and CRTAP to chromosome 3p22 
397,407 suggested that defects in components of the collagen 3-hydroxylation complex 
might cause recessive osteogenesis imperfecta. 
The first cases of recessive OI with collagen overmodification and absence of a 
primary structural defect were identified in three probands with severely reduced or 
absent CRTAP mRNA in fibroblasts by real-time RT-PCR 109. Sequencing of the gene in 
these patients identified mutations consistent with loss of expression of CRTAP. 
Furthermore, in fibroblasts of all probands no CRTAP protein was detected by western 
analysis. In both the Crtap knock-out mouse and patients with null mutations of the 
CRTAP gene, the resulting absence of this protein abrogates 3-hydroxylation of type I 
collagen; only 0-21% of α1(I) Pro986 residues were 3-hydroxylated as demonstrated by 
tandem mass spectrometry of trypsin-digested collagen peptides 107,109.  
It was demonstrated that loss of CRTAP protein resulted in delayed folding of the 
collagen triple helix; collagen alpha chains exhibited delayed electrophoretic migration 
on PAGE analysis. Amino acid analysis of type I collagen from CRTAP-null fibroblasts 
revealed an increase in lysyl hydroxylation compared to normal control collagen (31-35% 
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versus 24% respectively) 109. The additional hydroxylysine residues provide increased 
substrate for glycosylation, which is consistent with the 1°C increase in thermal stability 
of the patient type I collagens on differential scanning calorimetry. These findings 
showed that absence of CRTAP protein or loss of the putative collagen chaperone 
function of the 3-hydroxylation complex causes severe to lethal bone dysplasia. An 
additional potential mechanism by which loss of the 3-hydroxylation modification causes 
bone dysplasia was demonstrated by Valli and coworkers, who observed by 
immunofluorescence of long-term cultures severe deficiency (10-15% of control) and 
disorganization of collagen deposited in extracellular matrix of CRTAP-deficient 
fibroblast cultures 408. Interestingly, CRTAP deficiency in humans results in a more 
severe phenotype than in the knock-out mouse. 
 
Prolyl 3-Hydroxylase 1 (P3H1) Deficiency 
Demonstration that deficiency of CRTAP resulted in severe to lethal OI suggested 
that the other components of the 3-hydroxylation complex were candidates for remaining 
cases with suspected recessive inheritance. Shortly after reports of CRTAP deficiency as 
the cause of type VII OI, screening for loss of expression of LEPRE1 (P3H1) in patient 
fibroblasts identified an additional cohort with 3-hydroxylation defects 110. In all cases, 
severely reduced or absent mRNA could be partially rescued by treatment of the 
fibroblasts with emetine, suggesting that mutations in LEPRE1 triggered nonsense-
mediated decay (NMD) of transcripts due to the presence of a premature termination 
codon (PTC). Sequencing of the 15 exons and surrounding intronic regions of LEPRE1 
genomic DNA from each of these cell lines revealed the causative mutations, all of which 
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are consistent with the reduction of LEPRE1 transcripts, as the resulting frameshifts lead 
to introduction of a PTC. 
The first report of P3H1 deficiency as the cause of type VIII OI noted a common 
mutation, LEPRE1 IVS5+1G>T (c.1080+1G>T), in seven of the 14 alleles identified 110, 
all from infants of African-American or contemporary West African descent. The 
recurrence of this mutation was noted in additional probands of African-American and 
Caribbean descent and has been identified in approximately one quarter (22/86) of mutant 
LEPRE1 alleles reported to date 409-412. Subsequent screening of contemporary West 
African and African-American cohorts using a high-throughput SNP assay yielded a 
0.40% carrier frequency for the recurring mutation among Mid-Atlantic African 
Americans, predicting an incidence of type VIII OI at approximately 1 in 250,000 
African American births 413. In addition, nearly 1.5% of contemporary West African  
 
genomic DNA samples representing several ethnic groups from Ghana, Benin and 
Nigeria were identified as heterozygous for this mutation (Figure 13), predicting an 
incidence of type VIII OI due to homozygosity for this mutation at approximately 1 in 
Figure 13. West African Origin of LEPRE1 c.1080+1G>T Mutation. Homozygosity for the 
c.1080+1G>T mutation causes type VIII osteogenesis imperfecta. Approximately 0.4% of 
African-Americans from the Mid-Atlantic United States, and 1.5% of West Africans from Ghana 
to Nigeria are carriers for this mutation. The mutation was not identified in genomic DNA 




18,000 births 413, equivalent to the rate of dominant OI in American and European 
Caucasian populations. Haplotype analysis of 15 African American and West African 
families support the conclusion that this founder mutation arose between the 12th and 14th 
centuries and was transported to the Americas with the Trans-Atlantic slave trade 413.   
Consistent with the mutations and resulting degradation of transcripts, P3H1 protein 
was absent from proband fibroblasts on Western analysis. Only one of these patients had 
a residual level of protein from his paternal allele, presumably translated from the small 
amount of in-frame transcripts that were detected. It was also confirmed that absence of 
P3H1 abolished 3-hydroxylation of the α1(I) Pro986 residue in type I collagen. The 3-
hydroxylation modification at this residue was detected by mass spectrometry in 0-21% 
of α1(I) chains from the collagens synthesized by patient fibroblasts. Deficiency of P3H1 
also affects other modifications of the helical region of the type I collagen chains. Type I 
collagen chains synthesized by fibroblasts derived from each patient migrate as broad 
bands on SDS-gels, consistent with overmodification by lysyl hydroxylase and the 
glycosylating enzymes. Amino acid analysis showed hydroxylation of more helical lysine 
residues in patient collagen than in a control sample. In collagen secreted from P3H1-null 
fibroblasts, 32-35% of lysyl residues were hydroxylated, compared to 24% hydroxylation 
of lysine residues in normal control collagen. This extent of lysyl hydroxylation is 
comparable to the level of overmodification found in collagen with a structural defect 
near the carboxyl end of the helix, as well as with patients with CRTAP deficiency, and 
show an increased melting temperature of 1°C compared to normal control, which is the 
expected consequence of collagen overmodification in the absence of a primary structural 
defect 109,414. Since these data are consistent with longer exposure of the collagen chains 
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to lysyl hydroxylase it has been concluded that loss of P3H1 protein or its role in the 3-
hydroxylation complex results in delayed folding of the collagen helix, which results in 
the overmodification. Of note, no discernable collagen modification abnormalities have 
been detected in the parents who are heterozygous carriers for the LEPRE1 mutations; gel 
migration of parental collagen is normal, as are the levels of LEPRE1 mRNA on real-
time RT-PCR. Parental 3-hydroxylation was only slightly reduced to 85-90% of Pro986 
residues versus normal control collagen.  
There is an additional metabolic aspect unique to recessive OI caused by deficiency 
of collagen 3-hydroxylation components. In classical OI, overmodified collagen resulting 
from glycine substitutions is secreted slower than from normal control cells 415. Pulse-
chase experiments comparing fibroblast collagen synthesis from cases with P3H1 
deficiency and normal controls to observe collagen secretion kinetics demonstrate that, 
similar to classical OI, there is a 15-20 minute delay in the rate of type I collagen 
secretion from P3H1-null fibroblasts 110. However, in contrast to dominant OI, total 
collagen secretion per cell by P3H1-deficient cells is increased 20-50% compared to 
normal controls. Slower secretion of overmodified collagens is expected to cause ER 
stress with upregulation of the Unfolded Protein Response (UPR) pathway 416-418. Since 
the UPR response results in downregulation of translation, the occurrence of increased 
collagen synthesis in P3H1-deficient fibroblasts is counterintuitive but may hint to a 
direct or indirect role for P3H1 in regulating collagen synthesis and secretion, as well as 
proline metabolism 110. 
The P3h1-/- mouse, which contains a frameshifting deletion of exons 1-3 of the 
Lepre1 gene, has a phenotype similar to that of the Crtap-/- mouse. As with the Crtap-/- 
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mouse, collagen secretion and electrophoretic migration on PAGE analysis is delayed 419. 
These findings are consistent with the overmodification of lysine residues of type I 
collagen that was found in tissues; collagens have a 32-42% increase in lysyl 
hydroxylation, and 49-140% increase in glucosylgalactosyl-hydroxylysine content in skin 
and bone, respectively. P986 3-hydroxylation was completely absent in type I collagen 
from tendon, skin and bone 419,420. Collagen fibrils in dermal tissue of P3h1-/- mice have 
normal diameters, but are less dense and are interspersed with aggregates compared to 
wild-type skin, while fibrils from tendon are increased in diameter. Similar to 
observations in the Crtap-/- mouse, the net phenotypic effect of absence of the P3H 
complex components and the abnormal collagen that is deposited into extracellular 
matrix of P3h1-/- mice is 10-25% growth deficiency from 3 to 13 weeks of age, 
progressive kyphoscoliosis and rhizomelia. Long bone parameters are decreased, 
including a 7% reduction in CtA and 6% reduction in CtTh at 20 weeks of age. In 
addition to the 14% decrease in volumetric BMD, femurs from 20-week mice 
demonstrate 12-13% reductions in stiffness and force to failure, respectively, again 
demonstrating the weakness of bone tissue as a result of loss of prolyl 3-hydroxylase 
complex activity. However, a more detailed analysis of bone formation parameters, 
including mineral density and histomorphometric measurements, is lacking for this 
mouse model of recessive OI.  
 
Cyclophilin B Deficiency 
A total of eight human cases with PPIB mutations, causing type IX OI, have been 
reported 103,421-424. The majority of these mutations lead to PTCs or misfolded protein and 
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result in a severe to lethal phenotype 422,423. The probands with CyPB deficiency lack the 
overlapping phenotypic and collagen biochemical findings that are consistent with a 
dysfunctional 3-hydroxylation complex and observed for types VII and VIII OI, 
including the occurrence of rhizomelia. Of the four cases that have been investigated 
beyond mutation identification, two lethal cases have mutations that decrease collagen 3-
hydroxylation to 30-33% of α1(I) P986 residues. The two other cases of CyPB deficiency 
present with a moderate phenotype and normal levels of α1(I) P986 hydroxylation. The 
most interesting of the moderate cases, a PPIB mutation (c.26T>G) in siblings with 
moderate OI, defines the PPIB start codon 109. Although the NCBI Reference Sequence 
(NP_000933.1) for CyPB protein predicts a M9R substitution, it was never demonstrated 
which nucleotides of the cDNA sequence were utilized as the initiation codon 425. 
However, M1 is not evolutionarily conserved among species and expression plasmids 
lacking M1 produce functional protein 426. Furthermore, the complete absence of CyPB 
protein in guanidinium extracts of proband cell extracts after proteasomal inhibition 
demonstrated that PPIB c.25-27 was indeed the actual start codon 425. P3H1 and CRTAP 
levels are one-third and two-thirds normal in the PPIB-null cells by western analysis, 
demonstrating a non-critical role of CyPB in enhancing complex stability. However, 
despite the absence of CyPB, P3H complex activity is sufficient to normally hydroxylate 
α1(I) Pro986. This data suggests that partial modification of α1(I) P986 in two of the 
reported cases of PPIB deficiency may be a result of a truncated CyPB protein product 
that interferes with complex function. Furthermore, normal collagen modification in the 
total absence of CyPB suggests a normal rate of folding, and supports the existence of 
additional cis-trans isomerases involved in collagen folding in human cells 421. 
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As with humans, absence of CyPB protein causes severe bone dysplasia in mice. A 
Ppib knockout mouse containing an out-of-frame exon 2/4 junction has non-lethal 
recessive OI 112. Although CyPB is undetectable on western blots of thymocyte, 
splenocyte and embryonic fibroblast lysates, Ppib transcripts are only reduced to 25% 
versus wild-type in splenocyte cultures. In contrast to the type IX OI cases, murine 
collagen biochemistry differs from both human PTC and start codon mutations. Collagen 
migration demonstrates a delayed baseline rather than a broadened band on PAGE 
analysis, but helical modification was not quantitated in the mouse collagen. Pro986 3-
hydroxylation was absent in collagen from murine skin, bone and tendon, although partial 
persistence of complex components is suggested by detection of reduced levels of P3H1 
in murine fibroblasts. The differences in collagen modification between the KO mouse 
and human start codon mutation may reflect alternative binding partners supporting 
P3H1/CRTAP stability or redundancy for PPIases in humans. Furthermore, procollagen 
is retained in the ER and is not properly transported into the Golgi, as determined by 
fluorescent microscopy. At the tissue level, dermal collagen fibrils from CyPB-deficient 
mice have diameters that are increased by 50% compared to wild-type collagen dermal 
fibrils in longitudinal sections. Phenotypically, this mouse shows no size difference with 
wild-type littermates at weaning, but kyphosis and growth deficiency progress with age 
until knockout mice weigh 31% (10g) less than wild-type at 6 months of age. From 7 
weeks to 29 weeks of age, these mice have reduced trabecular bone volume (BV/TV, 
↓50-75%) due to increased trabecular spacing (TbSp, ↑25-40%) and reduced trabecular 
number (TbN, ↓10-33%) 112.  
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An additional animal model with a recessively inherited PPIB mutation exists in 
American Quarter Horses, which contain a missense mutation resulting in the skin 
condition hereditary equine regional dermal asthenia (HERDA) 427. The mutation, a PPIB 
c.115G>A missense mutation, results in an amino terminus p.Gly6Arg substitution and 
occurs with a 17.3%  frequency in the Quarter Horse population. Horses homozygous for 
the HERDA mutation are normal at birth, but by two years of age begin to present with 
skin ulceration and poorly resolving wounds with skin sloughing. No bone phenotype has 
been reported in these animals. Although the p.Gly6Arg substitution does not interfere 
with peptidyl-prolyl isomerase activity of recombinant mutant protein against a succinyl-
Ala-Ala-Pro-Phe-methyl coumarylamide substrate in vitro, cell culture assays 
demonstrate delayed folding of type I collagen in HERDA fibroblasts. Rather than 
delayed electrophoretic migration of collagen due to overmodification caused by delayed 
folding, dermal collagen from the HERDA horse migrates faster than wild-type collagen, 
while tendon-derived fibrils are smaller and branched. The apparent undermodification of 
collagen in the presence of CyPB p.Gly6Arg protein has been hypothesized to be due to 
the loss of an interaction between mutant CyPB and lysyl hydroxylase 1 (LH1), as 
ascertained in CyPB pull-down assays 427. It is unknown, however, if CyPB is required 
for LH1 activity or if isomerization of peptidyl-prolyl bonds in the collagen substrate is 
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Purpose: Deficiency of prolyl 3-hydroxylase 1, encoded by LEPRE1, causes recessive 
osteogenesis imperfecta. We previously identified a LEPRE1 mutation, exclusively in 
African Americans and contemporary West Africans. We hypothesized that this allele 
originated in West Africa and was introduced to the Americas with the Atlantic slave 
trade. We aimed to determine the frequency of carriers for this mutation among African 
Americans and West Africans, and the mutation origin and age. Methods: Genomic 
DNA was screened for the mutation using PCR and restriction digestion, and a custom 
TaqMan genomic SNP assay. The mutation age was estimated using microsatellites and 
short tandem repeats spanning 4.2 Mb surrounding LEPRE1 in probands and carriers. 
Results: Approximately 0.4% (95% C.I.: 0.22-0.68%) of Mid-Atlantic African 
Americans carry this mutation, estimating recessive OI in 1/260,000 births in this 
population. In Nigeria and Ghana, 1.48% (95% C.I.: 0.95-2.30%) of unrelated individuals 
are heterozygous carriers, predicting 1/18,260 births will be affected with recessive OI, 
equal to the incidence of de novo dominant OI. The mutation was not detected in 
Africans from surrounding countries. All carriers shared a haplotype of 63-770 Kb, 
consistent with a single founder for this mutation. Using linkage disequilibrium analysis, 
the mutation was estimated to have originated between 650 and 900 years before present 
(1100-1350 C.E.). Conclusions: We identified a West African founder mutation for 
recessive OI in LEPRE1. Nearly 1.5% of Ghanians and Nigerians are carriers. The 
estimated age of this allele is consistent with introduction to North America via the 
Atlantic slave trade (1501 – 1867 C.E).  




Classical osteogenesis imperfecta (OI), or “brittle bone disease”, is a connective 
tissue disorder characterized by susceptibility to bone fractures, blue sclerae and growth 
deficiency 352. Most (85%) individuals with OI have autosomal dominant mutations in 
COL1A1 or COL1A2 (OMIM #166200, #166210, #166220, #259420), which alter the 
structure or synthesis of type I collagen 116. Collagen mutations cause a range of OI 
phenotypes, from mild to perinatal lethality, described by the Sillence Classification 348. 
Autosomal dominant OI has an incidence of approximately 1/15-20,000 births, with over 
90% of cases resulting from de novo mutations 348,349,351. Mutation “hotspots” in COL1A1 
and COL1A2 are associated with independent recurrences of mutations, rather than 
founder mutations 116. 
Type I collagen is a heterotrimer of two α1(I) and one α2(I) chains which is subject 
to post-translational modification during chain synthesis and folding by prolyl 4-
hydroxylase (P4H) and lysyl hydroxylase (PLOD1), with subsequent glycosylation of 
some hydroxylysine residues 9. An additional post-translational modification system 
exists for types I, II and V collagen, which results in 3-hydroxylation of the α1(I) and 
α1(II) Pro986 residues 428. Partial modification of the α1(II) Pro944 and α2(I) Pro707 
residues has also been reported 429. These modifications occur in the endoplasmic 
reticulum by the collagen prolyl 3-hydroxylation complex, consisting of prolyl 3-
hydroxylase 1 (P3H1, encoded by LEPRE1), cartilage-associated protein (CRTAP) and 
cyclophilin B (CyPB/PPIB). Deficiency of proteins comprising the collagen prolyl 3-
hydroxylation complex causes autosomal recessive OI. Null mutations in CRTAP (type 
VII OI, OMIM # 610682), LEPRE1 (type VIII OI, OMIM# 610915) and PPIB (type IX 
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OI, OMIM #259440) cause a moderate to lethal osteochondrodystrophy that overlaps 
phenotypically with dominant types II, III and IV OI, but has several distinctive clinical 
features 107,109,110,409,421,422, including white sclerae, rhizomelia and extreme bone 
undermineralization. Surviving children with type VIII OI also present with extreme 
growth deficiency and bulbous metaphyses 110,409. Recessive OI caused by deficiency of 
components of the collagen 3-hydroxylation complex accounts for about 5-7% of severe 
cases of OI in North America 109,410.   
Among the first cases of type VIII OI reported, we identified homozygosity for the 
same mutation within several African American and West African émigré families in 
North America 110. This mutation accounts for about one-third (21/62) of all mutant 
alleles currently reported in type VIII OI 430,431. The mutation (LEPRE1 c.1080+1G>T) 
results in multiple alternatively spliced transcripts, each containing a premature 
termination codon (PTC). Homozygosity for this mutation is perinatal lethal, while 
compound heterozygosity with a different LEPRE1 mutation is compatible with survival 
into the second decade of life, and heterozygous carriers are clinically unaffected 110. We 
hypothesized that the LEPRE1 c.1080+1G>T allele arose in West Africa prior to the 
African diaspora and was introduced to the Americas during the Atlantic slave trade. We 
screened contemporary African American and African cohorts to determine the 
prevalence of carriers and illuminate the history of this mutation. Haplotype analysis of 
mutant alleles demonstrated one shared core haplotype surrounding the LEPRE1 gene on 
chromosome 1. Our findings are consistent with a founder mutation in West Africa more 




MATERIALS AND METHODS 
 
Cohort Selection and Acquisition 
 
African American cohorts from Pennsylvania (NeoGen)432 and Maryland (Maryland 
Department of Health and Mental Hygiene) contained randomly chosen anonymized 
newborn metabolic screening cards with parental racial designation. Because samples 
were anonymized it was not possible to exclude twins or multiple samples within a 
family. Leukocyte genomic DNA from African Americans and contemporary Africans 
enrolled in the African American Diabetes Mellitus Study (AADM)433 and Howard 
University Family Study of Hypertension (HUFS)434 were obtained from the District of 
Columbia, and the West African countries of Ghana and Nigeria. Related individuals in 
AADM and HUFS were excluded by pedigree analysis. Genomic DNA from individuals 
originating from the Central African countries of Cameroon, Chad, Central African 
Republic and Congo was collected in Cameroon for an African genetic diversity study 
435. Senegalese samples were collected for a prostate cancer susceptibility study in 




DNA was extracted from newborn metabolic screening cards and screened for the 
LEPRE1 mutation by PCR and restriction enzyme digestion with BslI (New England 
Biolabs, Ipswich, MA) and the resulting restriction products were analyzed by 10% 
PAGE. In brief, a 6 mm punch from each card was rehydrated in TE buffer, then treated 
with 5% Chelex-100 resin (BioRad, Hercules, CA) for 25 minutes at 55°C to remove 
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heme groups. Samples were centrifuged to pellet the resin and the supernatant was used 
directly for PCR, as follows: 50 µl reactions contained 15 µl of dried blood extract, 1% 
Perfect Match (Stratagene, La Jolla, CA), 3% DMSO, 15 pmol LEPRE1 I4 sense 
(5’GGCCATCATGTTAAGTAGCAGGCAC CAGCT-3’) and LEPRE1 I5 antisense (5’-
CTCCCTGTGCTCCCTTCTCCTCTGAATAAC-3’) primers with 1.0 U High Fidelity 
Platinum Taq polymerase (Invitrogen, Carlsbad, CA). After an initial 5 minute 
denaturation at 94°C, reactions were incubated for 40 cycles of 94°C for 1 minute, 63°C 
for 1 minute and 72°C for 1 minute, followed by 7 minutes at 72°C. 
Genomic DNA was isolated from leukocytes (District of Columbia, Ghana, Nigeria, 
Cameroon, Chad, Central African Republic and Congo) or buccal swabs (Senegal) and 
whole-genome amplification (WGA) was performed using the Illustra GenomiPhi DNA 
Amplification kit (GE Healthcare, Piscataway, NJ). Amplification products were 
quantitated with PicoGreen (Invitrogen, Carlsbad, CA) using a standard curve generated 
from normal control genomic DNA. For each sample, 20 ng of WGA DNA was screened 
using a custom TaqMan genomic SNP assay (Applied Biosystems, Foster City, CA) to 
detect the mutation with probes specific for each allele. A 91 bp PCR product 
corresponding to nucleotides g.9130 – 9221 of the LEPRE1 gene was amplified under 
standard conditions on an ABI 7000 Sequence Detection System using forward 
(LEPRE1-AFR_F, 5’-TTGGCCTATTATGCAGCTATGCTT-3’) and reverse (LEPRE1-
AFR_R, 5’-GGCAGCTGTCATAACAGAAGGAA-3’) primers at a concentration of 0.9 
µM. Detection of PCR products was obtained by inclusion of 0.2 µM MGB probes 
specific for the normal “G” allele (LEPRE1-AFR_V, 5’-VIC-CCCGTGAGGTGAGAG 











compared to normal (G/G), heterozygous (G/T) and homozygous (T/T) control samples. 
The TaqMan allelic discrimination assay was used for automated allele calling of the 
measured fluorescence. Samples designated as carriers by this assay were confirmed by 




To confirm the origin and determine the age of the mutation, the size of the 
conserved haplotype on the mutant allele was determined using microsatellites and short 
tandem repeats (STRs). Fourteen markers covering a 4.2 Mb region surrounding the 
LEPRE1 gene on chromosome 1p were chosen using the UCSC Genome Browser 
(http://genome.usc.edu). PCR amplification of the microsatellite markers was performed 
using 200 ng genomic DNA or WGA DNA in 25 µl reactions using the HotStar PCR 
amplification System (Qiagen, Germantown, MD). Amplification was performed using 
15 pmol fluorescently labeled primers and MgCl2 concentrations as described (Table 1). 
After an initial 15 min denaturation at 95°C, reactions were incubated at 94°C for 30 sec, 
at primer-specific annealing temperatures of 52-57°C (see TA in Table 1) for 30 sec and 
72°C for 30 sec for 35 cycles, followed by 72°C for 10 min. Amplification products were 
separated by capillary electrophoresis on an ABI 3730 Automated Sequencer and 
analyzed using Genemapper software (Applied Biosystems, Foster City, CA). Allele calls 
were binned to confirm the expected distribution of fragment sizes.   
Calculation of the mutation age in generations was performed with the method of 




t= (1/Θ)(log(1-p0) – log(Y0 - n p0) + log(n)) 
 
where (t) is the mutation age in generations, (n) is the number of mutation bearing 
chromosomes sampled, (Y0) is the number of chromosomes carrying both the mutation 
and the ancestral marker allele, Theta (Θ) is the recombination fraction between the 
marker and the mutation, and (p0) is the frequency of the ancestral marker allele in the 
normal chromosomes (non-mutation carrying chromosomes). We assumed a 20-year time 




Identification of Recurring Mutation in African Americans 
 
To determine the carrier frequency of the LEPRE1 c.1080+1G>T mutation among 
African Americans, we screened genomic DNA from African Americans from the Mid-  
 
Figure 14. Screening of genomic DNA for the LEPRE1 c.1080+1G>T mutation. (A) Scatter 
plot of the results from a representative genotyping of WGA DNA using a custom genomic SNP 
assay. Amplification of the normal “G” allele (VIC-labeled probe) is plotted along the X axis; 
amplification of the mutant “T” allele (FAM-labeled probe) is plotted along the Y axis. Individual 
results plotted as x’s. NTC, no template control, squares; TT, homozygous mutant genomic DNA 
control sample, diamonds; G/T, heterozygous genomic DNA control sample, triangles; GG, 
homozygous normal DNA control sample, circles. (B) Genotyping of genomic DNA extracted from 
newborn metabolic screening cards by PAGE analysis of BslI-digested PCR products. The 
mutation eliminates a BslI site and results in the presence of a 112 bp fragment (lane 6) after 
restriction digestion. STD, 25 bp DNA size standard; lanes 1-8, reactions from 8 anonymized 




Atlantic United States. DNA from 1429/1594 (89.6%), 631/757 (83.4%) and 995/1002 
(99.3%) individuals from Pennsylvania, Maryland and the District of Columbia could be 
genotyped (Figure 14A). Twelve carriers were identified among the 3055 genotyped 
African Americans, and confirmed by BslI digestion of independent PCR products 
(Figure 14B). Heterozygous carriers (Table 2) were detected in 5 of 1429 (0.35%) 
Pennsylvania samples, 2 of 631 (0.32%) Maryland samples, and 5 of 995 (0.50%) 
samples from the District of Columbia, supporting a 0.39 ± 0.11% (12/3055) overall 
carrier frequency for the LEPRE1 mutation among Mid-Atlantic African Americans. 
These data predict that cases of type VIII OI, due to homozygosity of the c.1080+1G>T 






Pennsylvania and Maryland newborn metabolic screening cards, and WGA genomic DNA samples 
from AA cohorts were generously provided by F.D. Porter, S.R. Panny, F. Gulamali-Majid, A. 
Adeyemo and C.N. Rotimi, and studied under protocols 08-CH-N050 (NICHD, Principle 
Investigator J.C. Marini) and 07-45 (Maryland Department of Health and Mental Hygiene, 
Principle Investigator J.C. Marini). Assays performed by W.A. Cabral and A.M. Barnes. 
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We previously noted that carriers of the c.1080+1G>T mutation were African 
Americans or African immigrants of West African origin 110. Therefore, we investigated 
the prevalence of carriers among contemporary West Africans. Using a genomic SNP 
assay, 1665/1690 (98.5%) WGA gDNA samples representing 7 groups related by 
language from Ghana and Nigeria were genotyped (Table 3). Within the cohort, 381 
samples were eliminated because they were from related individuals according to 
pedigree analysis. We identified 9 carriers among 453 samples (1.99%) from Ghana, 
including 2/142 (1.4%) Ga, 3/280 (1.1%) Akan, and 1/28 (3.6%) Ewe, as well as among 
the Gonja and Hausa ethnic groups, in which frequency cannot be meaningfully 
calculated because of low sample number. The 818 Nigerian samples yielded 10 carriers 
(1.22%), including 7/635 (1.10%) Yoruba and 3/183 (1.64%) Ibo samples. Combined 
with 13 samples not affiliated with a specific West African ethnic group, our screening 
identified 19/1284 (1.48%) carriers for the LEPRE1 mutation among contemporary West 
Africans. The high carrier frequency predicts that this mutation alone will cause recessive 
type VIII OI in approximately 1/18,260 births in West Africa, equivalent to the incidence 




To determine whether the LEPRE1 mutation was localized specifically to the 
Ghana/Nigeria region of West Africa or whether it was Pan-African, we screened DNA 






WGA genomic DNA samples from African cohorts were acquired by S.A. Tishkoff, T.R. 
Rebbeck, S.M. Gueye, A. Adeyemo and C.N. Rotimi. Assays performed by W.A. Cabral 




Nigeria (Table 3). Among the 1647 genotyped African samples, we were unable to 
identify a single carrier for the mutation among 561 Senegal, 864 Cameroon, 95 Chad, 69 
Central African Republic, 34 Congo or 24 samples collected in Cameroon but of 
unspecified origin. 
 
Haplotype Analysis and Estimated Age of LEPRE1 c.1080+1G>T Mutation 
We next determined the haplotype surrounding this mutation in African American 
and West African alleles from 15 families (Figure 15). In the 12 unrelated West African 
families with 16 independent mutant alleles, we found a conserved haplotype of 
approximately 63 - 425 Kb surrounding LEPRE1 (Table 4), extending from between 
D1S2861 and the LEPRE1 gene to the region between markers STR#3 and STR#5. In 
one African family (080), the mutation chromosome could not be determined with 
certainty for these three markers immediately surrounding LEPRE1, although the 
genotype of the mutant allele carrier in this family is compatible with the ancestral 
haplotype. Because of this uncertainty, this individual was excluded from calculations. 
Two (#3F4 and #3G4) of 25 independent normal chromosomes in these African families 
carried the conserved haplotype, suggesting that the mutation occurred on an ancestral 
haplotype which exists with an undetermined, but possibly non-negligible, frequency 
among West Africans.  
For the three African American families with four independent mutant alleles, the 
conserved region surrounding LEPRE1 was approximately 770 Kb - 1.2 Mb (Table 5) 
and extended from between markers D1S2645 and D1S463 to the region between 






Figure 15. Pedigrees of African American (AA) and West African (WA) families included 
in haplotype analysis. Black shading denotes the LEPRE1 c.1080+1G>T allele, while gray 
shading denotes a second mutant LEPRE1 allele. Pedigree analysis by W.A. Cabral, D. Chitayat, 





American mutant alleles corresponds to the conserved region from West African families 
026, 080 and 223. It is noteworthy that the full haplotype was not found in nine African 
Americans unrelated to our study families who are not carriers of the mutation, although 
one of these individuals (AA cohort, #30) shared the ancestral haplotype markers around 
LEPRE1 from D1S2861 to STR#5.  
The age of the mutation was estimated using linked markers on chromosome 1 
haplotypes from carrier families. Based on marker assignments for all individuals in the 
15 combined African and African American families, we estimate the mutation age 
between 416 and 1066 years at markers STR#3 and D1S2861, respectively. However, 
calculations using independent mutant chromosomes from the combined African and 
African American families narrowed the mutation age range to 458 - 548 years. The 
number of independent African American carriers was insufficient for a separate 
calculation. 
When analysis was limited to our 12 West African triads, calculations including all 
family members yielded an estimated age of 622 - 2340 years old. The mutation age 
range was further refined to 648 - 894 years using only independent mutant chromosomes 
at markers STR#3 and D1S2861.  Thus, the West African haplotypes date this mutation 
to the 12th - 14th century, prior to the transatlantic slave trade, which occurred from the 












We have identified a founder mutation in the gene encoding P3H1 that causes 
autosomal recessive type VIII osteogenesis imperfecta, a severe to lethal bone dysplasia. 
The LEPRE1 c.1080+1G>T mutation originated in West Africa, where nearly 1.5% of 
contemporary Ghanians and Nigerians are carriers. The mutant allele was presumptively 
brought to North America via the Atlantic slave trade, resulting in a carrier frequency 
among African Americans of 0.32-0.50%. Type VIII OI joins sickle cell disease, and 
end-stage kidney disease (ESKD) resulting from APOL1 variants as examples of single 
gene defects transported from Africa to the Americas 439. Previously reported founder 
mutations for recessive OI have occurred in genetically isolated populations, including a 
First Nations Tribe of Quebec with type VII OI 107,440, and the Irish Traveler population 
with type VIII OI 409,441. 
The high carrier frequency of this LEPRE1 mutation among West Africans results in 
distinctive OI inheritance patterns in West Africa compared to North America and 
Europe. While severe to lethal OI has been reported in West Africa 442,443, this study is 
the first to address the prevalence of OI in West African populations. Our data predicts 
that the incidence of recessive OI in West Africa due to this mutation is about 1/20,000 
births, equivalent to the incidence of de novo dominant OI in North America and Europe. 
In comparison, recessive OI accounts for approximately 5 - 7% of severe OI cases in 
North America and Europe and type VIII OI is calculated to occur in approximately 
1/250,000 African American births. 
The occurrence of  LEPRE1 c.1080+1G>T within a conserved haplotype confirms a 
founder effect, rather than the presence of a mutation “hotspot”. Furthermore, no 
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individuals from outside this region of West Africa were identified as carriers, suggesting 
that LEPRE1 c.1080+1G>T is not a Pan-African mutation. The carrier incidence is higher 
in Ghana than Nigeria, consistent with a mutation that began in Ghana and was carried 
eastward. The mutation expanded among groups with similar languages; all carriers 
except one belong to ethnic groups that speak languages of the Kwa or Volta-Niger 
branches of the Niger-Congo family. Haplotype analysis also dates this mutation to 
approximately 648 - 894 years ago, placing its origin within the 12th - 14th centuries. This 
date is prior to the Atlantic slave trade, which peaked from the late 17th to mid-19th 
centuries 444. Interestingly, combining the West African and African American haplotype 
data decreases the estimated age of the mutation, compared to West African haplotypes 
alone (458 - 548 years versus 648 - 894 years), consistent with descent of the African 
American alleles from a limited number of West African founders who did not represent 
the full African allelic variation. In fact, the conserved region around LEPRE1 in African 
American carriers corresponds to a subset of contemporary West African haplotypes. 
However, we cannot rule out incomplete ascertainment because only 4 independent 
African American mutant alleles were analyzed. It is also possible that the West African 
haplotypes represent continued recombination events since the end of the slave trade. 
During the nearly 400 years of the Atlantic slave trade, more than 12 million slaves 
were transported, about 10.7 million of whom survived to disembark in the New World 
444,445. More than a third (38.1%) of these Africans originated from the region of West 
Africa then known as the Gold Coast, the Bight of Benin and the Bight of Biafra 445,446. 
These three areas included the territories of the Akan, Ewe, Ga, Yoruba, and Ibo, whose 
contemporary members are carriers of the LEPRE1 mutation. Thus, it is not surprising to 
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identify mutation carriers among African Americans of the Mid-Atlantic United States. 
Assuming a 1.48% carrier incidence among the approximately 130,000 slaves from West 
Africa who disembarked in the American colonies 445, it is possible that as many as 1900 
carriers were transported to North America. This number of carriers is more than 
sufficient to make a second founder effect unlikely, as would have occurred if only a few 
carriers were transported. The incidence of carriers among African Americans would not 
have been decreased by immigration from the Caribbean after World War II 447, or by 
direct immigration from Africa to the United States during the last two decades, which 
have both included a high proportion of West Africans 448. 
Only about 3.6% of all slaves transported in the Atlantic slave trade were sent to the 
future United States. The majority of slaves were transported to the Caribbean and South 
and Central America, with their origins and destinations reflecting the European colonial 
regions of influence 444,445. Since the majority of Africans sent to Brazil by the 
Portuguese originated in West Central and Southeast Africa (Angola, Congo and 
Mozambique), we do not expect a significant number of carriers for this LEPRE1 
mutation among Brazilians of African descent. In contrast, the British, French, and 
Spanish traders obtained a large proportion of their slaves from the current Ghana/Nigeria 
area. Over 1.5 million West Africans, 39% of all West Africans transported during the 
slave trade, were sent to the British Caribbean, including Jamaica, Barbados, Antigua, 
Trinidad and the Grenadines, where they constituted 68% of disembarking slaves. The 
French and Spanish areas of the Caribbean each received over 10% of all West African 
slaves, with nearly half of the slaves in Martinique, Cuba and Spanish Central America 
originating in West Africa 445. Therefore, the carrier frequency of this mutation on 
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multiple Caribbean islands may be higher than among Mid-Atlantic African Americans. 
The LEPRE1 mutation may be useful for African ancestry studies among Caribbean 
populations because of its specific region of origin and simple, rapid analysis. 
A high carrier frequency for a lethal mutation is rare within a population that is not 
geographically isolated. Disease founder alleles have expanded within non-
geographically isolated ethnic groups such as Eastern European Jews, with Tay-Sachs 
and Gaucher disease carrier incidences of 1:31 and 1:20 449,450, and among Finnish 
isolates, who have carrier frequencies for multiple recessive diseases as high as 1:45 or 
1:60 451. There are several possible causes for the high West African carrier frequency of 
the LEPRE1 allele. First, despite its lethality in a homozygous state, the LEPRE1 
mutation may act as a neutral variant in the heterozygous state. In fact, the heterozygous 
parents of our patients are apparently healthy. A second possibility is that heterozygosity 
for this mutation may provide some protection against one of the infectious diseases 
endemic to this region, for example, by maintaining the integrity of connective tissues. 
The best-known disease mutation which confers selective advantage is sickle-cell trait 
(HbS), which provides resistance to malarial infection and is found in 8% of African 
Americans, and as much as a quarter of the West African population 452,453. In addition, 
variants of apolipoprotein L-1 (APOL1) which are associated with lysis of T. brucei 
rhodesiense are common in Africa and are now linked to susceptibility to end-stage 
kidney disease (ESKD) in African Americans 439. The APOL1 gene cluster occurs on a 
region of chromosome 22 which shows strong evidence of evolutionary selection. 
However, the LEPRE1 carrier frequency is lower than expected for a mutation conferring 
selective advantage, and a protective role against West African endemic diseases is not 
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apparent. A third possibility is the LEPRE1 lethal allele may be linked to a neighboring 
gene on chromosome 1 that is undergoing selection, as a so-called “hitchhiker”, a 
possibility requiring further sequencing to investigate. 
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Cyclophilin B (CyPB), encoded by PPIB, is an ER-resident PPIase that occurs both 
independently and as a component of the collagen prolyl 3-hydroxylation complex. CyPB 
is proposed to be the major PPIase catalyzing the rate-limiting step in collagen folding. 
Mutations in PPIB cause recessively inherited osteogenesis imperfecta type IX, a 
moderately severe to lethal bone dysplasia. To investigate the role of CyPB in collagen 
folding and post-translational modifications, we generated Ppib-/- mice that recapitulate 
the OI phenotype. KO mice are small, with reduced femoral aBMD, BV/TV, and MOI. 
Ppib transcripts are absent in skin, fibroblasts, femora and calvarial osteoblasts, and 
CyPB is absent from KO osteoblasts and fibroblasts on western blots. Only residual (2-
11%) collagen prolyl 3-hydroxylation is detectable in KO cells and tissues. Collagen 
folds more slowly in the absence of CyPB, supporting its rate-limiting role in folding. 
However, treatment of KO cells with cyclosporine A causes further delay in folding, 
supporting the potential existence of another collagen PPIase. Ppib-/- fibroblast and 
osteoblast collagen has normal total lysyl hydroxylation, while increased collagen 
diglycosylation is observed. LC/MS analysis of bone and osteoblast type I collagen 
revealed site-specific alterations of helical lysine hydroxylation, in particular, 
significantly reduced hydroxylation of helical crosslinking residue K87. Consequently, 
underhydroxylated forms (HLNL and LP) of di- and trivalent crosslinks are strikingly 
increased in KO bone, leading to increased total crosslinks and decreased helical 
hydroxylysine- to lysine-derived crosslink ratios. The altered crosslink pattern was 
associated with decreased collagen deposition into matrix in culture and altered fibril 
structure in tissue, and presumably reduced bone strength. These findings suggest a novel 
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role for CyPB in supporting the activity of specific collagen lysyl hydroxylase(s), 
especially LH1, by an unknown mechanism. Thus, CyPB not only facilitates collagen 
folding directly, but also indirectly regulates collagen hydroxylation, glycosylation, 
crosslinking and fibrillogenesis.  
     
AUTHOR SUMMARY 
Osteogenesis imperfecta (OI), or brittle bone disease, is characterized by 
susceptibility to fractures from minimal trauma and growth deficiency. Deficiency of 
components of the collagen prolyl 3-hydroxylation complex, CRTAP, P3H1 and CyPB, 
cause recessive types VII, VIII and IX OI, respectively. We have previously shown that 
mutual protection within the endoplasmic reticulum accounts for the overlapping severe 
phenotype of patients with CRTAP and P3H1 mutations. However, the bone dysplasia in 
patients with CyPB deficiency is distinct in terms of phenotype and type I collagen 
biochemistry. Using a knock-out mouse model of type IX OI, we have demonstrated that 
CyPB is the major, although not unique, peptidyl prolyl cis-trans isomerase that catalyzes 
the rate-limiting step in collagen folding. CyPB is also required for activity of the 
collagen prolyl 3-hydroxylation complex; collagen α1(I) P986 modification is lost in the 
absence of CyPB. Unexpectedly, CyPB was found to also influence collagen helical lysyl 
hydroxylation in a tissue-, cell- and residue-specific manner. Thus CyPB facilitates 
collagen folding directly, but also indirectly regulates collagen hydroxylation, 
glycosylation, crosslinking and fibrillogenesis through its interactions with other collagen 





Type I collagen, the most abundant protein component of the extracellular matrix of 
skin, tendon and bone, is a heterotrimer consisting of two α1(I) and one α2(I) chains 
encoded by the COL1A1 and COL1A2 genes, respectively. The pro-alpha chains of type I 
collagen contain an uninterrupted helical region consisting of 338 repeats of the Gly-Xaa-
Yaa triplet. Biosynthesis of procollagen is a complex process that requires several co- and 
post-translational modifications within the endoplasmic reticulum, including formation of 
disulfide bonds within the propeptide extensions, isomerization of peptidyl-prolyl bonds, 
hydroxylation of Yaa lysyl and prolyl residues, and glycosylation of hydroxylysines 9. 
The post-translational modifications occur before, and to a major extent stabilize, 
collagen helical folding. After secretion into the pericellular space and processing of 
propeptide extensions, the mature collagen heterotrimer is incorporated into heterotypic 
collagen fibrils. The fibrils are then stabilized by intermolecular aldehyde-derived 
crosslinks formed from specific collagen lysyl and hydroxylysyl residues by lysyl 
oxidases (LOX) 454,455.  
Dominant mutations in COL1A1 or COL1A2 cause classical osteogenesis imperfecta 
(OI), with susceptibility to fractures from minimal trauma and growth deficiency 116. 
Glycine substitutions in the collagen alpha chains delay folding and increase exposure to 
modifying enzymes, resulting in collagen overmodification. Some OI cases (≈10%) have 
recessive inheritance, caused by deficiency of proteins that interact with collagen for 
folding or post-translational modification 354. Most commonly, recessive OI involves the 
collagen prolyl 3-hydroxylation complex, consisting of prolyl 3-hydroxylase 1 
(P3H1/LEPRE1, leucine- and proline-enriched proteoglycan 1), cartilage-associated 
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protein (CRTAP) and cyclophilin B (CyPB/PPIB, peptidyl-prolyl cis-trans isomerase B). 
This complex is responsible for 3-hydroxylation of the Xaa position α1(I) P986 residue 
in types I and II collagen 2,106,107. Loss of individual components abrogates collagen P986 
3-hydroxylation 107,110,422,456. CRTAP and P3H1 are mutually supportive in the complex; 
deficiency of either component causes severe to lethal OI with rhizomelia, classified as 
OI types VII and VIII, respectively 457. However, loss of the CRTAP/P3H1 complex does 
not decrease the level of CyPB, and, conversely, the CRTAP/P3H1 complex is only 
partially decreased in the absence of CyPB. 
CyPB/PPIB, is an ER-localized member of the immunophilin family of proteins with 
PPIase activity 93,458. Cis-trans isomerization of peptidyl-prolyl bonds is especially 
important for type I collagen folding because prolines constitute nearly one-sixth of its 
primary sequence. Studies published over twenty years ago demonstrated that exposure 
of cells to the cyclophilin inhibitor cyclosporine A (CsA) slows the rate of collagen 
folding and results in overmodification of lysyl residues 108. Thus, CyPB is thought to be 
the major, and possibly unique, collagen peptidyl-prolyl cis-trans isomerase 403. 
However, collagen biochemical data from the few reported patients with CyPB 
deficiency is inconsistent. Two patients with PPIB mutations causing moderate OI have 
normal levels of collagen prolyl 3-hydroxylation 421,423, while in two lethal OI cases of 
CyPB deficiency, α1(I) P986 3-hydroxylation decreases to 30% of normal 422,423. Overall 
collagen overmodification was detected in both lethal cases, but in only one moderately 
severe patient.  
In an attempt to clarify the inconsistencies among the human cases of PPIB/CyPB 
deficiency, we generated a Ppib knockout mouse model. Collagen biochemical studies 
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demonstrate cell- and tissue-specific dysregulation of collagen helical lysyl hydroxylation 
and glycosylation in the absence of CyPB. In addition, reduced hydroxylation of specific 
collagen helical lysine residues involved in intermolecular crosslinks led to a shift in the 
pattern of crosslinks in bone tissue, and reduced collagen deposition into matrix. These 
studies imply that CyPB has a role in lysyl hydroxylation that is independent of collagen 
folding, and establish a novel function for CyPB in collagen biosynthesis.  
 
 
MATERIALS AND METHODS 
Generation of Ppib-Null Mice 
ES cell gene trap lines with a β-geo reporter construct inserted in intron 1 of the Ppib 
gene were produced by BayGenomics (UCSF, CA) and obtained from the Mutant Mouse 
Regional Resource Center (Davis, CA) 459. The gene trap construct contains intron 1 and 
a portion of exon 2 to include splice acceptor sequence from the mouse En2 gene, 
followed by a β-galactosidase /neomycin (β-geo) reporter-selection cassette and SV40 
polyadenylation signal. Cells were expanded for isolation of mRNA and quantitation of 
Ppib expression. A heterozygous clone from cell line RST139 was shown to have half-
normal Ppib expression by real-time RT-PCR, and was injected into C57BL/6 
blastocysts. Founders were generated by mating chimeric males with 129/P2/OlaHsd 
females to retain the 129 background of the ES cell line. A second line was generated for 
experiments by backcrossing F1 mice into C57BL/6 for 5 generations. 
Genomic DNA for genotyping was isolated using the Red Extract-n-Amp tissue PCR 
kit (Sigma) and amplified by hemi-nested PCR using a sense primer located in Ppib exon 
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1 (5’-TGCCCGGACCCTCCGTGGCCAACGATAAGA-3’), an antisense primer 
corresponding to intron 1 of En2 (5’-GGCATCTCCCCTTCAGTCTTCCTGTCCAGG-
3’), and an antisense primer downstream of the inserted construct internal to Ppib intron 
1 (5’-GGGGGGCTGGGGGAGTCTGGGTTATTCTCT-3’). Complete absence of Ppib 
transcripts was verified by real-time RT-PCR of mRNA isolated from femoral tissue and 
skin of F2 Ppib homozygous knock-out mice. Animal care and experiments were 
performed in accordance with a protocol approved by the NICHD ACUC committee. 
 
Skeletal Staining, Growth curves, X-ray, DXA analysis, micro-CT 
For skeletal staining, skin and viscera were removed from dead P1 newborn pups. 
Pups were fixed in 95% ethanol for 7 days and stained with 0.3% Alcian Blue 8GS and 
0.1% Alizarin Red S 460. Excess stain was removed with 1% KOH and increasing 
concentrations of glycerol. For growth curves, mice were fed regular rodent chow and 
weighed weekly from 3 to 24 weeks of age. Skeletal characteristics of F6 wild-type, 
heterozygous and homozygous Ppib-null littermates were analyzed at age 8 weeks. 
Radiographs were performed by Faxitron (30 kV for 1 min). Areal bone mineral density 
(aBMD) scans of mouse femurs were acquired using a GE Lunar PIXImus2 (GE 
Healthcare) and internal calibration standards. To determine femoral length, femora were 
dissected and cleaned of soft tissue, leaving the epiphyses intact. Femurs were measured 
from the proximal head to the distal end of the medial and lateral condyles with a digital 
caliper.  
Left femora of 8-week old mice were analyzed by µQCT for both structural and 
mineral parameters using a SkyScan1174 compact micro-CT scanner (MicroPhotonics) 
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operating at 50kV with an X-ray source current of 800µA, according to manufacturer 
directions. BMD was calibrated with hydroxyapatite phantoms. Morphometric analyses 
of trabecular and cortical regions was performed using CTAn software (v.1.13) and 3D 
images were generated using CTvol software (v.2.2). The trabecular region of interest 
(ROI) was located just proximal to the distal femoral growth plate and extended 10% 
total femoral length. The diaphyseal cortical ROI centered on the femur midpoint, 
spanning 15% total femoral length.  
 
Cell culture 
Primary fibroblast (FB) and calvarial osteoblast (OB) cultures were derived from 3-
day old pups by standard procedures 461. Cells from digestions 3-5 were plated at a 
density of 5,000 cells/cm2 and cultured in αMEM with 10% FBS, 2mM glutamine, 1% 
pen-strep and 8% CO2. FB cultures were derived from dermal tissue dissected from the 
abdomens of newborn pups. FB were allowed to grow out from dermal samples for 2 
weeks, released by trypsin digestion and cultured in DMEM containing 10% fetal bovine 
serum, 2mM glutamine, 1% pen-strep and 5% CO2.  
 
Analysis of Gene Expression 
Total RNA was extracted from cell cultures or tissues dissected from F6 mice using 
TriReagent (Molecular Research Center) according to the manufacturer’s protocol. Total 
RNA was treated with DNA-free (Life Technologies), then reverse-transcribed using a 
High Capacity cDNA Archive Kit (Life Technologies). Real-time RT-PCR was 
performed using Taqman Assays on Demand (Life Technologies, Ppib, 
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Mm00478295_m1; Plod1, Mm01255760_m1; Plod3, Mm00478798_m1; Glt25d1, 
Mm00600638_m1; Glt25d2, Mm01290012_m1; Gapdh, Mm99999915_g1). Relative 
expression of genes of interest was measured in triplicate, normalized to Gapdh 
transcripts, and quantified relative to wild-type calvarial OB.  
 
Western Blot Analysis 
FB and OB cultures were lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% Na-
deoxycholate, 0.1% SDS, 50 mM Tris, pH 7.4) supplemented with protease inhibitor 
cocktail (Sigma). Protein concentration was determined using the BCA Protein Assay Kit 
(Thermo Scientific). Samples (15 µg protein) were subjected to SDS-PAGE on 10% 
acrylamide gels under denaturing conditions and electroblotted onto nitrocellulose 
membranes. The membranes were blocked overnight in 5% non-fat milk in TBST. After 
washing in TBST, membranes were incubated overnight at 4°C in TBST containing 2.5% 
non-fat milk and primary antibody (diluted 1:1000). After washing in 1X TBST, 
membranes were incubated with the corresponding IRDye infrared secondary antibody 
(diluted 1:10,000) (LI-COR Biosciences). Proteins were visualized using an Odyssey 
Infrared Imaging System (LI-COR Biosciences). The primary antibodies used include 
anti-P3H1 (Novus Biologicals), rabbit anti-actin (Santa Cruz Biotechnology), rabbit anti-
CyPB (Abnova), rabbit anti-PLOD1 (Santa Cruz Biotechnology), rabbit anti-PLOD3 
(Proteintech), and goat anti-GLT25D1 (Santa Cruz Biotechnology). Anti-mouse CRTAP 





Biochemical Analysis of Type I Collagen 
Steady-state collagen analysis was performed as previously described 355. Collagens 
were prepared by pepsin digestion (50 µg/ml) of procollagen samples, separated on 6% 
SDS-urea- polyacrylamide gels and visualized by autoradiography. 
For analysis of collagen modification in cell culture, confluent FB and OB were 
stimulated for collagen synthesis in DMEM or αMEM containing 0.1% FBS and 100 
µg/ml ascorbate for three days, with daily collection. Collected medium was buffered 
with 100 mM Tris-HCl, pH 7.4, and cooled to 4°C. Protease inhibitors were added to the 
following final concentrations: 25 mM EDTA, 0.02% NaN3, 1 mM 
phenylmethylsulfonylfluoride, 5 mM benzamidine, and 10 mM N-ethylmaleimide. 
Procollagens were precipitated from media with ammonium sulfate overnight at 4°C. 
Procollagen was collected by centrifugation, resuspended in 0.5 M acetic acid and 
digested with 0.1 mg/ml pepsin at 4°C overnight. Selective salt precipitation of collagen 
with 0.9 M NaCl in 0.5 M acetic acid was performed twice. Purified collagen samples 
were resuspended in 0.5 M acetic acid, dialyzed against 5mM acetic acid overnight and 
lyophilized before further analyses. 
Differential Scanning Calorimetry (DSC) scans were performed as previously 
described 462. Thermograms were recorded in 0.2 M sodium phosphate, 0.5 M glycerol, 
pH 7.4, from 10 to 50°C at 0.125 and 1°C/min heating rates in a Nano II DSC instrument 
(Calorimetry Sciences Corporation).  
Analysis of tissue-derived collagens was performed using skin, femora and humeri 
from 2 month old mice (n=5). After marrow was flushed with cold PBS, bone samples 
were pulverized in liquid N2, demineralized with EDTA at 4oC for 2 weeks, and 
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lyophilized. Skin dissected from the backs of mice was minced and lyophilized after 
removal of hair, fat and muscle. Two mg of the dried samples were then reduced with 
standardized NaB3H4, hydrolyzed with 6N HCl and subjected to amino acid and cross-
link analyses as previously described 463-465. The extent of Lys hydroxylation in collagen 
was calculated as hydroxylysine (Hyl) / hydroxyproline (Hyp) X300 (i.e. ~300 residues 
of Hyp/collagen). The cross-link precursor aldehydes and reducible cross-links were 
measured as reduced forms and cross-links were quantified as moles/mole of collagen.  
 
Characterization of collagen post-translational modifications 
Collagen 3-hydroxylation was analyzed by in-gel tryptic digestion of SDS-PAGE-
purified type I collagen alpha chains. Electrospray mass spectrometry was performed on 
the tryptic peptides using an LCQ Deca XP ion-trap mass spectrometer equipped with in-
line liquid chromatography (Thermo Finnigan) using a C8 capillary column (300 µm x 
150 mm; Grace Vydac 208MS5.315) eluted at 4.5 µl per min. 
Site-specific modification of lysyl residues was determined by LC/MS/MS on a 
Waters Q-Tof Premier mass spectrometer coupled to a nanoACQUITY UPLC system 
(Waters Corporation) as reported 124. Tryptic peptides containing Lys residues, their 
hydroxylated and/or glycosylated forms were identified from the LC/MS/MS analyses 
using manual interpretation of the MS/MS spectra. Relative quantitation of lysine (Lys), 
hydroxylysine (Hyl), galactosyl-Hyl (G-Hyl) and glucosylgalactosyl-Hyl (GG-Hyl) at a 
specific glycosylation site was performed by dividing the total ion abundance determined 
for each species by the sum of the ion abundances of all observed species containing that 
particular site.   
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Collagen Folding Assays 
An intracellular collagen folding assay was performed as described 108. Confluent 
cells were stimulated overnight in media with 10% FBS and 100 µg/ml ascorbic acid, and 
then incubated in serum free media containing 100µg/ml ascorbic acid for 2 hr. Cells 
were pulsed with 1.4 µCi/ml 14C-proline for 15 min to label procollagen chains, 
followed by collection of the cell layer every 5 min. Each sample was digested for 2 min 
at 20oC with 0.2% Triton X-100, 100 µg/ml trypsin, and 250 µg/ml chymotrypsin in PBS 
(Sigma). Digestions were stopped by addition of 1 mg/ml soybean trypsin inhibitor 
(Sigma). Samples were precipitated overnight, collected by centrifugation, 
electrophoresed on 3-8% Tris-acetate gels (Life Technologies) and quantitated by 
densitometry of autoradiograms. 
 
Collagen Synthesis and Secretion Kinetics 
For pulse-chase assays, performed as described 466, wild-type and homozygous Ppib-
null FB were grown to confluence. For each cell line, two wells were used for cell counts. 
Procollagens were harvested at the indicated times, digested with pepsin and precipitated. 
Samples were loaded for equivalent cell number, on 3-8% Tris-acetate gels and 
quantitated by densitometry.  
 
Collagen Matrix Deposition 
Wild-type and homozygous Ppib-null FB and OB were grown to confluence and 
stimulated every other day for 14 days with fresh DMEM (fibroblasts) or αMEM 
(osteoblasts) containing 10% FBS and 100 µg/ml ascorbic acid, as described 467. Matrix 
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collagens were sequentially extracted at 4°C, with neutral salt for newly incorporated 
collagen, then acetic acid for collagens with acid-labile cross-links, and, finally, by 
pepsin digestion for collagens with mature cross-links 468. All fractions were 
electrophoresed on 6% polyacrylamide-urea-SDS gels. Samples were loaded for 
equivalent densitometry signal; the total signal for each fraction was calculated by 
adjusting the gel signal by the total volume of that fraction. In separate experiments, 
quantitation of matrix deposited in culture was performed using Raman 
microspectroscopy. Cultures were fixed in 1% paraformaldehyde and analyzed as 
previously described 103. Matrix collagen:cell organics ratios were evaluated from 
decomposition of corrected spectra of collagen-free cytoplasm and purified collagen in 
the amide III spectral region. 
 
TEM Analysis of Murine Dermal Collagen Fibrils 
A dermal biopsy was obtained from abdominal skin of wild-type and homozygous null 
mice, then processed as described 177. Representative areas of the stained grids were 





Generation and phenotype of Ppib-Null Mice 
Ppib-null mice were produced from an ES cell line carrying a gene trap insertion in 
intron 1 of Ppib. Two ESC lines, RST059 and RST139, were screened by real-time RT-
PCR. Expression of Ppib in RST059 and RST139 was decreased to 76 ± 5% and 54 ± 
3%, respectively, of wild-type levels. Because RST139 ES cells were more likely to have 
one null Ppib allele, we proceeded with generation of a mouse line in the C57BL/6 
background using these cells.  
Genomic DNA from homozygous mutant mice was amplified by heminested PCR 
(Figure 16A) and sequenced to demonstrate insertion of the gene trap vector 123 bp from 
the 5’-end of the1066 bp Ppib intron 1. The insertional mutation interrupts transcription 
of Ppib in cells and tissues isolated from Ppib-/- mice. Expression of Ppib in primary 
fibroblast (FB) and osteoblast (OB) cultures from newborn mice, as well as in dermal and 
femoral tissues of 8 week-old mice, was reduced in cells and tissues heterozygous for the 
gene-trapped allele, and completely absent from homozygous cells and tissues (Figure 
16B). Thus, Ppib expression is completely blocked in the gene trap mutant allele, versus 
a previously reported Ppib-null mouse, which retained 30% of wild-type transcripts 112. 
Heterozygous mice were bred into the C57BL/6 line. The genotype distribution among 
offspring of F4 and F5 het x het crosses deviated from the Mendelian ratio, with 30 and 
50% lethality of homozygous pups from F4 and F5 matings, respectively. In surviving 
homozygous offspring of F5 matings, growth deficiency became apparent soon after 
weaning. Knockout mice weighed about 25% less than wild-type and heterozygous 











Figure 16. Generation of a murine model of Cyclophilin B deficiency. (A) Diagram of 
knock-out allele containing β-geo reporter construct inserted into intron 1 of Ppib gene, left. 
Hemi-nested primers (arrows) for PCR-based genotyping selectively amplify the wild-type 
allele (255bp) or the gene-trapped allele (364bp), right. Genotypes in offspring of matings 
between mice heterozygous for the gene-trapped allele are noted as wild-type (+/+), 
heterozygous (+/-) or homozygous (-/-). (B) Verification of Ppib expression by Real-time RT-
PCR using total RNA isolated from primary cultures and tissues from newborns and 8-week 
mice, respectively. Values represent the average of two independent fibroblast and osteoblast 
cultures, and five independent dermal and femoral samples. (C) Lengths of femora and tibiae 
from 8-week old wild-type (+/+), heterozygous (+/-) and homozygous (-/-) knock-out mice. 
Rhizomelia was not detected. (D) Growth curves of male and female mice from weaning (3 
weeks) to 24 weeks of age. The gene-trapped ES cell line was generated by Mutant Mouse 
Regional Resource Center and screened for Ppib expression by W. Chang. Genotyping, Real-
time RT-PCR, BMD and growth curve analyses were designed and performed by W.A. Cabral. 
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and tibial lengths were reduced 7% and 10% versus wild-type mice and heterozygotes (p 
< 0.00004 and p < 0.02, respectively) (Figure 16C). However, in contrast to Crtap and 
P3H1 null mice 107,419, Ppib-/- mice do not have rhizomelia. The ratio of femoral to tibial 
length is comparable to wild-type (0.886 ± 0.020 vs 0.861 ± 0.035, p = 0.07).   
 
Ppib is Required for Bone Development 
Skeletal abnormalities of Ppib-/- mice include decreased mineralization and abnormal 
shape of calvaria, shortened limbs and a deformed and flared rib cage (Figure 17A); these 
features are accentuated in lethal null pups. Heterozygous mice are essentially normal. At 
2 months of age, the rib cage of both heterozygous and homozygous mice has a narrow 
apex and drooping ribs at the base, providing limited space under the ribs for abdominal 
contents, which puff out the abdomen (Figure 17B). Homozygous mice also have 
kyphosis.  
Adult knockout mice are osteoporotic; they have decreased aBMD of femora (p = 
0.001) and vertebrae (p = 0.02) (Figure 17C). Femora of 2-month male Ppib-/- mice 
display altered cortical and trabecular structure on µCT analysis (Figure 17D). Their 
trabecular bone volume is half of wild-type, with reduction of both trabecular number and 
thickness. Ppib-/- trabeculae display the more rod-like architecture found in 
postmenopausal osteoporotic bone 469,470, as revealed by an increased structural model 
index (SMI, p = 0.0003). Femoral cortical bone is thinner, with decreased bone area and 





Figure 17. Absence of Ppib expression affects bone development. (A) Staining of newborn 
skeletons with Alizarin red (bone) and Alcian blue (cartilage) reveals undermineralization of 
calvaria and ribs. Homozygous mice have smaller size of whole skeleton and long bones, and a 
deformed rib cage. (B) X-rays of 8-week old mice. (C) DXA analysis of 8-week old mice 
(n=10/genotype). (D) Structural parameters of wild-type (+/+), heterozygous (+/-) and homozygous 
(-/-) femora at 8 weeks of age characterize reduced bone formation in CyPB-deficient mice (n = 
9/genotype). Left, 3D reconstructions illustrate reduced trabecular and cortical bone volumes. 
Right, Trabecular parameters are decreased in homozygous (-/-) femora, including reduced bone 
volume (Tb BV/TV, p = 0.01), thickness (Tb Th, p = 0.04) and number (Tb N, p = 0.01). The 
increased trabecular bone pattern factor (Tb Pf, p = 0.004) indicates poor connectivity in CyPB-
deficient trabecular bone versus wild-type. Structure Model Index (SMI), which indicates the 
extent of plates (0) and rods (3) is increased in homozygous (-/-) compared to wild-type (+/+) 
trabecular bone (p = 0.0003). Cortical bone parameters of CyPB-deficient mice are also reduced, 
with reductions in cross-sectional thickness (Cs Th, p = 0.008), area (B Ar, p = 0.02) and cortical 
bone volume (Ct BV/TV, p = 0.005). Skeletal staining, Faxitron and DXA were performed and 
analyzed by W.A. Cabral. Bone structural parameters determined by uCT analysis were provided 





Figure 18. Synthesis of Type I collagen. (A) Western blots of cell lysates with antibodies to 
collagen 3-hydroxylation complex components. (B) SDS-Urea PAGE analysis of steady-state 
labeled type I collagen form wild-type (+/+), heterozygous (+/-) and homozygous (-/-) Ppib-/- 
fibroblasts (FB) and osteoblasts (OB). (C) Differential scanning calorimetry (DSC) analysis 
reveals no differences in thermal stability (Tm) of type I collagen secreted by fibroblast cultures. 
(D) Pulse-chase analysis of type I collagen synthesized and secreted by fibroblasts and 
osteoblasts in culture. Primary cell cultures, biochemical and Western analyses were generated 
and performed by W.A. Cabral. DSC was performed by E. Makareeva. 
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CyPB stabilizes prolyl 3-hydroxylation complex structure and function  
We examined the stability and function of the collagen 3-hydroxylation complex. In 
Ppib-/- FB and OB, complete absence of CyPB was associated with a 50% reduction in 
P3H1 (Figure 18A), but did not alter CRTAP levels. Although CyPB was decreased in  
heterozygous cells, P3H1 and CRTAP were unchanged. Despite substantial levels of 
P3H1 and CRTAP in Ppib-/- cells, 3-hydroxylation of α1(I)P986 residues was severely 
reduced. In Ppib-/- mice, only 5-11% of OB and FB and 1-2% of dermal and bone tissue 
collagen α1(I) P986 residues were modified, in contrast to wild type and heterozygous 





Samples were generated by W.A. Cabral, and analyzed by M. Terajima, M. Yamauchi, 
D.R. Eyre and M.A. Weis. 
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The secondary prolyl 3-hydroxylation site was also undermodified; Ppib-null OB and 





CyPB role in collagen folding and helical modification   
Type I collagen alpha chains from Ppib-/- FB and OB have delayed and broadened gel 
migration, consistent with delayed folding and overmodification of lysyl residues (Figure 
18B). Collagen overmodification in the absence of a structural defect is expected to 
increase thermal stability 109,110. However, type I collagen secreted by wild-type, 
heterozygous and homozygous null cells had equivalent melting temperatures (Tm) by 
differential scanning calorimetry (Figure 18C). In agreement with Tm results, amino acid 
Figure 19. Cyclophilin B catalyzes folding of type I collagen. (A) Assay for intracellular 
folding of type I collagen in fibroblast cultures. Data represents the average from two 
independent cell lines for each genotype. (B) Assay for intracellular folding of type I 




analysis of type I collagen secreted by Ppib-/- FB and OB revealed normal proportions of 
hydroxylated lysine and proline residues (Table 6).  
To resolve these apparent discrepancies, we utilized a direct intracellular collagen 
folding assay. Accumulation of intracellular protease-resistant collagen was significantly 
slower in Ppib-null FB than in wild-type cells (Figure 19A). In Ppib-/- OB, the delay in 
type I collagen folding compared to wild-type was nearly double that in FB (Figure 19B). 
Notably, in both cell cultures, addition of the inhibitor CsA further delayed the rate of 
collagen folding in Ppib-/- as well as wild-type cells. These data suggest that, although 
CyPB is the primary PPIase involved in catalyzing folding of the type I collagen helix, 
other PPIases may also be capable of supporting this function. 
 
CyPB Role in Site-Specific Regulation of Collagen Post-translational Modifications  
The apparent discrepancy between slower folding rate and normal total lysyl 
hydroxylation of    collagen from Ppib-/- mice led to a more detailed analysis of collagen 
hydroxylation and subsequent glycosylation in null cells and tissues. Biochemical 
analysis of Ppib-/- skin tissue  showed a substantial decrease in lysyl hydroxylation (18% 
of wild-type) (Figure 20A) and glycosylation (40-50% of wild-type) (Figure 20B) in total 
collagen extracts. A site-specific analysis of skin and fibroblast lysine modification and 
crosslink patterns will be presented elsewhere. Decreased modification of skin-derived 
type I collagen resulted in slightly faster gel migration (Figure 20C). However, Ppib-/- 
bone collagen lysyl hydroxylation was slightly increased in heterozygous (p = 0.0002) 
and homozygous (p = 0.005) mice (Figure 20D), with corresponding increases in 




(Figure 20F). In addition, Ppib-/- bone extracts show a substantial decrease in type V 
collagen alpha chains.  
Detailed characterization of lysine residues in collagen from OB cultures and bone 
tissue showed site-specific changes in lysine hydroxylation and glycosylation, and 
differences between cultured cells and tissues (Table 7; Figure 21A). In Ppib-/- OB 
collagen, only α1(I) K87, α2(I) K87 and K174 are underhydroxylated, with about 20% of 
K87 residues in Ppib-/- collagen unhydroxylated versus <1% of wild-type. However,  
Figure 20. Post-translational modification of Type I collagen from tissues. (A) Total lysyl 
hydroxylation of type I collagen is dramatically reduced in dermal tissue from Ppib-/- mice. (B) 
Post-translational hydroxylation and glycosylation of type I collagen lysines in dermal tissue from 
Ppib-/- mice. (C) SDS-Urea PAGE analysis of pepsin extracts from dermal tissue demonstrates 
increased electrophoretic migration of Ppib-/- type I collagen alpha chains compared to wild-type. 
(D) Total lysyl hydroxylation of type I collagen extracted from bone tissue of heterozygous (+/-) 
and homozygous (-/-) Ppib-null mice compared to wild-type (+/+) bone collagen. (E) Analysis of 
post-translational lysine hydroxylation and glycosylation in Ppib-/- bone-derived type I collagen. 
(F) Type I collagen extracted from bone tissue displays backstreaking of α1(I) chains on SDS-Urea 
and is consistent with post-translational overmodification. Samples were generated by W.A. 
Cabral. Modification data generated and analyzed by M. Terajima, M. Yamauchi, D.R. Eyre and 






Figure 21. Altered post-translational modification of specific Type I collagen lysine 
residues in the absence of Cyclophilin B. (A) Quantitation of type I collagen lysine 
modifications by mass spectrometric analysis. Results were obtained from media of primary 
osteoblast cultures, or from 3-5 independent tissue samples for each genotype. White, Lys, 
lysine; Yellow, Hyl, hydroxylysine; Red, G-Hyl, galactosyl-hydroxylysine; Black, GG-Hyl, 
glucosylgalactosyl-hydroxylysine. (B) Modification of α1(I) and α2(I) K87 residues, 
important for crosslinking of type I collagen heterotypic fibrils in tissue. K, lysine; OH, 
hydroxylysine; G, galactosylhydroxylysine; GG, glucosylgalactosylhydroxylysine. Samples 
were generated by W.A. Cabral. Modification data generated and analyzed by I. Perdivara, 







Samples were generated by W.A. Cabral. Modification data generated and analyzed by I. 
Perdivara, under the supervision of K.B. Tomer. 
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hydroxylation of other helical lysines from Ppib-/- OB collagen was normal or subtly 
increased, i.e. α1(I) K603 and K756 hydroxylation were increased 14% and 9%, 
respectively (Table 7). Bone tissue collagen from Ppib-/- mice has an even more striking  
increase in the proportion of lysine residues involved in crosslink formation that are 
unhydroxylated. Hydroxylation of α2(I) and α1(I) K87 residues is decreased 30-40%, 
respectively, and α2(I) K933 hydroxylysine content is decreased 38%, compared to wild- 
type bone (Table 7). Decreased hydroxylation is also evident at α2(I) K174, but other 
residues do not have significant changes. 
Glycosylation patterns are also altered in Ppib-/- collagen. In wild-type OB collagen, a 
major helical cross-linking residue, α1(I) K87, has the highest proportion of 
diglycosylation, while α2(I) K87 is mainly non-glycosylated (Table 7 and Figure 21B), 
as we previously reported 124,471. In Ppib-/- collagen, mono- and di-glycosylation of α1(I)  
K87 is decreased in tissue and OB culture collagen, and α2(I) K87 di-glycosylation is 
only slightly increased in OB culture collagen, despite slow helical folding (Figure 21B). 
In OB and bone-derived Ppib-/- collagen, all other lysine residues assayed have 
substantial increases in glycosylation, corresponding with delayed intracellular collagen 
folding. We observed increased glycosylation at α1(I) K174, K564, K603, K756 and 
α2(I) K219 in Ppib-/- OB collagen, and to a lesser extent in Ppib-/- bone-derived collagen,  
(Table 7), in agreement with the increased total lysyl hydroxylation and broad gel 
migration (Figure 20D, E). 
Collagen helical lysine modifications are catalyzed primarily by lysyl hydroxylase 1 
(LH1) for hydroxylation, GLT25D1, for galactosylation of hydroxylysine 121, and LH3, 
which harbors both lysyl hydroxylase and glucosyltransferase activities 83,86,126,471. By 
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real-time RT-PCR, we found a modest increase in transcript levels for all three enzymes 
in Ppib-/- FB cultures, but not in skin, OB or femoral tissue (Figure 22A-C). Importantly, 
the protein levels of these enzymes were normal on western blots of FB and OB lysates 
(Figure 22D). These data verify that expression levels of the modifying enzymes do not 
account for the alterations in lysine modification demonstrated in collagen from Ppib-/- 
cells and tissues. 
 
Absence of CyPB affects collagen synthesis and secretion  
 The combined effects of CyPB absence, slower collagen folding and abnormal 
modification, impact procollagen synthesis and secretion. Pulse-chase experiments show 
increased (nearly double) total collagen synthesis by CyPB-deficient OB, while 
fibroblasts produce about half the amount of collagen as wild-type cells (Figure 18D, 
upper). The kinetics of collagen secretion is only slightly delayed for Ppib-/- FB and OB 
(Figure 18D, lower). This finding is similar to our previous report on FB with null 
mutations in LEPRE1 110, but distinct from the reported increased rate of secretion in FB 
with null mutations in CRTAP 107, and of uncertain physiological significance.  
 
Absence of CyPB Affects Collagen Matrix Deposition and Crosslinking  
To determine the consequences of altered collagen post-translational modification on 
extracellular matrix, we analyzed collagen deposition into matrix in culture. Sequential 
extraction of the incorporated labeled collagen revealed that collagen deposited into 
maturely cross-linked matrix by OB (Figure 23A, left) and FB was decreased 80% and 




matrix corroborated the biochemical analysis (Figure 23A, right), indicating a two-thirds 
reduction in matrix collagen content compared to wild-type. 
Consistent with the marked reduction in hydroxylation of the helical crosslinking 
lysine in bone in the absence of CyPB, there was a significant difference in the 
crosslinking pattern. For divalent crosslinks, there was a nearly three-fold increase in the 
helical lysine-involved crosslink, hydroxylysinonorleucine (HLNL), in homozygous 
humeral bone (p = 1.9 x 10-8), while the helical hydroxylysine-involved 
dihydroxylysinonorleucine (DHLNL) is comparable to wild-type bone (Figure24A).  The 
increase in HLNL crosslinks decreases the DHLNL/HLNL ratio in Ppib-/- humerii (p= 
0.0004).  For the trivalent mature crosslinks, hydroxylysylpyridinoline (HP) crosslinks 
Figure 22. Expression of ER resident collagen helical lysine modification enzymes. (A-C) 
Real-time RT-PCR of total RNA from two independent cell cultures of newborn fibroblasts (FB) 
and calvarial osteoblasts (OB), and 5 independent skin and femoral samples for each genotype at 
8 weeks of age. (D) Western blots of cell lysates probing for lysyl hydroxylase 1 (LH1/PLOD1), 
lysyl hydroxylase 3 (LH3/PLOD3), glycosyltransferase 25 domain containing 1 (GLT25D1), and 
β-actin in wild-type (+/+), heterozygous (+/-) and homozygous (-/-) Ppib-null cells and tissues. 




were unchanged in Ppib-/- bone relative to wild-type. However, the helical lysine-
involved crosslink, lysylpyridinoline (LP), was markedly increased by four to five-fold in 
Ppib-/- humerii (p = 2.8 x 10-9) and femoral tissue (p = 0.0001), respectively (Figure 24B). 
The resulting HP/LP ratio in CyPB-deficient bone is decreased 4.25-fold in humeral (p = 
0.00004) and 5.6-fold in femoral bone tissue (p = 0.003). It is also quite noteworthy, in 
the context of both the reduced collagen deposition into Ppib-/- osteoblast matrix and the 
increase in non-hydroxylated forms of crosslinks in tissue, that total bone collagen 
crosslinks were increased in null mice versus wild-type at 2 months of age  
(DHLNL+HLNL, p=0.002; HP+LP, p = 0.00004 and 0.003 for humerus and femora, 
respectively).  
      The abnormal collagen modification and crosslinking affects the structure and 
organization of collagen fibrils.  In dermal fibrils of Ppib-/- mice, we noted the presence 
of disorganized aggregate forms, as well as a 25% increase in the average fibril diameter 
(p = 1.7 x 10-15), and a broader distribution of fibril diameters (p = 4.0 x 10-8) (Figure 
23B). In contrast to dermal fibrils, collagen fibrils from femoral tissue were less densely 
packed and had visibly decreased diameters compared to wild-type. Bone fibril diameters 
were not quantitated because multiple bundle orientations in each field does not allow a 





Figure 23. Dysregulation of collagen deposition and fibril assembly. (A) Left, Deposition of type I 
collagen by osteoblasts into extracellular matrix in culture. Post-confluent cultures were pulsed for 24 
hr, followed by serial extraction of incorporated collagens from the media (M), neutral salt (NS), acid 
soluble (AA, immaturely crosslinked) and pepsin soluble (P, maturely crosslinked) fractions of the 
matrix. Right, Matrix collagen to cell organics ratio from Raman micro-spectroscopy shows 
decreased collagen content in matrix deposited by homozygous Ppib-null (-/-) versus wild-type (+/+) 
osteoblasts in culture (p =  0.002). (B) Transmission electron micrographs of femoral and dermal 
collagen fibrils from 8 week-old wild-type (+/+) and CyPB-deficient mice (-/-). Diameters of 200 
dermal fibrils were measured for each sample and plotted, right. Samples generated by W.A. Cabral. 
PAGE and fibril diameter distribution analysis performed by W.A. Cabral. TEM performed by J.F.E. 






Figure 24. Abnormal crosslink profile in Ppib-null mouse bone. (A) Quantitation of divalent 
crosslinks in murine humerii reveals increased HLNL (hydroxylysinonorleucine) crosslinks, 
which require helical lysine residues, but no change in DHLNL (dihydroxylysinonorleucine) 
crosslinks, which involve helical hydroxylysine residues. (B) Quantitation of trivalent crosslinks 
in murine humerii and femora. Total pyridinoline crosslinks are increased due to an increase in 
lysyl pyridinoline (LP), but not hydroxylysyl pyridinoline (HP) crosslinks in bone. Samples were 
generated by W.A. Cabral. Crosslink data generated and analyzed by M. Terajima, M. 




To investigate the role of CyPB/PPIB in post-translational modification and folding of 
type I collagen, we generated a CyPB knockout mouse using a Ppib gene-trapped ES cell 
line. We confirmed complete absence of Ppib transcripts in cultured cells, as well as 
dermal and bone tissue of homozygous null mice. Furthermore, CyPB was undetectable 
in immunoblots of both fibroblast and osteoblast cultures. The resulting murine 
phenotype reproduces the clinical findings in patients with PPIB deficiency, including 
growth deficiency with bone deformities, reduced bone mineral density and decreased 
trabecular and cortical bone volume. Collagen folding is delayed in Ppib-/- cells, and 
further folding delay by CsA inhibition provides support for an additional collagen 
PPIase. Unexpectedly, CyPB deficiency also results in tissue- and site-specific alterations 
of post-translational hydroxylation and glycosylation of type I collagen, which 
secondarily affect fibril assembly, crosslinking in matrix, and bone mineralization. 
Our initial goal in generating this mouse model of CyPB deficiency was to address the 
inconsistent findings of type I collagen lysyl and P986 hydroxylation among patients with 
type IX OI. In our Ppib KO mice, α1(I) P986 3-hydroxylation is nearly absent from 
dermal and bone collagen, demonstrating that CyPB is required in vivo for 3-
hydroxylation complex activity in tissues. This is consistent with the 3-hydroxylation 
status reported in bone and skin collagen in a previous Ppib murine model, as well as 
with <1% modification of P986 residues in α1(I), α1(II) and α2(V) chains from bone, 
skin and cartilage of Crtap-null mice 107,112,405. P986 3-hydroxylation of type I collagen 
was absent in tail tendon and bone and was reduced, but not absent, in skin of P3H1-null 
mice 419,420. Furthermore, the finding that absence of CRTAP and CyPB, but not P3H1, 
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completely abrogates α1(I) P986 hydroxylation raises the possibility that there is tissue-
specific functional redundancy of P3H isoforms in mice. We also observed a 50% 
reduction of 3-hydroxylation at the secondary α2(I) P707 site in collagen from skin and 
bone, suggesting that P3H1 or other P3H isoforms can modify this site without requiring 
CyPB for activity. For other sites and/or collagen alpha chains, the requirement for CyPB 
may be quite stringent. Delayed electrophoretic migration of collagen alpha chain, caused 
by increased post-translational modification, is considered to be a reliable surrogate assay 
for slower helix folding. Steady-state collagen from Ppib-/- cultured fibroblasts and 
osteoblasts has delayed gel mobility, consistent with the significant delay in helical 
folding of type I collagen demonstrated in direct intracellular folding assays in both cell 
types. Collagen folding in Ppib-/- fibroblasts and osteoblasts was delayed 5 to 8 minutes, 
respectively. By comparison, fibroblast cell lines from OI patients harboring typical 
structural defects in type I collagen demonstrated 5 to 60 minutes delay in formation of 
the collagen helix versus control cells, depending on the glycine substitution 356.  
Treatment of control fibroblast and osteoblast cultures with cyclosporin A (CsA), a 
non-specific cyclophilin inhibitor, resulted in a 10-12 minute delay in collagen folding, 
similar to published experiments 99,108. Unexpectedly, CsA treatment of CyPB-deficient 
cells further increased the collagen folding delay by 6-8 minutes beyond that seen in 
untreated cells. These data suggest that another CsA-sensitive PPIase is capable of partial 
compensation for CyPB deficiency, and may be involved in collagen folding under 
normal conditions. We previously reported a type IX OI patient with total absence of 
CyPB due to a start codon substitution 421. Fibroblast collagen from this patient had 
normal helical modification suggestive of normal collagen folding, prompting us to 
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propose redundancy of collagen cis-trans isomerases. The identity of this PPIase is open 
to speculation. Only one cyclophilin, but at least six FK506 binding proteins (FKBPs), 
occur in the rER 93,458. Until recently, FKBP65, which binds gelatin and is partially 
inhibited by CsA in vitro, was an attractive candidate 101. However, addition of FK506 to 
cell cultures does not delay collagen folding, and absence of FKBP65 in patients with OI, 
Bruck syndrome and Kuskokwim disease has negligible effects on collagen helical 
folding 103,472,473, limiting FKBP65 to at most a compensatory role in the absence of 
CyPB. Similarly, mutations in FKBP14, which encodes FKBP22, were identified in an 
Ehlers-Danlos like-syndrome similar to the kyphoscoliotic type of EDS (EDS VIA) 
caused by LH1 deficiency, but their types I, III and V collagens showed normal 
electrophoretic migration 474.  
One of the striking findings of this study was the difference in post-translational 
modification in collagen isolated from cell cultures versus dermis and bone. Ppib-/- 
fibroblast and osteoblast steady-state type I collagen has significant electrophoretic delay, 
but normal total hydroxylysine content, which suggested that increased glycosylation 
delayed gel mobility. In contrast, collagen extracted from dermal tissue of CyPB-
deficient mice has an 80% decrease in total helical hydroxylysine content, leading to 
more rapid gel migration of alpha chains than collagen from wild-type skin. The 
decreased hydroxylation of collagen in dermal tissue of the Ppib-/- mouse is similar to the 
dermal tissue data from American quarter horses with hyperelastosis cutis caused by a 
homozygous Ppib missense mutation that does not impair its isomerase function in vitro. 
The significantly decreased hydroxylysine content of dermal collagen in the horse is 
proposed to result from loss of a CyPB-LH1 interaction required for LH1 activity 427.  
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Type I collagen extracted from humerii of Ppib-/- mice had different post-
translational modification than both osteoblasts and dermal tissue. Bone-derived collagen 
alpha chains demonstrated subtle broadening and backstreaking on PAGE analysis, 
consistent with the increased global hydroxylation and glycosylation of lysyl residues 
determined by amino acid analysis. However, detailed mass spectrometric analysis 
revealed site-specific alterations in lysine post-translational modification of bone tissue 
collagen. We found dramatic underhydroxylation of lysine residues involved in the 
formation of intermolecular crosslinks in tissue, specifically at α1(I) K87 (57% Hyl in 
null vs 98% in WT), α2(I) K87 (45% Hyl in null vs 77% in WT), and α2(I) K933 (62% 
Hyl in null vs 100% in WT). Significant decreases in hydroxylation of these residues are 
also seen in CyPB-deficient osteoblast collagen. It is generally accepted that 
hydroxylation of helical lysine residues is catalyzed by LH1. However, LH1 stability 
does not appear to be affected in Ppib-/- tissues based on western blot analysis (Figure 
22). Whether CyPB contributes to LH1 folding, or stabilizes its activity by binding, are 
among the possibilities to be investigated. Thus absence of CyPB from bone has critical 
direct and indirect effects on collagen, affecting both collagen folding and the activity of 
a major collagen-modifying enzyme, respectively. This gives CyPB a pivotal role in 
determining the structure of secreted collagen.     
The site-specific changes in lysine hydroxylation seen in CyPB-deficient cells and 
tissues raises the possibility of an additional regulatory mechanism in bone, where there 
is apparent functional redundancy of LH activity directed at helical lysines not involved 
in crosslinking. Primary LH1 and LH2 deficiency demonstrated that LH1 hydroxylates 
lysines in the collagen triple helix while LH2 functions as the telopeptidyl lysyl 
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hydroxylase 81,475-477. However, collagen demonstrated variable decreases in Hyl content 
in bone from Ehlers-Danlos Type VIA patients (10-43% of normal) and a Plod1 KO 
mouse (75% of wild-type), although specific helical lysines involved in crosslinks were 
always underhydroxylated based on decreased HP/LP crosslink ratios 72,478,479. Thus, 
although LH1 appears to be required as the primary hydroxylase for helical domain 
crosslinking lysines in bone collagen, the relative roles of LH1, LH2 and LH3 at other 
helical sites and in other tissues is less well understood. LH3, which has LH, 
galactosyltransferase and glucosyltransferase activity in vitro and in culture 83,84,471,480, 
could be the source of helical Hyl and even increased lysine glycosylation, in Ppib-/- bone 
481. Both a KO murine model for LH3 and a mouse with inactivated LH3 hydroxylation 
have faster gel migration of fibroblast type I collagen 482. In the single human case of 
LH3 deficiency reported, the disaccharide derivative of pyridinoline crosslinks was 
absent in the patient’s urine 126.  
The intracellular hydroxylation of collagen helical K87 and telopeptidyl lysine 
residues determines the collagen crosslink pathway in bone matrix. Crosslinks between 
collagen molecules in extracellular matrix are crucial to skeletal function because they 
contribute to matrix stability, bone strength and elasticity. In both dominant OI caused by 
primary collagen defects and recessive OI caused by CRTAP and P3H1 deficiency, the 
overhydroxylation of collagen helical lysines leads to increased divalent DHLNL/HLNL 
and trivalent HP/LP collagen crosslink ratios 115,483-486. In contrast, in Ppib-/- mice the 
underhydroxylation of K87 residues in tissue collagen results in substantial decreases in 
DHLNL/HLNL and HP/LP ratios in bone. Notably, these changes are similar to findings 
in primary LH1 deficiency, in which bone-derived urinary peptides reflect decreased 
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hydroxylation of collagen lysine residues involved in crosslink formation 475, and 
decreased HP/LP ratios and increased total pyridinoline crosslinks were observed 75,89,475. 
The cause of increased total crosslinks seen in Ppib-/- bone collagen is not clear. Possibly, 
decreased K87 hydroxylation and glycosylation may favor binding or activity of lysine 
oxidase at this site 124,487,488.  
Eyre and colleagues proposed that the collagen 3-hydroxylation modification 
supports matrix supramolecular assembly by fine-tuning the intermolecular alignment of 
collagen molecules to facilitate crosslink formation 115. Our finding of severe reduction in 
collagen deposition into matrix is consistent with this hypothesis. However, we now 
understand that collagen secreted by CyPB-deficient osteoblasts has site-specific 
alterations in hydroxylation and glycosylation as well as absent P986 3-hydroxylation, 
which could also alter matrix assembly in addition to changes in collagen crosslinking 
and fibril structure. Furthermore, although this investigation focused on type I collagen, 
extracts from Ppib-/- bone show a substantial decrease in the quantity of type V collagen 
alpha chains (Figure 20F).  
The effect of altered collagen crosslinking in Ppib-/- bone on mineralization remains 
to be explored. Bone from OI caused by collagen structural defects or CRTAP 
deficiency, whose crosslink pattern is opposite to this Ppib-/- mouse, is paradoxically 
hypermineralized. Collagen crosslinking and bone mineral crystallinity were strongly 
correlated in long bones of several congenic mouse strains 489. On the other hand, 
increased HP/LP ratios correlate with the ultimate compressive strength of trabecular 
bone, but are independent of BMD 490,491. Comparison of mineralization in Ppib-/- and 
classical OI bone will provide insight into the interaction of bone crosslinks and 
 
 164 
mineralization, and could point to collagen modification as an intracellular pathway by 
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Mechanism of 3-Hydroxylation Defects: Recessive OI 
  
The recent discovery that defects in the collagen prolyl 3-hydroxylase complex cause 
recessively inherited bone dysplasia has created a paradigm shift in osteogenesis 
imperfecta. Once considered the phenotypic outcome of collagen structural defects, OI is 
now thought of as a collagen-related disorder also encompassing the cellular machinery 
involved in collagen biosynthesis. Characterization of the distinct and shared metabolic 
pathways that are affected in dominant and recessive OI has dramatically altered our 
understanding of bone development, improved OI detection and diagnosis, and offered 
exciting new potential for therapeutic approaches to treating this disease. 
Null mutations in CRTAP and LEPRE1 (P3H1) cause severe to lethal recessive types 
VII and VIII OI with the distinctive features of extrememely low BMD (z ≤ -6), 
undertubulated long bones, bulbous metaphyses and rhizomelia (relative shortening of 
the proximal segment of the limbs) 354,492. Types VII and VIII OI are considered 
osteochondrodystrophies that affect both bone and cartilaginous tissues. This is likely due 
to the putative roles of secreted CRTAP and P3H1 proteins in these tissues, as well as to 
the intracellular roles of the P3H complex as a collagen folding chaperone and in 3-
hydroxylation of α1(I) and α1(II) P986 residues in osteoblasts of bone and chondrocytes 
of cartilage, respectively. Furthermore, the overlapping phenotypes resulting from 
CRTAP and P3H1 deficiency can also be attributed to their mutual stabilization in the 
ER; absence of one component results in complete loss of both 457. Thus all cases of 
CRTAP and P3H1 deficiency share the biochemical feature of type I collagen 
overmodification that is commonly seen in moderate to severe forms of dominant OI 354. 
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In dominant OI overmodification of collagen alpha chains is clearly due to a delay in 
helical folding and subsequent increased exposure to the post-translational modifying 
enzymes in the ER. The same increased hydroxylation and glycosylation of type I 
collagen helical lysyl residues occurs in CRTAP and P3H1 deficiency, and may reflect a 
role for the P3H complex as a collagen folding chaperone.  
However, it is still unclear if absence of the complex or absence of the collagen 
modification is the underlying defect of collagen prolyl 3-hydroxylase deficiency in types 
VII and III OI. Indeed, the collagen 3-hydroxylation modification itself has been 
proposed as a passive marker of intracellular complex chaperone activity 456, a local 
stabilizing modification to the triple helix 114,493, a non-collagenous protein binding site 
494, and as a recognition sequence that mediates intermolecular alignment required for 
efficient collagen fibril assembly 115. Generation of mouse models expressing either type 
I or type II collagens unable to be modified by the P3H complex should help to clarify 
the pathophysiology of these disorders. 
 
Frequency of Recessive OI 
 
Osteogenesis imperfecta occurs with a frequency of 1 in 15-20,000 births in 
Caucasian American and Northern European populations. Of these cases, approximately 
85% are due to dominant mutations of COL1A1 and COL1A2 causing Classical OI. 
Homozygosity or compound heterozygosity for collagen mutations is extremely rare, 
with only three reported instances, and in most populations familial recurrence of OI is 
attributed to autosomal dominant parental mosaicism 358. However, familial recurrence of 
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severe forms of OI due to recessive inheritance of collagen 3-hydroxylation defects may 
account for as much as 5% of OI cases in North America and Europe. In contrast to the 
low frequency of recessive OI types in Caucasian populations, a few isolated populations 
have been identified with high carrier frequencies of recessive alleles that cause types VII 
and VIII OI.  
The first of the recurring mutations was identified in an isolated First Nations 
community in northern Quebec, affected individuals of which were first characterized 
with type VII OI 107. Although the carrier frequency of the CRTAP c.472-1021C>G 
mutation within this small community (approximately 2500 individuals) has not been 
established, haplotype analysis of one large three-generation pedigree, including 8 
affected, suggests a founder mutation six to eight generations ago 407. A recurring 
LEPRE1 mutation (c.232delC) also occurs in the genetically isolated Irish Travellers 409, 
which according to one estimate may cause recessive OI in as many as 1% of births in 
this population 495. This rate of OI in Irish Travellers predicts that 1 in 5 individuals may 
be carriers for the c.232delC allele. 
The most recent data reveals that over one quarter (22/82) of the disease-causing 
alleles reported for LEPRE1 are represented by the c.1080+1G>T mutation. Commonly 
referred to as the West African allele, this mutation was initially identified in four of five 
children first identified with type VIII OI 110. Each of the probands harbouring this 
mutation were children of African American or West African émigré families, suggesting 
the presence of a recurring mutation among individuals of West African descent. Using 
anonymized samples, we determined an African American carrier frequency of 0.4% by 
screening genomic DNA from more than 3000 infants of the Mid-Atlantic region of the 
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United States 413. The carrier frequency among African Americans predicts an incidence 
of type VIII OI due to this mutation alone at 1 in 250,0000 births, which is in the range of 
typical rare recessive conditions. Thus among the nearly 600,000 African American 
infants born in the U.S. each year, only two or three cases of recessive OI due to 
homozygosity for the LEPRE1 c.1080+1G>T mutation would be expected to occur. 
However, given the estimated rate of lethal OI as 1 in 40-60,000 births in North America, 
the carrier frequency suggest that 15-23% of cases of lethal OI in African Americans will 
be caused by homozygosity for the West African allele. Thus, while the LEPRE1 
c.1080+1G>T mutation does not contribute significantly to overall African American 
perinatal deaths in the U.S., the frequency of carriers makes it important for genetic 
counseling purposes. 
An additional 3000 genomic DNA samples from contemporary African cohorts 
provided convincing evidence for our hypothesis of a West African origin for this allele; 
the mutation was detected in nearly 1.5% of samples screened from Ghana and Nigeria, 
but was not identified among additional cohorts from other African regions 413. The high 
carrier frequency (1.5%) for this mutation among cohorts from sub-Saharan West Africa 
predicts that recessive type VIII OI will occur with the same incidence as dominant OI (1 
in 18,260 births) in these regions. These numbers represent the potential for a substantial 
public health burden in West African countries, since dominant and recessive forms of OI 
are expected to occur with equal frequency in this population. Furthermore, a recent 
report suggests that severe to lethal forms of OI are as common as mild to moderate 
forms among Nigerians, and is consistent with the mild to lethal range of phenotypes in 
dominant OI and the severe to lethal range seen in P3H1 deficiency 496,497. 
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The West African allele is the only recurring OI-causing mutation that has been 
characterized in a geographically widespread population, in this case due to the African 
Diaspora. The occurrence of this mutation within a conserved haplotype among carriers 
not only confirms a founder effect, but also is consistent with a mutation that occurred 
between 650 and 900 years ago, prior to the Atlantic slave trade 413. Thus it was not 
surprising to find additional carriers in regions affected by the slave trade. For example, 
we have also identified this mutation in 5/863 (0.58%) Jamaican newborn genomic 
DNAs that were screened, estimating an occurrence of Type VIII OI due to 
homozygosity for LEPRE1 c.1080+1G>T at 1/109,958-119,163 births (unpublished 
data).  
It should be noted that Irish Travellers and individuals of West African descent are 
not the only ethnic populations affected by molecular defects in LEPRE1 498. While the 
West African allele is a substantial factor, the number of recessive LEPRE1 alleles, as 
well as the number of reported cases of Type VIII OI, outnumber those that have been 
reported for types VII and IX OI, due to mutations in CRTAP and PPIB, combined 499. 
Deficiency of cyclophilin B, caused by mutations in PPIB, is the least frequently 
occurring cause of recessive OI. However, the small number of human cases and animal 








The Ppib-Null Mouse: A Unique Model of Recessive OI 
 
Although recessive OI has now been sufficiently investigated to draw some general 
conclusions about the mechanism of recessive OI in cases of CRTAP and P3H1 
deficiency, the picture has been less clear for PPIB/Cyclophilin B deficiency. The loss of 
α1(I) P986 modification and presence of collagen alpha chain overmodification is a 
defining biochemical feature of CRTAP and P3H1 deficiency, and cases of types VII and 
VIII OI are uniformly severe to lethal in phenotype.  
At the present time only 8 cases of type IX OI due to PPIB mutations have been 
reported (Table 8), only 4 of which have been investigated beyond mutation 
identification 421-423. These cases differ from those with CRTAP or P3H1 deficiency in 
that rhizomelia is absent, although they share the features of broad, undertubulated long 
bones and white sclerae. Two of these cases with moderate OI phenotypes have 




absence of cyclophilin B protein on immunoblots, but do not cause a reduction of 
collagen α1(I) P986 3-hydroxylation 421,423. The remaining two cases with lethal OI 
demonstrate decreased (30%), but not absent, 3-hydroxylation of collagen resulting from 
their mutations (c.120delC/c.313G>A, p.Val42Serfs*16/p.Gly105Arg; c.556_559del, 
p.Lys186Glnfs*8) 421,422. Importantly, in the cases in which partial hydroxylation of P986 
residues was observed, the PPIB mutations result in either normal levels of transcripts or 
residual levels of cyclophilin B protein. Accordingly, these data suggest the presence of a 
truncated cyclophilin B protein that functions in a dominant negative manner within the 
P3H complex, resulting in a dysfunctional complex that partially modifies the substrate 
and causes collagen overmodification. Thus, regardless of which components of the 3-
hydroxylation complex are absent, all cases of types VII-IX OI that have complete 
absence of P986 hydroxylation result in collagen overmodification. In contrast, the 
proband with the start codon mutation completely lacked cyclophilin B protein, had 
normal P986 3-hydroxylation and normal collagen modification 421. As discussed more 
fully below, this may be due to redundancy for cyclophilin B function by an unknown 
ER-resident protein. 
Two animal models for PPIB deficiency have been previously reported. The first of 
these is HERDA, a progressive skin fragility syndrome observed in American Quarter 
horses caused by a naturally occurring missense mutation (c.115G>A, p.G6R) 427. This 
mutation results in a substitution at the amino terminus of processed PPIB that does not 
alter the substrate-binding site. Although the in vitro isomerase activity of mutant 
cyclophilin B was intact, collagen folding was delayed in fibroblasts. This horse model of 
PPIB deficiency exhibits normal P986 3-hydroxylation and decreased collagen post-
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translational modification resulting in a skin phenotype without apparent bone dysplasia. 
The surprising finding in this study was the decreased hydroxylysine content of equine 
dermal tissue, presumably due to a loss of physical interaction between HERDA 
cyclophilin B and LH1 that was demonstrated in immunoprecipitation experiments. In 
contrast, a previously reported knock-out mouse model of PPIB deficiency demonstrates 
absent 3-hydroxylation and delayed electrophoretic migration consistent with increased 
post-translational modification, similar to the collagen biochemistry of CRTAP and P3H1 
deficiency 112. As with the human cases, the information from the animal models 
demonstrates that the presence of an abnormal cyclophilin B protein results in at least 
partial modification of the P986 residue. Unlike the human cases, however, complete 
absence of cyclophilin B abrogates prolyl 3-hydroxylation of the collagen substrate. Both 
animal models resulted in collagen post-translational modification that differed from each 
other, as well as the human cases. Therefore we developed a Ppib-null mouse with the 
goal of addressing the inconsistencies between the human cases, as well as the 
differences between the previously reported animal models and human cases. 
Ppib expression is completely blocked in the gene trap mutant allele used in our 
mouse model, compared with a previously reported Ppib-knockout mouse that retains 
25% of wild-type transcripts. Total absence of Ppib expression in the mouse results in 
growth deficiency and reduced femoral and tibial lengths, as seen in other mouse models 
with deficiency of P3H complex components 107,112,419. In contrast to the Crtap-/- and 
P3h1-/- mice, however, Ppib-/- mice do not have rhizomelia. Surviving Ppib-/- mice have a 
severely osteoporotic bone phenotype, accentuated by reduced structural parameters, 
decreased bone mineral density, and significantly reduced bone strength. Furthermore, 
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the 40-50% perinatal lethality seen in Ppib-/- mice probably reflects the full range of 
phenotypes seen in humans with CyPB deficiency. Thus our mouse model of CyPB 
deficiency faithfully reproduces the phenotypic features found in human cases of type IX 
OI 421-423. 
The critical role of CyPB for 3-hydroxylation of both type I collagen sites (i.e., α1(I) 
P986 and α2(I) P707) in mice is evident from the nearly complete loss of modification of 
α1(I) chains and the 50% reduction in 3-hydroxylation of α2(I) chains. These data 
suggest that the remaining P3H complex (CRTAP and P3H1) components do not 
function in the absence of CyPB in mice for the α1(I) P986 site, but that a partially 
redundant system is involved in modification of the α2(I) P707 site. Thus it seems likely 
that functional redundancy by a P3H isoform that does not require CyPB can compensate 
for α2(I) P707 modification, or another unidentified protein compensates for CyPB’s 
role. 
We have verified CyPB’s role as a peptidyl-prolyl cis-trans isomerase involved in 
type I collagen folding. In the absence of CyPB, the formation of trypsin-resistant 
collagen helices was significantly delayed, seemingly recapitulating the delayed folding 
of collagen in the presence of cyclosporine A that was demonstrated in earlier studies 
99,108. However, we have demonstrated that addition of cyclosporine A to Ppib-/- cells 
further increases the delay in collagen folding, suggesting the presence of an additional 
cyclosporine-sensitive factor involved in catalyzing collagen folding. Although CyPB has 
long been considered to be the unique isomerase to catalyze the rate-limiting step in 
helical folding, our data demonstrate an addition factor of unknown identity that is able to 
function in this manner. 
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The most striking findings in our study are the differences in modification of type I 
collagen synthesized in cultured cells versus tissues. Specifically, modification of 
collagen synthesized in culture does not necessarily reflect the extent of modification 
seen in tissues. For instance, PAGE and amino acid analysis of type I collagen alpha 
chains synthesized by both fibroblasts and osteoblasts demonstrated normal lysyl 
hydroxylation with increased glycosylation, resulting in delayed electrophoretic 
migration. However, type I collagen extracted from dermis was undermodified and 
showed increased electrophoretic mobility, while collagen extracted from bone tissue was 
overmodified. These findings highlight the tissue-specific roles of collagen-specific 
modifying enzymes in the ER. First, the loss of lysyl hydroxylation in the absence of 
CyPB in dermis supports the recent hypothesis that LH1 requires CyPB for modification 
of the collagen substrate 427. Second, the presence of overmodified type I collagen in 
bone tissue demonstrates that osteoblasts either do not require the CyPB-LH1 interaction 
for modification of lysyl residues, or an alternative isomerase interacts with LH1 for its 
activity, or an alternative lysyl hydroxylase isoform can compensate for loss of LH1 
function in bone tissue. Currently, LH3 is a prime candidate for this compensatory 
function, since it is expressed in bone and has been demonstrated to exhibit hydroxylase, 
galactosyl-, and glucosyltransferase activities in vitro and in culture 83,84,471. It remains to 
be determined whether loss of LH activity towards type I collagen in the absence of 
CyPB is due to loss of LH1 activity catalyzed by CyPB, or if LH1 is unable to recognized 
the collagen substrate with peptidyl-prolyl bonds in the cis conformation. 
Surprisingly, the loss of post-translational modification was most notable at amino 
terminal helical lysine residues involved in intermolecular crosslinks in extracellular 
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matrix. Thus the loss of hydroxylation at K87 residues, which are involved in crosslink 
formation, results in an alteration of crosslink profiles. We found an increase in the 
LP/HP ratio in bone tissue, similar to the crosslink profile seen in bone of patients with 
Type VI Ehlers-Danlos Syndrome due to LH1 deficiency. However, although the bone 
phenotype in EDS VI patients can be described as osteopenic, the major phenotypic 
findings in these individuals are hyperextensible skin and joints 76. While these features 
are noted in the CyPB-deficient mouse, the phenotypic features of this mouse model are 
primarily that of a bone dysplasia.  
Controversies pertaining to the role of cyclophilin B in collagen synthesis remain. 
First, Pyott and colleagues suggest that inhibition or absence of cyclophilin B results in 
loss of peptidyl-prolyl isomerase activity important for the collagen C-propeptide 
conformation necessary for chain association 423. The authors hypothesized that the 
cyclosporin A-induced delay in the appearance of trypsin-resistant collagen helices seen 
in direct intracellular folding assays was misinterpreted as delayed folding, but was 
instead a result of delayed heterotrimer formation. However, we have been unable to 
detect any delays in procollagen chain incorporation in our mouse model, so this putative 
function of cyclophilin B remains to be independently verified. Furthermore, given the 
short delay in chain association which was observed (2-3 minutes), the physiological 
relevance of these findings is in question. 
A second controversy has risen over whether cyclophilin B is the unique cis-trans 
isomerase that catalyzes the rate-limiting step in collagen folding. We have demonstrated 
that cyclosporine A further increases the delay in the appearance of trypsin-resistant 
helices in direct intracellular folding assays performed on Ppib-null cells, consistent with 
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the presence of an additional collagen-interacting cyclosporine-sensitive PPIase in the 
ER. Importantly, our study has revealed tissue-specific differences in collagen 
biochemistry in the absence of cyclophilin B which are relevant for the bone phenotype 
exhibited in recessive OI. The absence of cyclophilin B in murine dermis and subsequent 
decreased hydroxylation and glycosylation of collagen lysine residues is consistent with a 
loss of interaction required for LH1 activity, thus implying that LH1-collagen interaction 
requires CyPB. However, in murine bone tissue the absence of cyclophilin B is 
accompanied by an increase in collagen post-translational modification. Taken together, 
these studies are consistent with a major, but not unique, role for cyclophilin B as a 
collagen cis-trans isomerase, and agree with our previous proposal of functional 
redundancy based on findings of normal collagen post-translational modification in the 
proband with a PPIB start codon mutation 421. Seven PPIases are located in the ER, 
including six FK506-binding proteins (FKBPs) and cyclophilin B 91,93; only cyclophilin B 
and FKBP65 have been demonstrated to physically interact with collagen in the ER 101. 
However, the genetic and biochemical evidence that exists suggests that FKBP65 does 
not have a role in helical modification or folding. FKBP65-deficient cells do not 
demonstrate a delay in collagen folding in direct folding assays (data not shown), and 
FKBP65 activity is only minimally inhibited by CsA and FK506 99. Formal verification, 
however, requires Ppib-Fkbp10 compound knock-out cells, or knock-down studies in 
Fkbp10- and Ppib-null cells. 
Future studies on our Ppib-null mouse model will address the question of collagen 
isomerase redundancy by creation of double knockouts or knockdown of candidate 
cyclophilins and FKBPs in order to replicate the increased delay of folding seen upon 
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cyclosporin A treatment of cyclophilin B-deficient cells. Also, the effect of altered 
collagen crosslinking in Ppib-/- bone on mineralization remains to be explored. Bone from 
patients or mouse models of OI caused by collagen structural defects or CRTAP 
deficiency contains a crosslink pattern that is opposite to this Ppib-/- mouse due to 
increased hydroxylysine derived crosslinks, and is paradoxically hypermineralized 
406,483,484,486,500. On the other hand, increased HP/LP ratios correlate with the ultimate 
compressive strength of trabecular bone, but are independent of BMD 490,491. Analysis of 
the process of mineralization, as well as the organization of the mineral component in 
Ppib-/- and classical OI bone will provide insight into the role of bone crosslinks in 
mineralization, and could point to collagen modification as an intracellular pathway by 
which osteoblasts can actively influence this process. In addition, since CyPB is known 
to directly interact with several ER-resident proteins 501, its role in ER stress and 
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